0001654954-23-000431.txt : 20230113 0001654954-23-000431.hdr.sgml : 20230113 20230113160706 ACCESSION NUMBER: 0001654954-23-000431 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20221130 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEHR TEST SYSTEMS CENTRAL INDEX KEY: 0001040470 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 942424084 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22893 FILM NUMBER: 23528843 BUSINESS ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 BUSINESS PHONE: 5106239400 MAIL ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 10-Q 1 aehr_10q.htm FORM 10-Q aehr_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to __________

 

Commission file number: 000-22893

 

AEHR TEST SYSTEMS

(Exact name of Registrant as specified in its charter)

 

California

 

94-2424084

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

400 Kato Terrace

Fremont, CA

 

94539

(Address of principal executive offices)

 

(Zip Code)

 

(510) 623-9400

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes☒     No☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒     No☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes       No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock Par value of $0.01 per share

AEHR

The NASDAQ Capital Market

 

Number of shares of the registrant’s common stock, $0.01 par value, outstanding as of December 31, 2022 was 27,759,445.

 

 

 

 

AEHR TEST SYSTEMS

 

FORM 10-Q

 

FOR THE QUARTER ENDED NOVEMBER 30, 2022

 

INDEX

 

 

 

 

PART I. FINANCIAL INFORMATION

 

 3

 

 

 

 

 

ITEM 1. Financial Statements (Unaudited)

 

 3

 

 

 

 

 

Condensed Consolidated Balance Sheets at November 30, 2022 and May 31, 2022

 

3

 

 

 

 

 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended November 30, 2022 and 2021

 

4

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended November 30, 2022 and 2021

 

5

 

 

 

 

 

Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended November 30, 2022 and 2021

 

6

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended November 30, 2022 and 2021

 

8

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements

 

9

 

 

 

 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

24

 

 

 

 

 

ITEM 3. Quantitative and Qualitative Disclosures About Market Risks

 

29

 

 

 

 

 

ITEM 4. Controls and Procedures

 

29

 

 

 

 

 

PART II. OTHER INFORMATION

 

 

 

 

 

 

 

ITEM 1. Legal Proceedings

 

31

 

 

 

 

 

ITEM 1A. Risk Factors

 

31

 

 

 

 

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

31

 

 

 

 

 

ITEM 3. Defaults Upon Senior Securities

 

31

 

 

 

 

 

ITEM 4. Mine Safety Disclosures

 

31

 

 

 

 

 

ITEM 5. Other Information

 

31

 

 

 

 

 

ITEM 6. Exhibits

 

32

 

 

 

 

 

SIGNATURES

 

33

 

 

 
2

Table of Contents

 

PART I. FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS (Unaudited)

 

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

(unaudited)

 

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

 

 

 

 

 

 

(1)

ASSETS

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$18,874

 

 

$31,484

 

Short-term investments

 

 

17,710

 

 

 

-

 

Trade and other accounts receivable, net

 

 

10,156

 

 

 

12,859

 

Inventories

 

 

17,972

 

 

 

15,051

 

Prepaid expenses and other current assets

 

 

823

 

 

 

613

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

65,535

 

 

 

60,007

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

1,263

 

 

 

1,203

 

Operating lease right-of-use assets

 

 

561

 

 

 

917

 

Other assets

 

 

184

 

 

 

201

 

 

 

 

 

 

 

 

 

 

Total assets

 

$67,543

 

 

$62,328

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$3,949

 

 

$4,195

 

Accrued expenses

 

 

2,566

 

 

 

3,610

 

Operating lease liabilities, short-term

 

 

551

 

 

 

794

 

Customer deposits and deferred revenue, short-term

 

 

3,680

 

 

 

2,415

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

10,746

 

 

 

11,014

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, long-term

 

 

65

 

 

 

212

 

Deferred revenue, long-term

 

 

25

 

 

 

69

 

Other liabilities

 

 

40

 

 

 

44

 

Total liabilities

 

 

10,876

 

 

 

11,339

 

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 27,732 shares and 27,120 shares at November 30, 2022 and May 31, 2022, respectively

 

 

277

 

 

 

271

 

Additional paid-in capital

 

 

119,094

 

 

 

117,686

 

Accumulated other comprehensive loss

 

 

(155)

 

 

(105)

Accumulated deficit

 

 

(62,549)

 

 

(66,863)

 

 

 

 

 

 

 

 

 

Total shareholders’ equity

 

 

56,667

 

 

 

50,989

 

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$67,543

 

 

$62,328

 

 

(1)

The condensed consolidated balance sheet at May 31, 2022 has been derived from the audited consolidated financial statements at that date.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
3

Table of Contents

 

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

Cost of sales

 

 

6,904

 

 

 

5,092

 

 

 

13,094

 

 

 

8,457

 

Gross profit

 

 

7,911

 

 

 

4,519

 

 

 

12,392

 

 

 

6,800

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

2,875

 

 

 

2,489

 

 

 

5,400

 

 

 

4,442

 

Research and development

 

 

1,551

 

 

 

1,313

 

 

 

3,049

 

 

 

2,634

 

Total operating expenses

 

 

4,426

 

 

 

3,802

 

 

 

8,449

 

 

 

7,076

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

3,485

 

 

 

717

 

 

 

3,943

 

 

 

(276)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

263

 

 

 

(1)

 

 

384

 

 

 

(10)

Gain from forgiveness of PPP loan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,698

 

Other (expense) income, net

 

 

(5)

 

 

35

 

 

 

19

 

 

 

58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax expense

 

 

3,743

 

 

 

751

 

 

 

4,346

 

 

 

1,470

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

(18)

 

 

(34)

 

 

(32)

 

 

(57)

Net income

 

$3,725

 

 

$717

 

 

$4,314

 

 

$1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$0.14

 

 

$0.03

 

 

$0.16

 

 

$0.06

 

Diluted

 

$0.13

 

 

$0.03

 

 

$0.15

 

 

$0.05

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

Diluted

 

 

29,080

 

 

 

28,342

 

 

 

28,934

 

 

 

26,849

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
4

Table of Contents

 

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$3,725

 

 

$717

 

 

$4,314

 

 

$1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive (loss) income, net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in unrealized loss on investments

 

 

(6)

 

 

-

 

 

 

(6)

 

 

-

 

Net change in cumulative translation adjustments

 

 

1

 

 

 

(44)

 

 

(44)

 

 

(80)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income

 

$3,720

 

 

$673

 

 

$4,264

 

 

$1,333

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
5

Table of Contents

 

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands)

(unaudited)

 

 

 

 

 

 

Additional

 

 

Accumulated

Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders’

 

Three Months Ended November 30, 2022

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances, August 31, 2022

 

 

27,395

 

 

$274

 

 

$117,668

 

 

$(150)

 

$(66,274)

 

$51,518

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

339

 

 

 

3

 

 

 

654

 

 

 

-

 

 

 

-

 

 

 

657

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(2)

 

 

-

 

 

 

(37)

 

 

-

 

 

 

-

 

 

 

(37)
Stock-based compensation     

 

 

-

 

 

 

-

 

 

 

809

 

 

 

-

 

 

 

-

 

 

 

809

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,725

 

 

 

3,725

 

Net unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(6)

 

 

-

 

 

 

(6)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1

 

 

 

-

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

27,732

 

 

$277

 

 

$119,094

 

 

$(155)

 

$(62,549)

 

$56,667

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

Total

 

 

 

Common Stock

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders’

 

Six Months Ended November 30, 2022

 

Shares

 

 

Amount

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances, May 31, 2022

 

 

27,120

 

 

$271

 

 

$117,686

 

 

$(105)

 

$(66,863)

 

$50,989

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

761

 

 

 

7

 

 

 

1,105

 

 

 

-

 

 

 

-

 

 

 

1,112

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(149)

 

 

(1)

 

 

(1,215)

 

 

-

 

 

 

-

 

 

 

(1,216)
Stock-based compensation

 

 

-

 

 

 

-

 

 

 

1,518

 

 

 

-

 

 

 

-

 

 

 

1,518

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,314

 

 

 

4,314

 

Net unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(6)

 

 

-

 

 

 

(6)

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(44)

 

 

-

 

 

 

(44)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

27,732

 

 

$277

 

 

$119,094

 

 

$(155)

 

$(62,549)

 

$56,667

 

 

 
6

Table of Contents

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders’

 

Three Months Ended November 30, 2021

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances, August 31, 2021

 

 

24,483

 

 

$245

 

 

$89,668

 

 

$(64)

 

$(75,617)

 

$14,232

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

663

 

 

 

6

 

 

 

1,360

 

 

 

-

 

 

 

-

 

 

 

1,366

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(8)

 

 

-

 

 

 

(157)

 

 

-

 

 

 

-

 

 

 

(157)

Proceeds from public offerings, net of issuance costs

 

 

1,697

 

 

 

17

 

 

 

24,013

 

 

 

-

 

 

 

-

 

 

 

24,030

 

Stock-based compensation 

 

 

-

 

 

 

-

 

 

 

718

 

 

 

-

 

 

 

-

 

 

 

718

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

717

 

 

 

717

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(44)

 

 

-

 

 

 

(44)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2021

 

 

26,835

 

 

$268

 

 

$115,602

 

 

$(108)

 

$(74,900)

 

$40,862

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

  Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Shareholders’

 

Six Months Ended November 30, 2021

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances, May 31, 2021

 

 

23,725

 

 

$237

 

 

$87,553

 

 

$(28)

 

$(76,313)

 

$11,449

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under employee plans

 

 

1,461

 

 

 

14

 

 

 

2,989

 

 

 

-

 

 

 

-

 

 

 

3,003

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(48)

 

 

-

 

 

 

(259)

 

 

-

 

 

 

-

 

 

 

(259)

Proceeds from public offerings, net of issuance costs

 

 

1,697

 

 

 

17

 

 

 

24,013

 

 

 

-

 

 

 

-

 

 

 

24,030

 

Stock-based compensation   

 

 

-

 

 

 

-

 

 

 

1,306

 

 

 

-

 

 

 

-

 

 

 

1,306

 

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,413

 

 

 

1,413

 

Foreign currency translation adjustment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(80)

 

 

-

 

 

 

(80)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2021

 

 

26,835

 

 

$268

 

 

$115,602

 

 

$(108)

 

$(74,900)

 

$40,862

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
7

Table of Contents

 

AEHR TEST SYSTEMS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

 

 

Six Months Ended

 

 

 

November 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$4,314

 

 

$1,413

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

1,503

 

 

 

1,306

 

Provision for doubtful accounts

 

 

24

 

 

 

-

 

Depreciation and amortization

 

 

191

 

 

 

149

 

Accretion of investment discount

 

 

(64)

 

 

-

 

Gain from forgiveness of PPP loan

 

 

-

 

 

 

(1,698)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Trade and other accounts receivable

 

 

2,618

 

 

 

(2,284)

Inventories

 

 

(3,094)

 

 

(4,212)

Prepaid expenses and other assets

 

 

(196)

 

 

(60)

Accounts payable

 

 

(210)

 

 

512

 

Accrued expenses

 

 

(1,045)

 

 

104

 

Customer deposits and deferred revenue

 

 

1,221

 

 

 

9,970

 

Income taxes payable

 

 

4

 

 

 

11

 

Net cash provided by operating activities

 

 

5,266

 

 

 

5,211

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of investments

 

 

(17,652)

 

 

-

 

Purchases of property and equipment

 

 

(99)

 

 

(132)

Net cash used in investing activities

 

 

(17,751)

 

 

(132)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Line of credit repayments, net

 

 

-

 

 

 

(1,400)

Proceeds from issuance of common stock under employee plans

 

 

1,112

 

 

 

3,003

 

Shares repurchased for tax withholdings on vesting of restricted stock units

 

 

(1,216)

 

 

(259)

Proceeds from issuance of common stock from public offering, net of issuance costs

 

 

-

 

 

 

24,030

 

Net cash (used in) provided by financing activities

 

 

(104)

 

 

25,374

 

 

 

 

 

 

 

 

 

 

Effect of exchange rates on cash, cash equivalents and restricted cash

 

 

(21)

 

 

(4)

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(12,610)

 

 

30,449

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, beginning of period(1)

 

 

31,564

 

 

 

4,662

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash, end of period(1)

 

$18,954

 

 

$35,111

 

 

(1)

Includes restricted cash in other assets.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
8

Table of Contents

 

AEHR TEST SYSTEMS

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES

 

The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations.

 

In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 2022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.

 

PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.

 

ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended November 30, 2022.

 

2. RECENT ACCOUNTING PRONOUNCEMENTS

 

Accounting Standards Not Yet Adopted

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis, with early adoption in or after fiscal 2021 permitted. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

 

 
9

Table of Contents

 

3. REVENUE

 

Revenue recognition

 

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

The Company sells its products primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

 

Disaggregation of revenue

 

The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.

 

The Company’s revenues by product category are as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

 

 

 

Systems

 

$7,400

 

 

$3,754

 

 

$16,494

 

 

$7,633

 

Contactors

 

 

6,607

 

 

 

5,090

 

 

 

7,101

 

 

 

6,042

 

Services

 

 

808

 

 

 

767

 

 

 

1,891

 

 

 

1,582

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$14,401

 

 

$9,107

 

 

$24,723

 

 

$14,250

 

Test During Burn-In

 

 

414

 

 

 

504

 

 

 

763

 

 

 

1,007

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

 
10

Table of Contents

 

The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$2,555

 

 

$895

 

 

$5,418

 

 

$1,401

 

Asia

 

 

12,216

 

 

 

8,716

 

 

 

20,024

 

 

 

13,853

 

Europe

 

 

44

 

 

 

-

 

 

 

44

 

 

 

3

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at the point in time when control transfers to customers. The following presents revenue based on timing of recognition (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

 

 

 

Products and services transferred at a point in time

 

$14,427

 

 

$9,270

 

 

$24,681

 

 

$14,560

 

Services transferred over time

 

 

388

 

 

 

341

 

 

 

805

 

 

 

697

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

Contract balances

 

A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.

 

Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the Condensed Consolidated Balance Sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of November 30, 2022 and May 31, 2022 were $3,705,000 and $2,484,000, respectively. During the three and six months ended November 30, 2022, the Company recognized $44,000 and $2,115,000, respectively, of revenues that were included in contract liabilities as of May 31, 2022.

 

Remaining performance obligations

 

On November 30, 2022, the Company had $135,000 of remaining performance obligations, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 49% of its remaining performance obligations as revenue in the remainder of fiscal 2023, and an additional 51% in fiscal 2024 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.

 

Costs to obtain or fulfill a contract

 

The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.

 

 
11

Table of Contents

 

4. EARNINGS PER SHARE

 

Basic earnings per share is determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted stock units (“RSUs”), Performance RSUs (“PRSUs”) and Amended and Restated 2006 Employee Stock Purchase Plan (“ESPP”) shares) outstanding during the period using the treasury stock method.

 

The following table presents the computation of basic and diluted net income per share (in thousands, except per share data):

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Numerator: Net income

 

$3,725

 

 

$717

 

 

$4,314

 

 

$1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic net income per share calculation

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

Effect of dilutive securities

 

 

1,501

 

 

 

2,137

 

 

 

1,524

 

 

 

1,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted net income per share

 

 

29,080

 

 

 

28,342

 

 

 

28,934

 

 

 

26,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

 

$0.14

 

 

$0.03

 

 

$0.16

 

 

$0.06

 

Diluted net income per share

 

$0.13

 

 

$0.03

 

 

$0.15

 

 

$0.05

 

 

For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. In the three and six months ended November 30, 2022, stock options to purchase 14,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive. In the three and six months ended November 30, 2021, stock options to purchase 5,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive.

 

 
12

Table of Contents

 

5. CASH, CASH EQUIVALENTS AND INVESTMENTS

 

The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2022 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,673

 

 

$-

 

 

$3,673

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

11,228

 

 

 

-

 

 

 

11,228

 

U.S. treasury securities

 

 

3,973

 

 

 

-

 

 

 

3,973

 

Total cash equivalents

 

 

15,201

 

 

 

-

 

 

 

15,201

 

Total cash and cash equivalents

 

$18,874

 

 

$-

 

 

$18,874

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,716

 

 

$6

 

 

$17,710

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

 

-

 

 

$80

 

Total cash, cash equivalents and investments

 

$36,670

 

 

$6

 

 

$36,664

 

 

Long-term investments are included in other assets on the accompanying condensed consolidated balance sheets.

 

Unrealized gains and temporary losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.

 

The unrealized loss of $6,000 as of November 30, 2022 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.

 

6. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.

 

The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

 

Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

 

Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.

 

Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.

 

 
13

Table of Contents

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2022 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

November 30, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$11,308

 

 

$11,308

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

21,683

 

 

 

21,683

 

 

 

-

 

 

 

-

 

Assets

 

$32,991

 

 

$32,991

 

 

$-

 

 

$-

 

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

 

 

Balance as of

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Assets

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

 

Included in money market funds as of November 30, 2022 and May 31, 2022 is $80,000 restricted cash representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.

 

There were no financial liabilities measured at fair value as of November 30, 2022 and May 31, 2022.

 

There were no transfers between Level 1 and Level 2 fair value measurements during the three months ended November 30, 2022.

 

The carrying amounts of financial instruments including cash equivalents, accounts receivable, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.

 

7. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET

 

Trade accounts receivable represents customer trade receivables. As of November 30, 2022 and May 31, 2022, there were no allowances for doubtful accounts. Trade accounts receivable is derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Other accounts receivable represents non-customer trade related receivables that are derived from the sale of raw materials to our subcontractors. The Company’s allowance for doubtful accounts is based upon historical experience and review of trade receivables by aging category to identify specific customers with known disputes or collection issues. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received.

 

8. INVENTORIES

 

Inventories are comprised of the following (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

Raw materials and sub-assemblies

 

$11,963

 

 

$9,507

 

Work in process

 

 

5,826

 

 

 

5,461

 

Finished goods

 

 

183

 

 

 

83

 

 

 

$17,972

 

 

$15,051

 

 

9. PRODUCT WARRANTIES

 

The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.

 

 
14

Table of Contents

 

 

The standard warranty period is one year for systems and ninety days for parts and service.

 

The following is a summary of changes in the Company’s liability for product warranties during the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the beginning of the period

 

$424

 

 

$505

 

 

$410

 

 

$494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accruals for warranties issued during the period

 

 

5

 

 

 

95

 

 

 

123

 

 

 

257

 

Adjustments to previously existing warranty accruals

 

 

-

 

 

 

72

 

 

 

61

 

 

 

72

 

Consumption of reserves

 

 

(118)

 

 

(257)

 

 

(283)

 

 

(408)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the end of the period

 

$311

 

 

$415

 

 

$311

 

 

$415

 

 

The accrued warranty balance is included in accrued expenses on the accompanying condensed consolidated balance sheets.

 

10. CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM

 

Customer deposits and deferred revenue, short-term (in thousands):

 

 

 

November 30,

 

 

 May 31,

 

 

 

2022

 

 

2022

 

Customer deposits

 

$3,561

 

 

$2,263

 

Deferred revenue

 

 

119

 

 

 

152

 

 

 

$3,680

 

 

$2,415

 

 

 

 

 

 

 

 

 

 

 

11. ACCUMULATED OTHER COMPREHENSIVE LOSS

 

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance at May 31, 2022

 

$(105)

 

$-

 

 

$(105)

Other comprehensive loss before reclassifications

 

 

(44)

 

 

(6)

 

 

(50)

Amounts reclassified out of accumulated other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive loss, net of tax

 

 

(44)

 

 

(6)

 

 

(155)

Balance at November 30, 2022

 

$(149)

 

$(6)

 

$(155)

 

 
15

Table of Contents

 

12. INCOME TAXES

 

The Company is subject to U.S federal and state and foreign income taxes as a corporation. The Company’s tax provision and the resulting effective tax rate for the interim period is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. The Company recorded a provision for income tax of $18,000 and $32,000 for the three and six months ended November 30, 2022 which consisted primarily of foreign withholding taxes and foreign income taxes. The Company recorded a provision for income tax of $34,000 and $57,000 for the three and six months ended November 30, 2021 which consisted primarily of foreign withholding taxes and foreign income taxes. The income tax provision was not significant due to available net operating loss and research and development credit carryforwards.

 

Income taxes have been provided using the liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and net operating loss and tax credit carryforwards measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse, or the carryforwards are utilized. Valuation allowances are established when it is determined that it is more likely than not that such assets will not be realized.

 

Since fiscal 2009, a full valuation allowance was established against all deferred tax assets, as management determined that it is more likely than not that certain deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions consistent with authoritative guidance. The guidance prescribes a “more likely than not” recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not expect any material change in its unrecognized tax benefits over the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income taxes.

 

13. LEASES

 

The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the condensed consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of 7 months to 3 years.

 

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

 

The weighted average remaining lease term for the Company’s operating leases was 1.0 years at November 30, 2022 and the weighted-average discount rate was 5.38%.

 

The Company’s operating lease cost was $189,000 and $379,000 for the three and six months ended November 30, 2022, respectively. The Company’s operating lease cost was $192,000 and $385,000 for the three and six months ended November 30, 2021, respectively.

 

 
16

Table of Contents

 

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

 

Six Months Ended

 

 

 

November 30,

 

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

Operating cash flows for operating leases

 

$415

 

 

$408

 

 

The following table presents the maturities of the Company’s operating lease liabilities as of November 30, 2022 (in thousands):

 

Fiscal year

 

Operating Leases

 

2023 (excluding the first six months of 2023)

 

$416

 

2024

 

 

168

 

2025

 

 

32

 

2026

 

 

18

 

Total future minimum operating lease payments

 

$634

 

Less: imputed interest

 

 

(18)

Present value of operating lease liabilities

 

$616

 

 

14. BORROWING AND FINANCING ARRANGEMENTS

 

On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base minus (b) the outstanding principal balance of any advances, under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.

 

On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.

 

 

 
17

Table of Contents

 

On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023. See note “18. SUBSEQUENT EVENTS” for the renewal of this Loan and Security Agreement.

 

At November 30, 2022, the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line at November 30, 2022 was $6,782,000. There are no financial covenants in the agreement.

 

15. LONG-TERM DEBT

 

On April 23, 2020, the Company obtained the Paycheck Protection Program Loan (the “PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matured on April 23, 2022 and bore interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.

 

Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. On June 12, 2021, the Company received confirmation from SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.

 

16. STOCK-BASED COMPENSATION

 

Stock-based compensation expense consists of expenses for stock options, RSUs, PRSUs, restricted shares, performance restricted shares and ESPP purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs and restricted shares, stock-based compensation cost is based on the fair value of the Company’s common stock at the grant date. All of the Company’s stock-based compensation is accounted for as an equity instrument. See Note 11 in the Company’s Annual Report on Form 10-K for fiscal 2022 filed on August 26, 2022 for further information regarding the 2016 Equity Incentive Plan (the “2016 Plan”) and the ESPP.

 

The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$85

 

 

$76

 

 

$177

 

 

$158

 

Selling, general and administrative

 

 

507

 

 

 

377

 

 

 

971

 

 

 

772

 

Research and development

 

 

201

 

 

 

265

 

 

 

355

 

 

 

376

 

Total stock-based compensation

 

$793

 

 

$718

 

 

$1,503

 

 

$1,306

 

 

As of November 30, 2022, there were $101,000 stock-based compensation expenses capitalized as part of inventory. As of November 30, 2021, there were no stock-based compensation expenses capitalized as part of inventory.

 

 
18

Table of Contents

 

During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $577,000 and $416,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $1,112,000 and $900,000, respectively.

 

As of November 30, 2022, the total compensation expense related to unvested stock-based awards under the 2016 Plan, but not yet recognized, was approximately $3,999,000, which is net of estimated forfeitures of $10,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.2 years.

 

During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $216,000 and $302,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $391,000 and $406,000, respectively.

 

As of November 30, 2022, the total compensation expense related to purchase rights under the ESPP but not yet recognized was approximately $527,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.0 year.

 

Valuation Assumptions

 

Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

 

Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

 

 
19

Table of Contents

 

Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

 

6

 

 

 

6

 

 

 

5

 

 

 

6

 

Volatility

 

 

112.45%

 

 

85%

 

 

116.41%

 

 

76%

Risk-free interest rate

 

 

4.07%

 

 

1.32%

 

 

3.10%

 

 

1.02%

Weighted average grant date fair value

 

$18.06

 

 

$14.16

 

 

$7.07

 

 

$2.50

 

 

The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2022 and 2021 were estimated using the following assumptions:

 

 

 

Three and Six Months Ended

 

 

Three and Six Months Ended

 

 

 

November 30, 2022

 

 

November 30, 2021

 

 

 

 

 

 

 

Expected term (in years)

 

0.5-2.0

 

 

0.5-2.0

 

Volatility

 

91%-203

%

 

101%-143

%

Risk-free interest rates

 

3.97%-4.12

%

 

0.05%-0.27

%

Weighted average grant date fair value

 

$11.17

 

 

$9.57

 

 

During the three and six months ended November 30, 2022, ESPP purchase rights of 43,000 were granted. During the three and six months ended November 30, 2021, ESPP purchase rights of 103,000 were granted. Total ESPP shares issued during the three and six months ended November 30, 2022 and 2021 were 109,000 and 75,000 shares, respectively. As of November 30, 2022 and 2021, there were 499,000 and 361,000 ESPP shares available for issuance, respectively.

 

The following tables summarize the Company’s stock option and RSU transactions during the three and six months ended November 30, 2022 (in thousands):

 

 

 

Available

 

 

 

Shares

 

Balance, May 31, 2022

 

 

1,826

 

 

 

 

 

 

Options granted

 

 

(103)

RSUs granted

 

 

(276)

Options cancelled and adjusted

 

 

6

 

 

 

 

 

 

Balance, August 31, 2022

 

 

1,453

 

Options granted

 

 

(5)

RSUs granted

 

 

(14)

 

 

 

 

 

Balance, November 30, 2022

 

 

1,434

 

 

The following table summarizes the stock option transactions during the three and six months ended November 30, 2022 (in thousands, except per share data):

 

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

103

 

 

$8.00

 

 

 

 

 

Options cancelled

 

 

(6)

 

$2.41

 

 

 

 

 

Options exercised

 

 

(102)

 

$2.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, August 31, 2022

 

 

1,592

 

 

$3.08

 

 

$18,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

4

 

 

$21.22

 

 

 

 

 

Options exercised

 

 

(168)

 

$2.31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

1,428

 

 

$3.23

 

 

$32,614

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at November 30, 2022

 

 

1,409

 

 

$3.23

 

 

$32,190

 

 

 
20

Table of Contents

 

The options outstanding and exercisable at November 30, 2022 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

at November 30, 2022

 

 

at November 30, 2022

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

51

 

 

 

4.89

 

 

$1.34

 

 

 

                      51

 

 

 

4.89

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

542

 

 

 

3.76

 

 

$1.71

 

 

 

385

 

 

 

3.61

 

 

$1.69

 

 

 

 

$2.03-$2.40

 

 

 

341

 

 

 

2.96

 

 

$2.21

 

 

 

328

 

 

 

2.87

 

 

$2.21

 

 

 

 

$2.76-$2.93

 

 

 

197

 

 

 

5.05

 

 

$2.91

 

 

 

65

 

 

 

3.89

 

 

$2.88

 

 

 

 

$3.46-$3.93

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

 

$8.00-$24.83

 

 

 

204

 

 

 

6.47

 

 

$9.52

 

 

 

23

 

 

 

6.38

 

 

$10.24

 

 

 

 

$1.34-$24.83

 

 

 

1,428

 

 

 

4.04

 

 

$3.23

 

 

 

945

 

 

 

3.32

 

 

$2.36

 

 

$22,412

 

 

The total intrinsic value of options exercised during the three and six months ended November 30, 2022 was $2,592,000 and $3,356,000, respectively. The total intrinsic value of options exercised during the three and six months ended November 30, 2021 was $9,133,000 and $11,035,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2022 was 4.02 years. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2021 was 4.22 years.

 

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

-

 

 

 

1,000

 

 

 

151,800

 

 

 

120,000

 

Weighted average market value on the date of the grant of annual RSUs

 

 

-

 

 

$24.57

 

 

$8.03

 

 

$3.17

 

Annual restricted shares granted

 

 

-

 

 

 

-

 

 

 

7,500

 

 

 

-

 

Weighted average market value on the date of the grant of annual restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions

 

 

-

 

 

 

-

 

 

 

-

 

 

 

89,000

 

Weighted average market value on the date of the grant of RSU in lieu of cash payment

 

 

-

 

 

 

-

 

 

 

-

 

 

$2.50

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

80,400

 

 

 

270,000

 

Performance restricted shares granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

23,700

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs, performance restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

$3.41

 

Stock-based compensation expense

 

$179,000

 

 

$

-

 

 

$283,000

 

 

$246,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

14,000

 

 

 

13,000

 

 

 

44,000

 

 

 

43,000

 

Weighted average market value on the date of the grant of RSUs

 

$18.50

 

 

$19.85

 

 

$11.35

 

 

$8.02

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

30,000

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

Stock-based compensation expense

 

$245,000

 

 

$

-

 

 

$490,000

 

 

$

-

 

 

 
21

Table of Contents

 

PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.

 

The following table summarizes the RSUs and PRSUs vested and unvested during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

60,000

 

 

 

18,000

 

 

 

202,000

 

 

 

29,000

 

Shares withheld to settle payroll taxes

 

 

2,000

 

 

 

-

 

 

 

150,000

 

 

 

-

 

RSUs and PRSUs unvested

 

 

394,000

 

 

 

237,000

 

 

 

394,000

 

 

 

237,000

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$10,272

 

 

$4,129

 

 

$10,272

 

 

$4,129

 

 

17. SEGMENT AND CONCENTRATION INFORMATION

 

The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note “3. REVENUE.”

 

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

United States

 

$1,210

 

 

$1,156

 

Asia

 

 

53

 

 

 

47

 

Europe

 

 

-

 

 

 

-

 

 

 

$1,263

 

 

$1,203

 

 

As of November 30, 2022, the operating lease right-of-use assets of $479,000 and $82,000 are allocated in the United States and Asia, respectively.

 

There were no revenues through distributors for the three and six months ended November 30, 2022 and 2021.

 

Sales to the Company’s five largest customers accounted for approximately 98% of its net sales for both the three and six months ended November 30, 2022. Two customers accounted for approximately 79% and 15% of the Company’s net sales in the three months ended November 30, 2022. Two customers accounted for approximately 74% and 18% of the Company’s net sales in the six months ended November 30, 2022. Sales to the Company’s five largest customers accounted for approximately 98% and 96% of its net sales in the three and six months ended November 30, 2021, respectively. One customer accounted for approximately 82% of the Company’s net sales in the three months ended November 30, 2021. One customer accounted for approximately 77% of the Company’s net sales in the six months ended November 30, 2021. No other customers represented more than 10% of the Company’s net sales in the three and six months ended November 30, 2022 and 2021.

 

 
22

Table of Contents

 

18. SUBSEQUENT EVENTS

 

On December 5, 2022, the Company entered into a Fourth Amendment to the lease agreement for the Company’s United States manufacturing and office facilities. The amendment extends the term of the lease for a period of eighty-six (86) calendar months, commencing on August 1, 2023 and expiring on September 30, 2030 (the “Expiration Date”) with an option for the Company to further extend the lease for one additional period of five (5) years after the Expiration Date. The amendment increases monthly base rent from $66,385 to $88,474 effective August 1, 2023, and an annual increase in monthly base rent of 4 percent throughout the remainder of the lease term. The amendment provides for two months of rent abatement, and an improvement allowance of up to $282,090.

 

On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record to that is generally acceptable to SVB, and (ii) the minimum net cash at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.

 

 
23

Table of Contents

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of the financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this Report and with our Annual Report on Form 10-K for the fiscal year ended May 31, 2022 and the consolidated financial statements and notes thereto.

 

In addition to historical information, this Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this Report, including those made by our management, other than statements of historical fact, are forward-looking statements. These statements typically may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “intend,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others and include, but are not limited to, statements concerning when we expect to recognize remaining performance obligations and statements concerning our expectations regarding our operations, business, strategies, prospects, revenues, expenses, costs and resources. These forward-looking statements include management’s judgments, estimates and assumptions and are subject to certain risks and uncertainties that could cause our actual results to differ materially from anticipated results or other expectations reflected in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Report and other factors beyond our control, and in particular, the risks discussed in “Part II, Item 1A. Risk Factors” and those discussed in other documents we file with the SEC. All forward-looking statements included in this document are based on our current expectations, and we undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://www.aehr.com/investor-relations/), SEC filings, press releases, public conference calls and webcasts. We use these channels to communicate with our investors and the public about our company, our products and services and other issues. It is possible that the information we post on our investor relations website could be deemed to be material information. Therefore, we encourage investors, the media and others interested in our company to review the information we post on our investor relations website.

 

OVERVIEW

 

We were founded in 1977 to develop and manufacture burn-in and test equipment for the semiconductor industry. Since our inception, we have sold more than 2,500 systems to semiconductor manufacturers, semiconductor contract assemblers and burn-in and test service companies worldwide. Our principal products currently are the FOX-XP, FOX-NP and FOX-CP wafer level and singulated die/module parallel test and burn-in systems, WaferPak Aligner, WaferPak contactors, DiePak Loader, DiePak carriers and test fixtures.

 

 
24

Table of Contents

 

Our net sales consist primarily of sales of systems, WaferPak Aligners and DiePak Loaders, WaferPak contactors, DiePak carriers, test fixtures, upgrades and spare parts, revenues from service contracts, and engineering development charges. Our selling arrangements may include contractual customer acceptance provisions, which are mostly deemed perfunctory or inconsequential, and installation of the product occurs after shipment and transfer of title.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to customer programs and incentives, product returns, bad debts, inventories, income taxes, financing obligations, warranty obligations, and long-term service contracts. Our estimates are derived from historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Those results form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a discussion of the critical accounting policies, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended May 31, 2022.

 

There have been no material changes to our critical accounting policies and estimates during the three and six months ended November 30, 2022 compared to those discussed in our Annual Report on Form 10-K for the fiscal year ended May 31, 2022.

 

RESULTS OF OPERATIONS

 

The following table sets forth items in our unaudited condensed consolidated statements of operations as a percentage of net sales for the periods indicated.

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

 

100.0%

 

 

100.0%

 

 

100.0%

 

 

100.0%

Cost of sales

 

 

46.6

 

 

 

53.0

 

 

 

51.4

 

 

 

55.4

 

Gross profit

 

 

53.4

 

 

 

47.0

 

 

 

48.6

 

 

 

44.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

19.4

 

 

 

25.9

 

 

 

21.2

 

 

 

29.1

 

Research and development

 

 

10.5

 

 

 

13.6

 

 

 

11.9

 

 

 

17.3

 

Total operating expenses

 

 

29.9

 

 

 

39.5

 

 

 

33.1

 

 

 

46.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

23.5

 

 

 

7.5

 

 

 

15.5

 

 

 

(1.8)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

1.8

 

 

 

--

 

 

 

1.5

 

 

 

(0.1)

Gain from forgiveness of PPP loan

 

 

--

 

 

 

--

 

 

 

--

 

 

 

11.1

 

Other (expense) income, net

 

 

--

 

 

 

0.3

 

 

 

0.1

 

 

 

0.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax expense

 

 

25.3

 

 

 

7.8

 

 

 

17.1

 

 

 

9.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

(0.2)

 

 

(0.3)

 

 

(0.2)

 

 

(0.3)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

25.1%

 

 

7.5%

 

 

16.9%

 

 

9.3%

 

 
25

Table of Contents

 

THREE MONTHS ENDED NOVEMBER 30, 2022 COMPARED TO THREE MONTHS ENDED NOVEMBER 30, 2021

 

NET SALES. Net sales increased to $14.8 million for the three months ended November 30, 2022 from $9.6 million for the three months ended November 30, 2021, an increase of 54.1%. The increase in net sales for the three months ended November 30, 2022 was primarily due to the increases in net sales of our wafer-level products. Net sales of our wafer-level products for the three months ended November 30, 2022 were $14.4 million, and increased approximately $5.3 million from the three months ended November 30, 2021 due to stronger demand related to silicon carbide applications.

 

GROSS PROFIT. Gross profit increased to $7.9 million for the three months ended November 30, 2022 from $4.5 million for the three months ended November 30, 2021, an increase of 75.1%. Gross profit margin increased to 53.4% for the three months ended November 30, 2022 from 47.0% for the three months ended November 30, 2021. The increase in gross profit margin of 6.4% was primarily due to manufacturing efficiencies from the increase in net sales resulting in a 2.4% gross profit margin increase, a decreased warranty provision resulting in a 1.7% gross profit margin increase, and a decrease in freight costs resulting in a 1.7% gross profit margin increase.

 

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses increased to $2.9 million for the three months ended November 30, 2022 from $2.5 million for the three months ended November 30, 2021, an increase of 15.5%. The increase in SG&A expenses was primarily the result of increases in headcount, bonuses, stock compensation and sales commissions.

 

RESEARCH AND DEVELOPMENT. R&D expenses increased to $1.6 million for the three months ended November 30, 2022 from $1.3 million for the three months ended November 30, 2021, an increase of 18.1%. The increase in R&D expenses was primarily due to increases in employment-related expenses and outside services.

 

INTEREST INCOME (EXPENSE), NET. Interest income, net was $263,000 for the three months ended November 30, 2022, compared with interest expense, net of $1,000 for the three months ended November 30, 2021. The interest income for the three months ended November 30, 2022 was due to interest earned on U.S. treasury and government securities.

 

OTHER (EXPENSE) INCOME, NET. Other expense, net was $5,000 for the three months ended November 30, 2022, compared with other income, net of $35,000 for the three months ended November 30, 2021. The changes were primarily due to fluctuations in the value of the dollar compared to foreign currencies during the referenced periods.

 

INCOME TAX EXPENSE. Income tax expense was $18,000 and $34,000 for the three months ended November 30, 2022 and 2021, respectively. Income tax expense was not significant due to available net operating loss and research and development credit carryforwards.

 

SIX MONTHS ENDED NOVEMBER 30, 2022 COMPARED TO SIX MONTHS ENDED NOVEMBER 30, 2021

 

NET SALES. Net sales increased to $25.5 million for the six months ended November 30, 2022 from $15.3 million for the six months ended November 30, 2021, an increase of 67.0%. The increase in net sales for the six months ended November 30, 2022 was primarily due to the increases in net sales of our wafer-level products. Net sales of our wafer-level products for the six months ended November 30, 2022 were $24.7 million, and increased approximately $10.5 million from the six months ended November 30, 2021 due to stronger demand related to silicon carbide applications.

 

 
26

Table of Contents

 

GROSS PROFIT. Gross profit increased to $12.4 million for the six months ended November 30, 2022 from $6.8 million for the six months ended November 30, 2021, an increase of 82.2%. Gross profit margin increased to 48.6% for the six months ended November 30, 2022 from 44.6% for the six months ended November 30, 2021. The increase in gross profit margin was primarily the result of manufacturing efficiencies due to an increase in net sales.

 

SELLING, GENERAL AND ADMINISTRATIVE. SG&A expenses increased to $5.4 million for the six months ended November 30, 2022 from $4.4 million for the six months ended November 30, 2021, an increase of 21.6%. The increase in SG&A expenses was primarily the result of increases in headcount, bonuses, stock compensation, and sales commissions.

 

RESEARCH AND DEVELOPMENT. R&D expenses increased to $3.0 million for the six months ended November 30, 2022 from $2.6 million for the six months ended November 30, 2021, an increase of 15.8%. The increase in R&D expenses was primarily due to increases in employment-related expenses and project expenses, partially offset by a decrease in outside services.

 

INTEREST INCOME (EXPENSE), NET. Interest income, net was $384,000 for the six months ended November 30, 2022, compared with interest expense, net of $10,000 for the six months ended November 30, 2021. The interest income for the six months ended November 30, 2022 was primarily due to interest earned on U.S. treasury and government securities. The interest expense for the six months ended November 30, 2021 was from the PPP Loan that we obtained on April 23, 2020.

 

GAIN FROM FORGIVENESS OF PPP LOAN. On June 12, 2021, we received confirmation from SVB that, on June 4, 2021, the Small Business Administration approved our PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000. As a result, we recognized a gain of $1,698,000.

 

OTHER (EXPENSE) INCOME, NET. Other income, net was $19,000 and $58,000 for the six months ended November 30, 2022 and 2021, respectively. The changes were primarily due to gains realized in connection with the fluctuation in the value of the dollar compared to foreign currencies during the referenced periods.

 

INCOME TAX EXPENSE. Income tax expense was $32,000 and $57,000 for the six months ended November 30, 2022 and 2021, respectively. Income tax expense was not significant due to available net operating loss and research and development credit carryforwards.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Net cash provided by operating activities was $5.3 million and $5.2 million for the six months ended November 30, 2022 and 2021, respectively. For the six months ended November 30, 2022, net cash provided by operating activities was primarily the result of net income of $4.3 million, a non-cash charge of stock-based compensation expense of $1.5 million and depreciation and amortization of $191,000. Other changes in cash from operations primarily resulted from a decrease in trade and other accounts receivable of $2.6 million, and an increase in customer deposits and deferred revenue of $1.2 million, partially offset by increases of $3.1 million and $196,000 in inventories, and prepaid expenses and other assets, respectively, and decreases of $1.0 million and $210,000 in accrued expenses and accounts payable, respectively. The decrease in accounts receivable was primarily due to the down payments from certain customers. The increase in customer deposits and deferred revenue was primarily due to the receipt of additional down payments from certain customers. The increase in inventory was due to purchasing to support expected future shipments for customer orders. The increase in prepaid expenses and other assets was primarily due to down payments to certain vendors and the renewal of insurance. The decrease in accrued expenses was primarily due to the payments of employees’ bonus and sales commissions. The decrease in accounts payable was primarily due to down payments applied toward vendor invoices. For the six months ended November 30, 2021, net cash provided by operating activities was primarily the result of net income of $1.4 million, as adjusted to exclude the effect of forgiveness of PPP loan of $1.7 million, and a non-cash charge of stock-based compensation expense of $1.3 million and depreciation and amortization of $149,000. Other changes in cash from operations primarily resulted from an increase in customer deposits and deferred revenue of $9.9 million, partially offset by increases in inventories of $4.2 million and accounts receivable of $2.3 million. The increase in customer deposits and deferred revenue was primarily due to the receipt of additional down payments from certain customers. The increase in inventory was to support expected future shipments for customer orders. The increase in accounts receivable was primarily due to an increase in sales for the six months ended November 30, 2021.

 

 
27

Table of Contents

 

Net cash used in investing activities was $17.8 million and $132,000 for the six months ended November 30, 2022 and 2021, respectively. During the six months ended November 30, 2022, net cash used in investing activities was due to the purchases of U.S. treasury securities of $17.7 million, and the purchases of property and equipment of $99,000. During the six months ended November 30, 2021, net cash used in investing activities was due to purchases of property and equipment.

 

Net cash used in financing activities was $104,000 for the six months ended November 30, 2022, compared with net cash provided by financing activities of $25.4 million for the six months ended November 30, 2021. Net cash used in financing activities during the six months ended November 30, 2022 was primarily due to the proceeds from issuance of common stock under employee plans of $1.1 million, offset by the shares repurchased for tax withholdings on vesting of RSUs of $1.2 million. Net cash provided by financing activities during the six months ended November 30, 2021 was primarily due to the net proceeds from issuance of common stock from public offering of $24.0 million, and the proceeds from the issuance of common stock under employee benefit plans of $3.0 million, partially offset by the shares repurchased for tax withholdings on vesting of RSUs of $259,000 and the net repayment of the line of credit of $1.4 million.

 

The effect of fluctuation in exchange rates decreased cash by $21,000 and $4,000 for the six months ended November 30, 2022 and 2021, respectively. The changes were due to the fluctuation in the value of the dollar compared to foreign currencies.

 

As of November 30, 2022 and May 31, 2022, we had working capital of $54.8 million and $49.0 million, respectively.

 

We lease our manufacturing and office space under operating leases. We entered into a non-cancelable operating lease agreement for our United States manufacturing and office facilities, which was renewed in December 2022 and expires in September 2030, see Note “18. SUBSEQUENT EVENTS.” As of November 30, 2022, our operating lease liabilities totaled $616,000. Under the lease agreement, we are responsible for payments of utilities, taxes and insurance.

 

From time to time, we evaluate potential acquisitions of businesses, products or technologies that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity. We have no present understandings, commitments or agreements with respect to any material acquisitions.

 

We anticipate that the existing cash balance and the available line of credit together with future income from operations, collections of existing accounts receivable, revenue from our existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet our working capital and capital equipment requirement needs over the next 12 months. Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, the timing and cost to introduce new and enhanced products and the timing and cost to implement new manufacturing technologies. While we successfully raised $25 million in the ATM public offering in October 2021 as a portion of a $75 million shelf registration, in the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. Any additional debt financing obtained by us in the future could also involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, if we raise additional funds through further issuances of equity, convertible debt securities or other securities convertible into equity, our existing stockholders could suffer significant dilution in their percentage ownership of the Company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.

 

 
28

Table of Contents

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We have not entered into any off-balance sheet financing arrangements and have not established any special purpose or variable interest entities.

 

OVERVIEW OF CONTRACTUAL OBLIGATIONS

 

There have been no material changes in the composition, magnitude or other key characteristics of our contractual obligations or other commitments as disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022, except the renewal of facility lease agreement, see Note “18. SUBSEQUENT EVENTS.”

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

 

We had no holdings of derivative financial or commodity instruments as of November 30, 2022 or May 31, 2022.

 

We are exposed to financial market risks, including changes in interest rates and foreign currency exchange rates. We only invest our short-term excess cash in government-backed securities with maturities of 12 months or less. We do not use any financial instruments for speculative or trading purposes. Fluctuations in interest rates would not have a material effect on our financial position, results of operations or cash flows.

 

A majority of our revenue and capital spending is transacted in U.S. Dollars. We also enter into transactions in other currencies, primarily Euros, New Taiwan Dollar, and Philippine Peso. Since our subsidiaries’ financial statements are based in their local currency and our condensed consolidated financial statements are based in U.S. Dollars, our subsidiaries and we recognize foreign exchange gains or losses in any period in which the value of the local currency rises or falls in relation to the U.S. Dollar. A 10% decrease in the value of the subsidiaries’ local currency as compared with the U.S. Dollar would not be expected to result in a significant change to our net income or loss. There have been no material changes in our risk exposure since the end of the last fiscal year, nor are any material changes to our risk exposure anticipated.

 

Item 4. CONTROLS AND PROCEDURES

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES. Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management as appropriate to allow for timely decisions regarding required disclosure.

 

 
29

Table of Contents

 

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING. There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

INHERENT LIMITATIONS OF INTERNAL CONTROLS. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within us have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

 
30

Table of Contents

 

PART II - OTHER INFORMATION

 

Item 1. LEGAL PROCEEDINGS

 

None.

 

Item 1A. RISK FACTORS

 

Please refer to the description of the risk factors associated with our business previously disclosed in Part I, Item 1A - “Risk Factors” of our Annual Report on Form 10-K for the year ended May 31, 2022 filed with the Securities and Exchange Commission on August 26, 2022.

 

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

Item 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

Item 5. OTHER INFORMATION

 

None.

 

 
31

Table of Contents

 

Item 6. EXHIBITS

 

Exhibit No.

 

Description

 

 

 

3.1(1)

 

Restated Articles of Incorporation of Registrant.

 

 

 

3.2(2)

 

Amended and Restated Bylaws of the Registrant.

 

 

 

10.1(3)

 

Fourth Amendment to Multi-Tenant Office Triple Net Lease, dated as of December 5, 2022, by and between Icon Owner Pool 1 SF Non-Business Parks, LLC and Aehr Test Systems.

 

 

 

31.1

 

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2

 

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1

 

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

(1) Incorporated by reference to the same-numbered exhibit previously filed with the Company’s Registration Statement on Form S-1 filed June 11, 1997 (File No. 333-28987).

 

(2) Incorporated by reference to Exhibit 3.1 previously filed with the Company’s Current Report on Form 8-K filed September 9, 2020 (File No. 000-22893).

 

(3) Incorporated by reference to Exhibit 10.1 previously filed with the Company’s Form 8-K filed with the SEC on December 8, 2022 (File No. 000-22893).

 

*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

 

 
32

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Aehr Test Systems

 

 

(Registrant)

 

 

 

 

 

Date: January 13, 2023

 By:

/s/ GAYN ERICKSON

 

 

 

Gayn Erickson

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

Date: January 13, 2023

 By:

/s/ KENNETH B. SPINK

 

 

 

Kenneth B. Spink

 

 

 

Vice President of Finance and Chief Financial Officer

 

 

 

(Principal Financial and Accounting Officer)

 

 

 
33

 

EX-31.1 2 aehr_ex311.htm CERTIFICATION aehr_ex311.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302(a) OF THE

SARBANES-OXLEY ACT

 

I, Gayn Erickson, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Aehr Test Systems;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 13, 2023

 /s/  GAYN ERICKSON

 

 

Gayn Erickson  
    President and Chief Executive Officer  
    (Principal Executive Officer)  

 

EX-31.2 3 aehr_ex312.htm CERTIFICATION aehr_ex312.htm

  EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302(a) OF THE

SARBANES-OXLEY ACT

 

I, Kenneth B. Spink, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of Aehr Test Systems;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 13, 2023 /s/ KENNETH B. SPINK

 

 

Kenneth B. Spink  
    Vice President of Finance and Chief Financial Officer  
    (Principal Financial and Accounting Officer)  

 

EX-32 4 aehr_ex32.htm CERTIFICATION aehr_ex32.htm

EXHIBIT 32

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Gayn Erickson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report of Aehr Test Systems on Form 10-Q for the period ended November 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Aehr Test Systems.

 

Date: January 13, 2023 By: /s/ GAYN ERICKSON

 

 

Gayn Erickson  
    President and Chief Executive Officer  

 

 

(Principal Executive Officer)

 

 

I, Kenneth B. Spink, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report of Aehr Test Systems on Form 10-Q for the period ended November 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Aehr Test Systems.

 

Date: January 13, 2023 By: /s/ KENNETH B. SPINK

 

 

Kenneth B. Spink  
    Vice President of Finance and  
    Chief Financial Officer  

 

 

(Principal Financial and Accounting Officer)

 

EX-101.SCH 5 aehr-20221130.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - PRODUCT WARRANTIES link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - PRODUCT WARRANTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - REVENUE (Details 1) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - REVENUE (Details 2) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - EARNINGS PER SHARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - PRODUCT WARRANTIES (Details) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - LEASES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000056 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000057 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000058 - Disclosure - LONGTERM DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000059 - Disclosure - STOCKBASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000060 - Disclosure - STOCKBASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000061 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 000062 - Disclosure - STOCKBASED COMPENSATION (Details 3) link:presentationLink link:calculationLink link:definitionLink 000063 - Disclosure - STOCK-BASED COMPENSATION (Details 4) link:presentationLink link:calculationLink link:definitionLink 000064 - Disclosure - STOCKBASED COMPENSATION (Details 5) link:presentationLink link:calculationLink link:definitionLink 000065 - Disclosure - STOCK-BASED COMPENSATION (Details 6) link:presentationLink link:calculationLink link:definitionLink 000066 - Disclosure - STOCK-BASED COMPENSATION (Details 7) link:presentationLink link:calculationLink link:definitionLink 000067 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000068 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 000069 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000070 - Disclosure - SUBSEQUENT EVENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 aehr-20221130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS Current assets: Cash and cash equivalents Short-term investments Trade and other accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets [Assets, Current] Property and equipment, net Operating lease right-of-use assets Other assets Total assets [Assets] LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Operating lease liabilities, short-term Customer deposits and deferred revenue, short-term Total current liabilities [Liabilities, Current] Operating lease liabilities, long-term Deferred revenue, long-term Other liabilities Total liabilities [Liabilities] Shareholders' equity: Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 27,732 shares and 27,120 shares at November 30, 2022 and May 31, 2022, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total shareholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and shareholders' equity [Liabilities and Equity] Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Net sales Cost of sales Gross profit [Gross Profit] Operating expenses: Selling, general and administrative Research and development Total operating expenses [Operating Expenses] Income (loss) from operations [Operating Income (Loss)] Interest income (expense), net Gain from forgiveness of PPP loan Other (expense) income, net Income before income tax expense [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income tax expense [Income Tax Expense (Benefit)] Net income [Net Income (Loss) Attributable to Parent] Net income per share Basic Diluted Shares used in per share calculations: Basic [Weighted Average Number of Shares Issued, Basic] Diluted [Weighted Average Number of Shares Outstanding, Diluted] CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Net income Other comprehensive (loss) income, net of tax: Net change in unrealized loss on investments Net change in cumulative translation adjustments Comprehensive income [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Income (loss) Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Issuance of common stock under employee plans, shares Issuance of common stock under employee plans, amount Shares repurchased for tax withholdings on vesting of restricted stock units, shares Shares repurchased for tax withholdings on vesting of restricted stock units, amount Proceeds from public offerings, net of issuance costs, shares Proceeds from public offerings, net of issuance costs, amount Stock-based compensation Net income Foreign currency translation adjustment Net unrealized loss on investments Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Cash flows from operating activities: Net income [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net income to net cash provided by operating activities: Stock-based compensation expense Provision for doubtful accounts Depreciation and amortization Accretion of investment discount [Accretion (Amortization) of Discounts and Premiums, Investments] Gain from forgiveness of PPP loan Changes in operating assets and liabilities: Trade and other accounts receivable Inventories [Increase (Decrease) in Inventories] Prepaid expenses and other assets [Prepaid expenses and other assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Customer deposits and deferred revenue Income taxes payable Net cash provided by operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from investing activities: Purchases of investments [Payments to Acquire Investments] Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Cash flows from financing activities: Line of credit repayments, net [Repayments of Lines of Credit] Proceeds from issuance of common stock under employee plans Shares repurchased for tax withholdings on vesting of restricted stock units [Payment, Tax Withholding, Share-Based Payment Arrangement] Proceeds from issuance of common stock from public offering, net of issuance costs Net cash (used in) provided by financing activities [Net cash (used in) provided by financing activities] Effect of exchange rates on cash, cash equivalents and restricted cash Net (decrease) increase in cash, cash equivalents and restricted cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash, cash equivalents and restricted cash, beginning of period(1) [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash, cash equivalents and restricted cash, end of period(1) BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] REVENUE REVENUE Revenue from Contract with Customer [Text Block] EARNINGS PER SHARE EARNINGS PER SHARE Earnings Per Share [Text Block] CASH, CASH EQUIVALENTS AND INVESTMENTS CASH, CASH EQUIVALENTS AND INVESTMENTS Cash and Cash Equivalents Disclosure [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] TRADE AND OTHER ACCOUNTS RECEIVABLE, NET TRADE AND OTHER ACCOUNTS RECEIVABLE, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] INVENTORIES INVENTORIES Inventory Disclosure [Text Block] PRODUCT WARRANTIES PRODUCT WARRANTIES Product Warranty Disclosure [Text Block] CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM ACCUMULATED OTHER COMPREHENSIVE LOSS ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] INCOME TAXES INCOME TAXES Income Tax Disclosure [Text Block] LEASES LEASES Lessee, Operating Leases [Text Block] BORROWING AND FINANCING ARRANGEMENTS BORROWING AND FINANCING ARRANGEMENTS: LONG-TERM DEBT LONG-TERM DEBT Long-Term Debt [Text Block] STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] SEGMENT AND CONCENTRATION INFORMATION SEGMENT AND CONCENTRATION INFORMATION Segment Reporting Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES Basis of Accounting, Policy [Policy Text Block] PRINCIPLES OF CONSOLIDATION ACCOUNTING ESTIMATES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements, Policy [Policy Text Block] Disaggregation of revenue Earnings per share Cash, cash equivalents and investments by security type Fair value by hierarchy Schedule of inventories Liability for product warranties CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables) Schedule of Customer deposits and deferred revenue Schedule of Changes in the components of accumulated other comprehensive loss, net of tax Supplemental cash flow information related to leases Maturity of operating lease liabilities Compensation costs related to the Company's stock-based compensation Fair value assumptions for Option Valuation Model Fair value assumptions of the ESPP purchase rights Stock option and RSU transactions Stock option transactions Options outstanding RSUs, PRSUs, restricted shares and performance restricted shares granted RSUs and PRSUs vested and unvested during period SEGMENT INFORMATION (Tables) Property and equipment by geographic region Product Or Service Axis Contactors Services Wafer-Level Test During Burn-In Systems Net Sales Plan Name Axis Statement Geographical Axis United States Asia Europe Net sales Timing Of Transfer Of Good Or Service Axis Products and Services Transferred at a Point in Time Services Transferred over Time Net sales Statement Scenario Axis Scenario Forecast [Member] Contract liabilities Recognition of contract liabilities Remaining performance obligations Remaining performance obligation revenue recognition Denominator for basic net income per share: weighted average shares outstanding Shares used in basic net income per share calculation Effect of dilutive securities Denominator for diluted net income per share Basic net income per share Diluted net income per share Award Type Axis Stock Option Options not included in the computation of diluted net income per share Defined Benefit Plan, Plan Assets, Category [Axis] Cost [Member] Gross Unrealized Loss Estimated Fair Value [Member] Money Market Funds [Member] US Treasury Securities [Member] Cash equivalents: Long-term investments: Cash Total cash and cash equivalents Total cash, cash equivalents and investments Short-term Investments Gross Unrealized Loss Unrealized loss Fair Value By Fair Value Hierarchy Level Axis Asset Class [Axis] Level 1 Assets [Member] Level 2 Level 3 U.S. treasury securities [Member] U.S. treasury securities [Member] Money Market Funds [Member] Investment securities Transfer between Level 1 and Level 2 fair value measurements Restricted cash Financial liabilities at fair value INVENTORIES (Details) Raw materials and sub-assemblies Work in process Finished goods Inventories PRODUCT WARRANTIES (Details) Balance at the beginning of the year [Standard and Extended Product Warranty Accrual] Accruals for warranties issued during the period Adjustments to previously existing warranty accruals Consumption of reserves [Standard and Extended Product Warranty Accrual, Decrease for Payments] Balance at the End of the year CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details) Total [Total] Customer deposits Deferred revenue Other Comprehensive Income Location [Axis] Cumulative Translation Adjustments [Member] Unrealized Loss on Investments, Net Member Balance at the beginning of the year Other comprehensive loss before reclassifications Amounts reclassified out of accumulated other comprehensive loss Other comprehensive loss, net of tax Balance at the ending of the year Provision For Income Tax Cash paid for amounts included in measurement of operating lease liabilities: Operating cash flows for operating leases LEASES (Details 1) Total future minimum operating lease payments Less: imputed interest [Lessee, Operating Lease, Liability, Undiscounted Excess Amount] Present value of operating lease liabilities 2023 (excluding the first three months of 2023) 2024 2025 2026 Range [Axis] Minimum [Member] Maximum [Member] Operating lease, weighted-average discount rate Operating lease, weighted-average remaining lease term Operating lease, cost Operating lease term Short-Term Debt, Type [Axis] Original Loan and Security Agreement Second Amendment To Loan And Security Agreement Customer Purchase Order First Amendment to Loan and Security Agreement Line of Credit, maximum borrowing Variable interest rate Borrowing under line of credit Balance available to borrow under the line of credit Revolving line maturity date Line Of Credit Facility Axis Silicon Valley Bank PPP loan Interest rate Total interest Recognized a gain on loan forgiveness STOCKBASED COMPENSATION (Details) Income Statement Location Axis Cost of Sales Selling, General and Administrative Research and Development Total stock-based compensation Expected term (in years) Volatility Risk-free interest rates Weighted-average grant date fair value Employee Stock Ownership Plan E S O P Disclosures By Plan Axis Maximum Employee Stock Purchase Plan Minimum Weighted-average grant date fair value [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value] Expected term (in years) Volatility Risk-free interest rates Stock Option and RSU Transactions [Member] Available shares, beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant] Options granted [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross] RSUs granted [RSUs granted] Options cancelled and adjusted Available shares, ending Outstanding Options Stock Option Transactions Options outstanding, beginning (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Options granted (in thousands) Options cancelled (in thousands) Options exercised (in thousands) [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period] Options outstanding, ending (in thousands) Options fully vested and expected to vest (in thousands) Weighted average exercise price outstanding, beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted average exercise price granted Weighted average exercise price cancelled Weighted average exercise price exercised Weighted average exercise price outstanding, ending Weighted average exercise price fully vested and expected to vest Aggregate intrinsic value, beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value] Aggregate intrinsic value, ending Aggregate intrinsic value for options fully vested and expected to vest Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis $1.34 $1.64-$1.86 $2.03-$2.40 $2.76-$2.93 $3.46-$3.93 $8.00-$24.83 $1.34-$24.83 Options outstanding, ending (in thousands) | shares Weighted average remaining contractual life (Years) options outstanding Weighted average exercise price outstanding, ending | $ / shares Option exercisable shares (in thousands) Weighted average remaining contractual life (Years) options exercisable Weighted average exercise price for options exercisable | $ / shares Aggregate intrinsic value for options exercisable | Employees Member Board Of Directors Annual RSUs granted Weighted average market value on the date of the grant of annual RSUs Annual restricted shares granted Weighted average market value on the date of the grant of annual restricted shares RSUs granted in lieu of cash payment for salary reductions Weighted average market value on the date of the grant of RSU in lieu of cash payment PRSUs granted based on revenue target thresholds maximum Performance restricted shares granted based on revenue target thresholds maximum Weighted average market value on the date of the grant of PRSUs, performance restricted shares Stock-based compensation expense [Stock or Unit Option Plan Expense] Weighted average market value on the date of the grant of PRSUs Net RSUs and PRSUs vested Shares withheld to settle payroll taxes RSUs and PRSUs unvested Intrinsic value of unvested RSUs and PRSUs (in thousands) Stock Option and RSU 2016 Equity Incentive Plan Employee Stock Purchase Plan Total intrinsic values of options exercised Stock Based Compensation Costs Capitalized As part of inventory Weighted average remaining contractual life of the options exercisable and expected to be exercisable ESPP purchase right granted ESPP share issued Unrecognized stock-based compensation Weighted average period for recognition of costs ESPP shares available for issuance Stock-based compensation related to the ESPP Stock-based compensation expense related to stock options and RSUs Estimated forfeitures of unvested stock based awards, amount SEGMENT AND CONCENTRATION INFORMATION (Details) United States [United States] Europe Europe [Member] Property and equipment, net SEGMENT AND CONCENTRATION INFORMATION (Details Narrative) Major Customers Axis Concentration Risk By Type Axis Segments [Axis] Five Largest Customers [Member] Customer A [Member] Customers B [Member] United States [Member] Asia [Member] Customers accounted for 10% or more of total revenues Operating lease right-of-use assets Subsequent Event Type [Axis] SUBSEQUENT EVENTS Subsequent Event [Member] Description of changes in monthly base rent Improvement allowance Revolving line matuity date Fourth amendment Lease expiry date Description about amendment third agreemnet Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. EX-101.CAL 7 aehr-20221130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 aehr-20221130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 aehr-20221130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - shares
6 Months Ended
Nov. 30, 2022
Dec. 31, 2022
Cover [Abstract]    
Entity Registrant Name AEHR TEST SYSTEMS  
Entity Central Index Key 0001040470  
Document Type 10-Q  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Current Reporting Status Yes  
Document Period End Date Nov. 30, 2022  
Entity Filer Category Non-accelerated Filer  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Entity Common Stock Shares Outstanding   27,759,445
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-22893  
Entity Incorporation State Country Code CA  
Entity Tax Identification Number 94-2424084  
Entity Address Address Line 1 400 Kato Terrace  
Entity Address City Or Town Fremont  
Entity Address State Or Province CA  
Entity Address Postal Zip Code 94539  
City Area Code 510  
Local Phone Number 623-9400  
Security 12b Title Common Stock Par value of $0.01 per share  
Trading Symbol AEHR  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Nov. 30, 2022
May 31, 2022
Current assets:    
Cash and cash equivalents $ 18,874 $ 31,484
Short-term investments 17,710 0
Trade and other accounts receivable, net 10,156 12,859
Inventories 17,972 15,051
Prepaid expenses and other current assets 823 613
Total current assets 65,535 60,007
Property and equipment, net 1,263 1,203
Operating lease right-of-use assets 561 917
Other assets 184 201
Total assets 67,543 62,328
Current liabilities:    
Accounts payable 3,949 4,195
Accrued expenses 2,566 3,610
Operating lease liabilities, short-term 551 794
Customer deposits and deferred revenue, short-term 3,680 2,415
Total current liabilities 10,746 11,014
Operating lease liabilities, long-term 65 212
Deferred revenue, long-term 25 69
Other liabilities 40 44
Total liabilities 10,876 11,339
Shareholders' equity:    
Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 27,732 shares and 27,120 shares at November 30, 2022 and May 31, 2022, respectively 277 271
Additional paid-in capital 119,094 117,686
Accumulated other comprehensive loss (155) (105)
Accumulated deficit (62,549) (66,863)
Total shareholders' equity 56,667 50,989
Total liabilities and shareholders' equity $ 67,543 $ 62,328
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Nov. 30, 2022
May 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS    
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 27,732,000 27,120,000
Common stock, shares outstanding 27,732,000 27,120,000
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)        
Net sales $ 14,815 $ 9,611 $ 25,486 $ 15,257
Cost of sales 6,904 5,092 13,094 8,457
Gross profit 7,911 4,519 12,392 6,800
Operating expenses:        
Selling, general and administrative 2,875 2,489 5,400 4,442
Research and development 1,551 1,313 3,049 2,634
Total operating expenses 4,426 3,802 8,449 7,076
Income (loss) from operations 3,485 717 3,943 (276)
Interest income (expense), net 263 (1) 384 (10)
Gain from forgiveness of PPP loan 0 0 0 1,698
Other (expense) income, net (5) 35 19 58
Income before income tax expense 3,743 751 4,346 1,470
Income tax expense (18) (34) (32) (57)
Net income $ 3,725 $ 717 $ 4,314 $ 1,413
Net income per share        
Basic $ 0.14 $ 0.03 $ 0.16 $ 0.06
Diluted $ 0.13 $ 0.03 $ 0.15 $ 0.05
Shares used in per share calculations:        
Basic 27,579 26,205 27,410 25,102
Diluted 29,080 28,342 28,934 26,849
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)        
Net income $ 3,725 $ 717 $ 4,314 $ 1,413
Other comprehensive (loss) income, net of tax:        
Net change in unrealized loss on investments (6) 0 (6) 0
Net change in cumulative translation adjustments 1 (44) (44) (80)
Comprehensive income $ 3,720 $ 673 $ 4,264 $ 1,333
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (loss)
Accumulated Deficit
Balance, shares at May. 31, 2021   23,725      
Balance, amount at May. 31, 2021 $ 11,449 $ 237 $ 87,553 $ (28) $ (76,313)
Issuance of common stock under employee plans, shares   1,461      
Issuance of common stock under employee plans, amount 3,003 $ 14 2,989 0 0
Shares repurchased for tax withholdings on vesting of restricted stock units, shares   (48)      
Shares repurchased for tax withholdings on vesting of restricted stock units, amount (259) $ 0 (259) 0 0
Proceeds from public offerings, net of issuance costs, shares   1,697      
Proceeds from public offerings, net of issuance costs, amount 24,030 $ 17 24,013 0 0
Stock-based compensation 1,306 0 1,306 0 0
Net income 1,413 0 0 0 1,413
Foreign currency translation adjustment (80) $ 0 0 (80) 0
Balance, shares at Nov. 30, 2021   26,835      
Balance, amount at Nov. 30, 2021 40,862 $ 268 115,602 (108) (74,900)
Balance, shares at Aug. 31, 2021   24,483      
Balance, amount at Aug. 31, 2021 14,232 $ 245 89,668 (64) (75,617)
Issuance of common stock under employee plans, shares   663      
Issuance of common stock under employee plans, amount 1,366 $ 6 1,360 0 0
Shares repurchased for tax withholdings on vesting of restricted stock units, shares   (8)      
Shares repurchased for tax withholdings on vesting of restricted stock units, amount (157) $ 0 (157) 0 0
Proceeds from public offerings, net of issuance costs, shares   1,697      
Proceeds from public offerings, net of issuance costs, amount 24,030 $ 17 24,013 0 0
Stock-based compensation 718 0 718 0 0
Net income 717 0 0 0 717
Foreign currency translation adjustment (44) $ 0 0 (44) 0
Balance, shares at Nov. 30, 2021   26,835      
Balance, amount at Nov. 30, 2021 40,862 $ 268 115,602 (108) (74,900)
Balance, shares at May. 31, 2022   27,120      
Balance, amount at May. 31, 2022 50,989 $ 271 117,686 (105) (66,863)
Issuance of common stock under employee plans, shares   761      
Issuance of common stock under employee plans, amount 1,112 $ 7 1,105 0 0
Shares repurchased for tax withholdings on vesting of restricted stock units, shares   (149)      
Shares repurchased for tax withholdings on vesting of restricted stock units, amount (1,216) $ (1) (1,215) 0 0
Stock-based compensation 1,518 0 1,518 0 0
Net income 4,314 0 0 0 4,314
Foreign currency translation adjustment (44) 0 0 (44) 0
Net unrealized loss on investments (6) $ 0 0 (6) 0
Balance, shares at Nov. 30, 2022   27,732      
Balance, amount at Nov. 30, 2022 56,667 $ 277 119,094 (155) (62,549)
Balance, shares at Aug. 31, 2022   27,395      
Balance, amount at Aug. 31, 2022 51,518 $ 274 117,668 (150) (66,274)
Issuance of common stock under employee plans, shares   339      
Issuance of common stock under employee plans, amount 657 $ 3 654 0 0
Shares repurchased for tax withholdings on vesting of restricted stock units, shares   (2)      
Shares repurchased for tax withholdings on vesting of restricted stock units, amount (37) $ 0 (37) 0 0
Stock-based compensation 809 0 809 0 0
Net income 3,725 0 0 0 3,725
Foreign currency translation adjustment 1 0 0 1 0
Net unrealized loss on investments (6) $ 0 0 (6) 0
Balance, shares at Nov. 30, 2022   27,732      
Balance, amount at Nov. 30, 2022 $ 56,667 $ 277 $ 119,094 $ (155) $ (62,549)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Cash flows from operating activities:    
Net income $ 4,314 $ 1,413
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 1,503 1,306
Provision for doubtful accounts 24 0
Depreciation and amortization 191 149
Accretion of investment discount (64) 0
Gain from forgiveness of PPP loan 0 (1,698)
Changes in operating assets and liabilities:    
Trade and other accounts receivable 2,618 (2,284)
Inventories (3,094) (4,212)
Prepaid expenses and other assets 196 60
Accounts payable (210) 512
Accrued expenses (1,045) 104
Customer deposits and deferred revenue 1,221 9,970
Income taxes payable 4 11
Net cash provided by operating activities 5,266 5,211
Cash flows from investing activities:    
Purchases of investments (17,652) 0
Purchases of property and equipment (99) (132)
Net cash used in investing activities (17,751) (132)
Cash flows from financing activities:    
Line of credit repayments, net 0 (1,400)
Proceeds from issuance of common stock under employee plans 1,112 3,003
Shares repurchased for tax withholdings on vesting of restricted stock units (1,216) (259)
Proceeds from issuance of common stock from public offering, net of issuance costs 0 24,030
Net cash (used in) provided by financing activities (104) 25,374
Effect of exchange rates on cash, cash equivalents and restricted cash (21) (4)
Net (decrease) increase in cash, cash equivalents and restricted cash (12,610) 30,449
Cash, cash equivalents and restricted cash, beginning of period(1) 31,564 4,662
Cash, cash equivalents and restricted cash, end of period(1) $ 18,954 $ 35,111
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES
6 Months Ended
Nov. 30, 2022
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES

1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES

 

The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations.

 

In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 2022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.

 

PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.

 

ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.

 

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended November 30, 2022.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.4
RECENT ACCOUNTING PRONOUNCEMENTS
6 Months Ended
Nov. 30, 2022
RECENT ACCOUNTING PRONOUNCEMENTS  
RECENT ACCOUNTING PRONOUNCEMENTS

2. RECENT ACCOUNTING PRONOUNCEMENTS

 

Accounting Standards Not Yet Adopted

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis, with early adoption in or after fiscal 2021 permitted. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE
6 Months Ended
Nov. 30, 2022
REVENUE  
REVENUE

3. REVENUE

 

Revenue recognition

 

The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.

 

Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.

 

A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.

 

For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to historical discounting trends for products and services and pricing practices in different geographies.

 

Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.

 

The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.

 

The Company sells its products primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors.

 

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.

 

Disaggregation of revenue

 

The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.

 

The Company’s revenues by product category are as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

 

 

 

Systems

 

$7,400

 

 

$3,754

 

 

$16,494

 

 

$7,633

 

Contactors

 

 

6,607

 

 

 

5,090

 

 

 

7,101

 

 

 

6,042

 

Services

 

 

808

 

 

 

767

 

 

 

1,891

 

 

 

1,582

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$14,401

 

 

$9,107

 

 

$24,723

 

 

$14,250

 

Test During Burn-In

 

 

414

 

 

 

504

 

 

 

763

 

 

 

1,007

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$2,555

 

 

$895

 

 

$5,418

 

 

$1,401

 

Asia

 

 

12,216

 

 

 

8,716

 

 

 

20,024

 

 

 

13,853

 

Europe

 

 

44

 

 

 

-

 

 

 

44

 

 

 

3

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at the point in time when control transfers to customers. The following presents revenue based on timing of recognition (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

 

 

 

Products and services transferred at a point in time

 

$14,427

 

 

$9,270

 

 

$24,681

 

 

$14,560

 

Services transferred over time

 

 

388

 

 

 

341

 

 

 

805

 

 

 

697

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

Contract balances

 

A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.

 

Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the Condensed Consolidated Balance Sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of November 30, 2022 and May 31, 2022 were $3,705,000 and $2,484,000, respectively. During the three and six months ended November 30, 2022, the Company recognized $44,000 and $2,115,000, respectively, of revenues that were included in contract liabilities as of May 31, 2022.

 

Remaining performance obligations

 

On November 30, 2022, the Company had $135,000 of remaining performance obligations, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 49% of its remaining performance obligations as revenue in the remainder of fiscal 2023, and an additional 51% in fiscal 2024 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.

 

Costs to obtain or fulfill a contract

 

The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.4
EARNINGS PER SHARE
6 Months Ended
Nov. 30, 2022
EARNINGS PER SHARE  
EARNINGS PER SHARE

4. EARNINGS PER SHARE

 

Basic earnings per share is determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted stock units (“RSUs”), Performance RSUs (“PRSUs”) and Amended and Restated 2006 Employee Stock Purchase Plan (“ESPP”) shares) outstanding during the period using the treasury stock method.

 

The following table presents the computation of basic and diluted net income per share (in thousands, except per share data):

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Numerator: Net income

 

$3,725

 

 

$717

 

 

$4,314

 

 

$1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic net income per share calculation

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

Effect of dilutive securities

 

 

1,501

 

 

 

2,137

 

 

 

1,524

 

 

 

1,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted net income per share

 

 

29,080

 

 

 

28,342

 

 

 

28,934

 

 

 

26,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

 

$0.14

 

 

$0.03

 

 

$0.16

 

 

$0.06

 

Diluted net income per share

 

$0.13

 

 

$0.03

 

 

$0.15

 

 

$0.05

 

 

For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. In the three and six months ended November 30, 2022, stock options to purchase 14,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive. In the three and six months ended November 30, 2021, stock options to purchase 5,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.4
CASH, CASH EQUIVALENTS AND INVESTMENTS
6 Months Ended
Nov. 30, 2022
CASH, CASH EQUIVALENTS AND INVESTMENTS  
CASH, CASH EQUIVALENTS AND INVESTMENTS

5. CASH, CASH EQUIVALENTS AND INVESTMENTS

 

The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2022 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,673

 

 

$-

 

 

$3,673

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

11,228

 

 

 

-

 

 

 

11,228

 

U.S. treasury securities

 

 

3,973

 

 

 

-

 

 

 

3,973

 

Total cash equivalents

 

 

15,201

 

 

 

-

 

 

 

15,201

 

Total cash and cash equivalents

 

$18,874

 

 

$-

 

 

$18,874

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,716

 

 

$6

 

 

$17,710

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

 

-

 

 

$80

 

Total cash, cash equivalents and investments

 

$36,670

 

 

$6

 

 

$36,664

 

 

Long-term investments are included in other assets on the accompanying condensed consolidated balance sheets.

 

Unrealized gains and temporary losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.

 

The unrealized loss of $6,000 as of November 30, 2022 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE OF FINANCIAL INSTRUMENTS
6 Months Ended
Nov. 30, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS  
FAIR VALUE OF FINANCIAL INSTRUMENTS

6. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.

 

The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

 

Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.

 

Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.

 

Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2022 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

November 30, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$11,308

 

 

$11,308

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

21,683

 

 

 

21,683

 

 

 

-

 

 

 

-

 

Assets

 

$32,991

 

 

$32,991

 

 

$-

 

 

$-

 

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

 

 

Balance as of

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Assets

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

 

Included in money market funds as of November 30, 2022 and May 31, 2022 is $80,000 restricted cash representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.

 

There were no financial liabilities measured at fair value as of November 30, 2022 and May 31, 2022.

 

There were no transfers between Level 1 and Level 2 fair value measurements during the three months ended November 30, 2022.

 

The carrying amounts of financial instruments including cash equivalents, accounts receivable, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.4
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET
6 Months Ended
Nov. 30, 2022
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET  
TRADE AND OTHER ACCOUNTS RECEIVABLE, NET

7. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET

 

Trade accounts receivable represents customer trade receivables. As of November 30, 2022 and May 31, 2022, there were no allowances for doubtful accounts. Trade accounts receivable is derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Other accounts receivable represents non-customer trade related receivables that are derived from the sale of raw materials to our subcontractors. The Company’s allowance for doubtful accounts is based upon historical experience and review of trade receivables by aging category to identify specific customers with known disputes or collection issues. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received.

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.4
INVENTORIES
6 Months Ended
Nov. 30, 2022
INVENTORIES  
INVENTORIES

8. INVENTORIES

 

Inventories are comprised of the following (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

Raw materials and sub-assemblies

 

$11,963

 

 

$9,507

 

Work in process

 

 

5,826

 

 

 

5,461

 

Finished goods

 

 

183

 

 

 

83

 

 

 

$17,972

 

 

$15,051

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.4
PRODUCT WARRANTIES
6 Months Ended
Nov. 30, 2022
PRODUCT WARRANTIES  
PRODUCT WARRANTIES

9. PRODUCT WARRANTIES

 

The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.

 

The standard warranty period is one year for systems and ninety days for parts and service.

 

The following is a summary of changes in the Company’s liability for product warranties during the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the beginning of the period

 

$424

 

 

$505

 

 

$410

 

 

$494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accruals for warranties issued during the period

 

 

5

 

 

 

95

 

 

 

123

 

 

 

257

 

Adjustments to previously existing warranty accruals

 

 

-

 

 

 

72

 

 

 

61

 

 

 

72

 

Consumption of reserves

 

 

(118)

 

 

(257)

 

 

(283)

 

 

(408)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the end of the period

 

$311

 

 

$415

 

 

$311

 

 

$415

 

 

The accrued warranty balance is included in accrued expenses on the accompanying condensed consolidated balance sheets.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.4
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM
6 Months Ended
Nov. 30, 2022
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM  
CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM

10. CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM

 

Customer deposits and deferred revenue, short-term (in thousands):

 

 

 

November 30,

 

 

 May 31,

 

 

 

2022

 

 

2022

 

Customer deposits

 

$3,561

 

 

$2,263

 

Deferred revenue

 

 

119

 

 

 

152

 

 

 

$3,680

 

 

$2,415

 

 

 

 

 

 

 

 

 

 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE LOSS
6 Months Ended
Nov. 30, 2022
ACCUMULATED OTHER COMPREHENSIVE LOSS  
ACCUMULATED OTHER COMPREHENSIVE LOSS

11. ACCUMULATED OTHER COMPREHENSIVE LOSS

 

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance at May 31, 2022

 

$(105)

 

$-

 

 

$(105)

Other comprehensive loss before reclassifications

 

 

(44)

 

 

(6)

 

 

(50)

Amounts reclassified out of accumulated other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive loss, net of tax

 

 

(44)

 

 

(6)

 

 

(155)

Balance at November 30, 2022

 

$(149)

 

$(6)

 

$(155)
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES
6 Months Ended
Nov. 30, 2022
INCOME TAXES  
INCOME TAXES

12. INCOME TAXES

 

The Company is subject to U.S federal and state and foreign income taxes as a corporation. The Company’s tax provision and the resulting effective tax rate for the interim period is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. The Company recorded a provision for income tax of $18,000 and $32,000 for the three and six months ended November 30, 2022 which consisted primarily of foreign withholding taxes and foreign income taxes. The Company recorded a provision for income tax of $34,000 and $57,000 for the three and six months ended November 30, 2021 which consisted primarily of foreign withholding taxes and foreign income taxes. The income tax provision was not significant due to available net operating loss and research and development credit carryforwards.

 

Income taxes have been provided using the liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and net operating loss and tax credit carryforwards measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse, or the carryforwards are utilized. Valuation allowances are established when it is determined that it is more likely than not that such assets will not be realized.

 

Since fiscal 2009, a full valuation allowance was established against all deferred tax assets, as management determined that it is more likely than not that certain deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions consistent with authoritative guidance. The guidance prescribes a “more likely than not” recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not expect any material change in its unrecognized tax benefits over the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income taxes.

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES
6 Months Ended
Nov. 30, 2022
LEASES  
LEASES

13. LEASES

 

The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the condensed consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of 7 months to 3 years.

 

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

 

The weighted average remaining lease term for the Company’s operating leases was 1.0 years at November 30, 2022 and the weighted-average discount rate was 5.38%.

 

The Company’s operating lease cost was $189,000 and $379,000 for the three and six months ended November 30, 2022, respectively. The Company’s operating lease cost was $192,000 and $385,000 for the three and six months ended November 30, 2021, respectively.

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

 

Six Months Ended

 

 

 

November 30,

 

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

Operating cash flows for operating leases

 

$415

 

 

$408

 

 

The following table presents the maturities of the Company’s operating lease liabilities as of November 30, 2022 (in thousands):

 

Fiscal year

 

Operating Leases

 

2023 (excluding the first six months of 2023)

 

$416

 

2024

 

 

168

 

2025

 

 

32

 

2026

 

 

18

 

Total future minimum operating lease payments

 

$634

 

Less: imputed interest

 

 

(18)

Present value of operating lease liabilities

 

$616

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.4
BORROWING AND FINANCING ARRANGEMENTS
6 Months Ended
Nov. 30, 2022
BORROWING AND FINANCING ARRANGEMENTS  
BORROWING AND FINANCING ARRANGEMENTS:

14. BORROWING AND FINANCING ARRANGEMENTS

 

On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base minus (b) the outstanding principal balance of any advances, under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.

 

On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.

 

On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023. See note “18. SUBSEQUENT EVENTS” for the renewal of this Loan and Security Agreement.

 

At November 30, 2022, the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line at November 30, 2022 was $6,782,000. There are no financial covenants in the agreement.

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.4
LONG-TERM DEBT
6 Months Ended
Nov. 30, 2022
LONG-TERM DEBT  
LONG-TERM DEBT

15. LONG-TERM DEBT

 

On April 23, 2020, the Company obtained the Paycheck Protection Program Loan (the “PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matured on April 23, 2022 and bore interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.

 

Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. On June 12, 2021, the Company received confirmation from SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION
6 Months Ended
Nov. 30, 2022
STOCK-BASED COMPENSATION  
STOCK-BASED COMPENSATION

16. STOCK-BASED COMPENSATION

 

Stock-based compensation expense consists of expenses for stock options, RSUs, PRSUs, restricted shares, performance restricted shares and ESPP purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs and restricted shares, stock-based compensation cost is based on the fair value of the Company’s common stock at the grant date. All of the Company’s stock-based compensation is accounted for as an equity instrument. See Note 11 in the Company’s Annual Report on Form 10-K for fiscal 2022 filed on August 26, 2022 for further information regarding the 2016 Equity Incentive Plan (the “2016 Plan”) and the ESPP.

 

The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$85

 

 

$76

 

 

$177

 

 

$158

 

Selling, general and administrative

 

 

507

 

 

 

377

 

 

 

971

 

 

 

772

 

Research and development

 

 

201

 

 

 

265

 

 

 

355

 

 

 

376

 

Total stock-based compensation

 

$793

 

 

$718

 

 

$1,503

 

 

$1,306

 

 

As of November 30, 2022, there were $101,000 stock-based compensation expenses capitalized as part of inventory. As of November 30, 2021, there were no stock-based compensation expenses capitalized as part of inventory.

During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $577,000 and $416,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $1,112,000 and $900,000, respectively.

 

As of November 30, 2022, the total compensation expense related to unvested stock-based awards under the 2016 Plan, but not yet recognized, was approximately $3,999,000, which is net of estimated forfeitures of $10,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.2 years.

 

During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $216,000 and $302,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $391,000 and $406,000, respectively.

 

As of November 30, 2022, the total compensation expense related to purchase rights under the ESPP but not yet recognized was approximately $527,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.0 year.

 

Valuation Assumptions

 

Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.

 

Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.

 

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.

Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

 

6

 

 

 

6

 

 

 

5

 

 

 

6

 

Volatility

 

 

112.45%

 

 

85%

 

 

116.41%

 

 

76%

Risk-free interest rate

 

 

4.07%

 

 

1.32%

 

 

3.10%

 

 

1.02%

Weighted average grant date fair value

 

$18.06

 

 

$14.16

 

 

$7.07

 

 

$2.50

 

 

The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2022 and 2021 were estimated using the following assumptions:

 

 

 

Three and Six Months Ended

 

 

Three and Six Months Ended

 

 

 

November 30, 2022

 

 

November 30, 2021

 

 

 

 

 

 

 

Expected term (in years)

 

0.5-2.0

 

 

0.5-2.0

 

Volatility

 

91%-203

%

 

101%-143

%

Risk-free interest rates

 

3.97%-4.12

%

 

0.05%-0.27

%

Weighted average grant date fair value

 

$11.17

 

 

$9.57

 

 

During the three and six months ended November 30, 2022, ESPP purchase rights of 43,000 were granted. During the three and six months ended November 30, 2021, ESPP purchase rights of 103,000 were granted. Total ESPP shares issued during the three and six months ended November 30, 2022 and 2021 were 109,000 and 75,000 shares, respectively. As of November 30, 2022 and 2021, there were 499,000 and 361,000 ESPP shares available for issuance, respectively.

 

The following tables summarize the Company’s stock option and RSU transactions during the three and six months ended November 30, 2022 (in thousands):

 

 

 

Available

 

 

 

Shares

 

Balance, May 31, 2022

 

 

1,826

 

 

 

 

 

 

Options granted

 

 

(103)

RSUs granted

 

 

(276)

Options cancelled and adjusted

 

 

6

 

 

 

 

 

 

Balance, August 31, 2022

 

 

1,453

 

Options granted

 

 

(5)

RSUs granted

 

 

(14)

 

 

 

 

 

Balance, November 30, 2022

 

 

1,434

 

 

The following table summarizes the stock option transactions during the three and six months ended November 30, 2022 (in thousands, except per share data):

 

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

103

 

 

$8.00

 

 

 

 

 

Options cancelled

 

 

(6)

 

$2.41

 

 

 

 

 

Options exercised

 

 

(102)

 

$2.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, August 31, 2022

 

 

1,592

 

 

$3.08

 

 

$18,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

4

 

 

$21.22

 

 

 

 

 

Options exercised

 

 

(168)

 

$2.31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

1,428

 

 

$3.23

 

 

$32,614

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at November 30, 2022

 

 

1,409

 

 

$3.23

 

 

$32,190

 

The options outstanding and exercisable at November 30, 2022 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

at November 30, 2022

 

 

at November 30, 2022

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

51

 

 

 

4.89

 

 

$1.34

 

 

 

                      51

 

 

 

4.89

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

542

 

 

 

3.76

 

 

$1.71

 

 

 

385

 

 

 

3.61

 

 

$1.69

 

 

 

 

$2.03-$2.40

 

 

 

341

 

 

 

2.96

 

 

$2.21

 

 

 

328

 

 

 

2.87

 

 

$2.21

 

 

 

 

$2.76-$2.93

 

 

 

197

 

 

 

5.05

 

 

$2.91

 

 

 

65

 

 

 

3.89

 

 

$2.88

 

 

 

 

$3.46-$3.93

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

 

$8.00-$24.83

 

 

 

204

 

 

 

6.47

 

 

$9.52

 

 

 

23

 

 

 

6.38

 

 

$10.24

 

 

 

 

$1.34-$24.83

 

 

 

1,428

 

 

 

4.04

 

 

$3.23

 

 

 

945

 

 

 

3.32

 

 

$2.36

 

 

$22,412

 

 

The total intrinsic value of options exercised during the three and six months ended November 30, 2022 was $2,592,000 and $3,356,000, respectively. The total intrinsic value of options exercised during the three and six months ended November 30, 2021 was $9,133,000 and $11,035,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2022 was 4.02 years. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2021 was 4.22 years.

 

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

-

 

 

 

1,000

 

 

 

151,800

 

 

 

120,000

 

Weighted average market value on the date of the grant of annual RSUs

 

 

-

 

 

$24.57

 

 

$8.03

 

 

$3.17

 

Annual restricted shares granted

 

 

-

 

 

 

-

 

 

 

7,500

 

 

 

-

 

Weighted average market value on the date of the grant of annual restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions

 

 

-

 

 

 

-

 

 

 

-

 

 

 

89,000

 

Weighted average market value on the date of the grant of RSU in lieu of cash payment

 

 

-

 

 

 

-

 

 

 

-

 

 

$2.50

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

80,400

 

 

 

270,000

 

Performance restricted shares granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

23,700

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs, performance restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

$3.41

 

Stock-based compensation expense

 

$179,000

 

 

$

-

 

 

$283,000

 

 

$246,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

14,000

 

 

 

13,000

 

 

 

44,000

 

 

 

43,000

 

Weighted average market value on the date of the grant of RSUs

 

$18.50

 

 

$19.85

 

 

$11.35

 

 

$8.02

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

30,000

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

Stock-based compensation expense

 

$245,000

 

 

$

-

 

 

$490,000

 

 

$

-

 

PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.

 

The following table summarizes the RSUs and PRSUs vested and unvested during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

60,000

 

 

 

18,000

 

 

 

202,000

 

 

 

29,000

 

Shares withheld to settle payroll taxes

 

 

2,000

 

 

 

-

 

 

 

150,000

 

 

 

-

 

RSUs and PRSUs unvested

 

 

394,000

 

 

 

237,000

 

 

 

394,000

 

 

 

237,000

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$10,272

 

 

$4,129

 

 

$10,272

 

 

$4,129

 

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND CONCENTRATION INFORMATION
6 Months Ended
Nov. 30, 2022
SEGMENT AND CONCENTRATION INFORMATION  
SEGMENT AND CONCENTRATION INFORMATION

17. SEGMENT AND CONCENTRATION INFORMATION

 

The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note “3. REVENUE.”

 

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

United States

 

$1,210

 

 

$1,156

 

Asia

 

 

53

 

 

 

47

 

Europe

 

 

-

 

 

 

-

 

 

 

$1,263

 

 

$1,203

 

 

As of November 30, 2022, the operating lease right-of-use assets of $479,000 and $82,000 are allocated in the United States and Asia, respectively.

 

There were no revenues through distributors for the three and six months ended November 30, 2022 and 2021.

 

Sales to the Company’s five largest customers accounted for approximately 98% of its net sales for both the three and six months ended November 30, 2022. Two customers accounted for approximately 79% and 15% of the Company’s net sales in the three months ended November 30, 2022. Two customers accounted for approximately 74% and 18% of the Company’s net sales in the six months ended November 30, 2022. Sales to the Company’s five largest customers accounted for approximately 98% and 96% of its net sales in the three and six months ended November 30, 2021, respectively. One customer accounted for approximately 82% of the Company’s net sales in the three months ended November 30, 2021. One customer accounted for approximately 77% of the Company’s net sales in the six months ended November 30, 2021. No other customers represented more than 10% of the Company’s net sales in the three and six months ended November 30, 2022 and 2021.

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.4
SUBSEQUENT EVENTS
6 Months Ended
Nov. 30, 2022
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

18. SUBSEQUENT EVENTS

 

On December 5, 2022, the Company entered into a Fourth Amendment to the lease agreement for the Company’s United States manufacturing and office facilities. The amendment extends the term of the lease for a period of eighty-six (86) calendar months, commencing on August 1, 2023 and expiring on September 30, 2030 (the “Expiration Date”) with an option for the Company to further extend the lease for one additional period of five (5) years after the Expiration Date. The amendment increases monthly base rent from $66,385 to $88,474 effective August 1, 2023, and an annual increase in monthly base rent of 4 percent throughout the remainder of the lease term. The amendment provides for two months of rent abatement, and an improvement allowance of up to $282,090.

 

On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record to that is generally acceptable to SVB, and (ii) the minimum net cash at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.

XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies)
6 Months Ended
Nov. 30, 2022
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES

The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations.

 

In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 2022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.

PRINCIPLES OF CONSOLIDATION

PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.

ACCOUNTING ESTIMATES

ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended November 30, 2022.

XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.4
RECENT ACCOUNTING PRONOUNCEMENTS (Policies)
6 Months Ended
Nov. 30, 2022
RECENT ACCOUNTING PRONOUNCEMENTS  
RECENT ACCOUNTING PRONOUNCEMENTS

Accounting Standards Not Yet Adopted

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis, with early adoption in or after fiscal 2021 permitted. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Tables)
6 Months Ended
Nov. 30, 2022
REVENUE  
Disaggregation of revenue

The Company’s revenues by product category are as follows (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Type of good / service:

 

 

 

 

 

 

 

 

 

 

 

 

Systems

 

$7,400

 

 

$3,754

 

 

$16,494

 

 

$7,633

 

Contactors

 

 

6,607

 

 

 

5,090

 

 

 

7,101

 

 

 

6,042

 

Services

 

 

808

 

 

 

767

 

 

 

1,891

 

 

 

1,582

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product lines:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wafer-level

 

$14,401

 

 

$9,107

 

 

$24,723

 

 

$14,250

 

Test During Burn-In

 

 

414

 

 

 

504

 

 

 

763

 

 

 

1,007

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Geographic region:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$2,555

 

 

$895

 

 

$5,418

 

 

$1,401

 

Asia

 

 

12,216

 

 

 

8,716

 

 

 

20,024

 

 

 

13,853

 

Europe

 

 

44

 

 

 

-

 

 

 

44

 

 

 

3

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at the point in time when control transfers to customers. The following presents revenue based on timing of recognition (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

 

 

 

Products and services transferred at a point in time

 

$14,427

 

 

$9,270

 

 

$24,681

 

 

$14,560

 

Services transferred over time

 

 

388

 

 

 

341

 

 

 

805

 

 

 

697

 

 

 

$14,815

 

 

$9,611

 

 

$25,486

 

 

$15,257

 

XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.4
EARNINGS PER SHARE (Tables)
6 Months Ended
Nov. 30, 2022
EARNINGS PER SHARE  
Earnings per share

The following table presents the computation of basic and diluted net income per share (in thousands, except per share data):

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Numerator: Net income

 

$3,725

 

 

$717

 

 

$4,314

 

 

$1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in basic net income per share calculation

 

 

27,579

 

 

 

26,205

 

 

 

27,410

 

 

 

25,102

 

Effect of dilutive securities

 

 

1,501

 

 

 

2,137

 

 

 

1,524

 

 

 

1,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for diluted net income per share

 

 

29,080

 

 

 

28,342

 

 

 

28,934

 

 

 

26,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

 

$0.14

 

 

$0.03

 

 

$0.16

 

 

$0.06

 

Diluted net income per share

 

$0.13

 

 

$0.03

 

 

$0.15

 

 

$0.05

 

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.4
CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)
6 Months Ended
Nov. 30, 2022
CASH, CASH EQUIVALENTS AND INVESTMENTS  
Cash, cash equivalents and investments by security type

The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2022 (in thousands):

 

 

 

Cost

 

 

Gross Unrealized Loss

 

 

Estimated Fair Value

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,673

 

 

$-

 

 

$3,673

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

11,228

 

 

 

-

 

 

 

11,228

 

U.S. treasury securities

 

 

3,973

 

 

 

-

 

 

 

3,973

 

Total cash equivalents

 

 

15,201

 

 

 

-

 

 

 

15,201

 

Total cash and cash equivalents

 

$18,874

 

 

$-

 

 

$18,874

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury securities

 

$17,716

 

 

$6

 

 

$17,710

 

Long-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$80

 

 

 

-

 

 

$80

 

Total cash, cash equivalents and investments

 

$36,670

 

 

$6

 

 

$36,664

 

XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
6 Months Ended
Nov. 30, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS  
Fair value by hierarchy

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2022 (in thousands):

 

 

 

Balance as of

 

 

 

 

 

 

 

 

 

 

November 30, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$11,308

 

 

$11,308

 

 

$-

 

 

$-

 

U.S. treasury securities

 

 

21,683

 

 

 

21,683

 

 

 

-

 

 

 

-

 

Assets

 

$32,991

 

 

$32,991

 

 

$-

 

 

$-

 

 

The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):

 

 

 

Balance as of

May 31, 2022

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

Assets

 

$28,609

 

 

$28,609

 

 

$-

 

 

$-

 

XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.4
INVENTORIES (Tables)
6 Months Ended
Nov. 30, 2022
INVENTORIES  
Schedule of inventories

Inventories are comprised of the following (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

Raw materials and sub-assemblies

 

$11,963

 

 

$9,507

 

Work in process

 

 

5,826

 

 

 

5,461

 

Finished goods

 

 

183

 

 

 

83

 

 

 

$17,972

 

 

$15,051

 

XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.4
PRODUCT WARRANTIES (Tables)
6 Months Ended
Nov. 30, 2022
PRODUCT WARRANTIES  
Liability for product warranties

The following is a summary of changes in the Company’s liability for product warranties during the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the beginning of the period

 

$424

 

 

$505

 

 

$410

 

 

$494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accruals for warranties issued during the period

 

 

5

 

 

 

95

 

 

 

123

 

 

 

257

 

Adjustments to previously existing warranty accruals

 

 

-

 

 

 

72

 

 

 

61

 

 

 

72

 

Consumption of reserves

 

 

(118)

 

 

(257)

 

 

(283)

 

 

(408)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at the end of the period

 

$311

 

 

$415

 

 

$311

 

 

$415

 

XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.4
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables)
6 Months Ended
Nov. 30, 2022
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables)  
Schedule of Customer deposits and deferred revenue

Customer deposits and deferred revenue, short-term (in thousands):

 

 

 

November 30,

 

 

 May 31,

 

 

 

2022

 

 

2022

 

Customer deposits

 

$3,561

 

 

$2,263

 

Deferred revenue

 

 

119

 

 

 

152

 

 

 

$3,680

 

 

$2,415

 

 

 

 

 

 

 

 

 

 

XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
6 Months Ended
Nov. 30, 2022
ACCUMULATED OTHER COMPREHENSIVE LOSS  
Schedule of Changes in the components of accumulated other comprehensive loss, net of tax

Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):

 

 

 

Cumulative Translation Adjustments

 

 

Unrealized Loss on Investments, Net

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Balance at May 31, 2022

 

$(105)

 

$-

 

 

$(105)

Other comprehensive loss before reclassifications

 

 

(44)

 

 

(6)

 

 

(50)

Amounts reclassified out of accumulated other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

Other comprehensive loss, net of tax

 

 

(44)

 

 

(6)

 

 

(155)

Balance at November 30, 2022

 

$(149)

 

$(6)

 

$(155)
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES (Tables)
6 Months Ended
Nov. 30, 2022
LEASES  
Supplemental cash flow information related to leases

The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):

 

 

 

Six Months Ended

 

 

 

November 30,

 

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of operating lease liabilities:

 

 

 

 

 

 

Operating cash flows for operating leases

 

$415

 

 

$408

 

Maturity of operating lease liabilities

The following table presents the maturities of the Company’s operating lease liabilities as of November 30, 2022 (in thousands):

 

Fiscal year

 

Operating Leases

 

2023 (excluding the first six months of 2023)

 

$416

 

2024

 

 

168

 

2025

 

 

32

 

2026

 

 

18

 

Total future minimum operating lease payments

 

$634

 

Less: imputed interest

 

 

(18)

Present value of operating lease liabilities

 

$616

 

XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Nov. 30, 2022
STOCK-BASED COMPENSATION  
Compensation costs related to the Company's stock-based compensation

The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2022 and 2021 (in thousands):

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

$85

 

 

$76

 

 

$177

 

 

$158

 

Selling, general and administrative

 

 

507

 

 

 

377

 

 

 

971

 

 

 

772

 

Research and development

 

 

201

 

 

 

265

 

 

 

355

 

 

 

376

 

Total stock-based compensation

 

$793

 

 

$718

 

 

$1,503

 

 

$1,306

 

Fair value assumptions for Option Valuation Model

Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected term (in years)

 

 

6

 

 

 

6

 

 

 

5

 

 

 

6

 

Volatility

 

 

112.45%

 

 

85%

 

 

116.41%

 

 

76%

Risk-free interest rate

 

 

4.07%

 

 

1.32%

 

 

3.10%

 

 

1.02%

Weighted average grant date fair value

 

$18.06

 

 

$14.16

 

 

$7.07

 

 

$2.50

 

Fair value assumptions of the ESPP purchase rights

The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2022 and 2021 were estimated using the following assumptions:

 

 

 

Three and Six Months Ended

 

 

Three and Six Months Ended

 

 

 

November 30, 2022

 

 

November 30, 2021

 

 

 

 

 

 

 

Expected term (in years)

 

0.5-2.0

 

 

0.5-2.0

 

Volatility

 

91%-203

%

 

101%-143

%

Risk-free interest rates

 

3.97%-4.12

%

 

0.05%-0.27

%

Weighted average grant date fair value

 

$11.17

 

 

$9.57

 

Stock option and RSU transactions

The following tables summarize the Company’s stock option and RSU transactions during the three and six months ended November 30, 2022 (in thousands):

 

 

 

Available

 

 

 

Shares

 

Balance, May 31, 2022

 

 

1,826

 

 

 

 

 

 

Options granted

 

 

(103)

RSUs granted

 

 

(276)

Options cancelled and adjusted

 

 

6

 

 

 

 

 

 

Balance, August 31, 2022

 

 

1,453

 

Options granted

 

 

(5)

RSUs granted

 

 

(14)

 

 

 

 

 

Balance, November 30, 2022

 

 

1,434

 

Stock option transactions

The following table summarizes the stock option transactions during the three and six months ended November 30, 2022 (in thousands, except per share data):

 

 

 

Outstanding Options

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

Number

 

 

Average

 

 

Aggregate

 

 

 

of

 

 

Exercise

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Value

 

Balances, May 31, 2022

 

 

1,597

 

 

$2.70

 

 

$9,290

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

103

 

 

$8.00

 

 

 

 

 

Options cancelled

 

 

(6)

 

$2.41

 

 

 

 

 

Options exercised

 

 

(102)

 

$2.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, August 31, 2022

 

 

1,592

 

 

$3.08

 

 

$18,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

4

 

 

$21.22

 

 

 

 

 

Options exercised

 

 

(168)

 

$2.31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, November 30, 2022

 

 

1,428

 

 

$3.23

 

 

$32,614

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options fully vested and expected to vest at November 30, 2022

 

 

1,409

 

 

$3.23

 

 

$32,190

 

Options outstanding

The options outstanding and exercisable at November 30, 2022 were in the following exercise price ranges (in thousands, except per share data):

 

 

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

at November 30, 2022

 

 

at November 30, 2022

 

Range of Exercise

Prices

 

 

Number Outstanding Shares

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Number Exercisable Shares

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$1.34

 

 

 

51

 

 

 

4.89

 

 

$1.34

 

 

 

                      51

 

 

 

4.89

 

 

$1.34

 

 

 

 

$1.64-$1.86

 

 

 

542

 

 

 

3.76

 

 

$1.71

 

 

 

385

 

 

 

3.61

 

 

$1.69

 

 

 

 

$2.03-$2.40

 

 

 

341

 

 

 

2.96

 

 

$2.21

 

 

 

328

 

 

 

2.87

 

 

$2.21

 

 

 

 

$2.76-$2.93

 

 

 

197

 

 

 

5.05

 

 

$2.91

 

 

 

65

 

 

 

3.89

 

 

$2.88

 

 

 

 

$3.46-$3.93

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

93

 

 

 

1.67

 

 

$3.83

 

 

 

 

$8.00-$24.83

 

 

 

204

 

 

 

6.47

 

 

$9.52

 

 

 

23

 

 

 

6.38

 

 

$10.24

 

 

 

 

$1.34-$24.83

 

 

 

1,428

 

 

 

4.04

 

 

$3.23

 

 

 

945

 

 

 

3.32

 

 

$2.36

 

 

$22,412

 

RSUs, PRSUs, restricted shares and performance restricted shares granted

The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Employees:

 

 

 

 

 

 

 

 

 

 

 

 

Annual RSUs granted

 

 

-

 

 

 

1,000

 

 

 

151,800

 

 

 

120,000

 

Weighted average market value on the date of the grant of annual RSUs

 

 

-

 

 

$24.57

 

 

$8.03

 

 

$3.17

 

Annual restricted shares granted

 

 

-

 

 

 

-

 

 

 

7,500

 

 

 

-

 

Weighted average market value on the date of the grant of annual restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

RSUs granted in lieu of cash payment for salary reductions

 

 

-

 

 

 

-

 

 

 

-

 

 

 

89,000

 

Weighted average market value on the date of the grant of RSU in lieu of cash payment

 

 

-

 

 

 

-

 

 

 

-

 

 

$2.50

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

80,400

 

 

 

270,000

 

Performance restricted shares granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

23,700

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs, performance restricted shares

 

 

-

 

 

 

-

 

 

$8.00

 

 

$3.41

 

Stock-based compensation expense

 

$179,000

 

 

$

-

 

 

$283,000

 

 

$246,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Members of Board of Directors:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

14,000

 

 

 

13,000

 

 

 

44,000

 

 

 

43,000

 

Weighted average market value on the date of the grant of RSUs

 

$18.50

 

 

$19.85

 

 

$11.35

 

 

$8.02

 

PRSUs granted based on revenue target thresholds maximum

 

 

-

 

 

 

-

 

 

 

30,000

 

 

 

-

 

Weighted average market value on the date of the grant of PRSUs

 

 

-

 

 

 

-

 

 

$8.00

 

 

 

-

 

Stock-based compensation expense

 

$245,000

 

 

$

-

 

 

$490,000

 

 

$

-

 

RSUs and PRSUs vested and unvested during period

The following table summarizes the RSUs and PRSUs vested and unvested during the three and six months ended November 30, 2022 and 2021:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

November 30,

 

 

November 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net RSUs and PRSUs vested

 

 

60,000

 

 

 

18,000

 

 

 

202,000

 

 

 

29,000

 

Shares withheld to settle payroll taxes

 

 

2,000

 

 

 

-

 

 

 

150,000

 

 

 

-

 

RSUs and PRSUs unvested

 

 

394,000

 

 

 

237,000

 

 

 

394,000

 

 

 

237,000

 

Intrinsic value of unvested RSUs and PRSUs (in thousands)

 

$10,272

 

 

$4,129

 

 

$10,272

 

 

$4,129

 

XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION (Tables)
6 Months Ended
Nov. 30, 2022
SEGMENT INFORMATION (Tables)  
Property and equipment by geographic region

Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):

 

 

 

November 30,

 

 

May 31,

 

 

 

2022

 

 

2022

 

United States

 

$1,210

 

 

$1,156

 

Asia

 

 

53

 

 

 

47

 

Europe

 

 

-

 

 

 

-

 

 

 

$1,263

 

 

$1,203

 

XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Net Sales $ 14,815 $ 9,611 $ 25,486 $ 15,257
Contactors        
Net Sales 6,607 5,090 7,101 6,042
Services        
Net Sales 808 767 1,891 1,582
Wafer-Level        
Net Sales 14,401 9,107 24,723 14,250
Test During Burn-In        
Net Sales 414 504 763 1,007
Systems        
Net Sales $ 7,400 $ 3,754 $ 16,494 $ 7,633
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Details 1) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Net sales $ 14,815,000 $ 9,611,000 $ 25,486,000 $ 15,257,000
Asia        
Net sales 12,216,000 8,716,000 20,024,000 13,853,000
United States        
Net sales 2,555,000 895,000 5,418,000 1,401,000
Europe        
Net sales $ 44,000 $ 0 $ 44,000 $ 3,000
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Details 2) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Net sales $ 14,815 $ 9,611 $ 25,486 $ 15,257
Products and Services Transferred at a Point in Time        
Net sales 14,427 9,270 24,681 14,560
Services Transferred over Time        
Net sales $ 388 $ 341 $ 805 $ 697
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2022
May 31, 2024
May 31, 2023
May 31, 2022
Contract liabilities $ 3,705,000 $ 3,705,000     $ 2,484,000
Recognition of contract liabilities 44,000 2,115,000      
Remaining performance obligations $ 135,000 $ 135,000      
Scenario Forecast [Member]          
Remaining performance obligation revenue recognition     51.00% 49.00%  
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.4
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
EARNINGS PER SHARE        
Net income $ 3,725 $ 717 $ 4,314 $ 1,413
Denominator for basic net income per share: weighted average shares outstanding 27,579 26,205 27,410 25,102
Shares used in basic net income per share calculation 27,579 26,205 27,410 25,102
Effect of dilutive securities 1,501 2,137 1,524 1,747
Denominator for diluted net income per share 29,080 28,342 28,934 26,849
Basic net income per share $ 0.14 $ 0.03 $ 0.16 $ 0.06
Diluted net income per share $ 0.13 $ 0.03 $ 0.15 $ 0.05
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.4
EARNINGS PER SHARE (Details Narrative) - shares
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Stock Option        
Options not included in the computation of diluted net income per share 14,000 5,000 14,000 5,000
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.4
CASH, CASH EQUIVALENTS AND INVESTMENTS (Details) - USD ($)
Nov. 30, 2022
May 31, 2022
Total cash and cash equivalents $ 18,874,000 $ 31,484,000
Cost [Member]    
Cash equivalents: 15,201,000  
Cash 3,673,000  
Total cash and cash equivalents 18,874,000  
Total cash, cash equivalents and investments 36,670,000  
Cost [Member] | Money Market Funds [Member]    
Cash equivalents: 11,228,000  
Long-term investments: 80,000  
Cost [Member] | US Treasury Securities [Member]    
Cash equivalents: 3,973,000  
Short-term Investments 17,716,000  
Gross Unrealized Loss    
Cash equivalents: 0  
Cash 0  
Total cash and cash equivalents 0  
Total cash, cash equivalents and investments 6,000  
Gross Unrealized Loss | Money Market Funds [Member]    
Cash equivalents: 0  
Long-term investments: 0  
Gross Unrealized Loss | US Treasury Securities [Member]    
Cash equivalents: 0  
Short-term Investments 6,000  
Estimated Fair Value [Member]    
Cash equivalents: 15,201,000  
Cash 3,673,000  
Total cash and cash equivalents 18,874,000  
Total cash, cash equivalents and investments 36,664,000  
Estimated Fair Value [Member] | Money Market Funds [Member]    
Cash equivalents: 11,228,000  
Long-term investments: 80,000  
Estimated Fair Value [Member] | US Treasury Securities [Member]    
Cash equivalents: 3,973,000  
Short-term Investments $ 17,710,000  
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.4
CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)
Nov. 30, 2022
USD ($)
Gross Unrealized Loss  
Unrealized loss $ 6,000
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
$ in Thousands
Nov. 30, 2022
May 31, 2022
Money Market Funds [Member]    
Investment securities $ 11,308 $ 28,609
U.S. treasury securities [Member]    
Investment securities 21,683  
Assets [Member]    
Investment securities 32,991 28,609
Level 1 | U.S. treasury securities [Member]    
Investment securities 21,683  
Level 1 | Money Market Funds [Member]    
Investment securities 11,308 28,609
Level 1 | Assets [Member]    
Investment securities 32,991 28,609
Level 2 | U.S. treasury securities [Member]    
Investment securities 0  
Level 2 | Money Market Funds [Member]    
Investment securities 0 0
Level 2 | Assets [Member]    
Investment securities 0 0
Level 3 | U.S. treasury securities [Member]    
Investment securities 0  
Level 3 | Money Market Funds [Member]    
Investment securities 0 0
Level 3 | Assets [Member]    
Investment securities $ 0 $ 0
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)
Nov. 30, 2022
May 31, 2022
FAIR VALUE OF FINANCIAL INSTRUMENTS    
Transfer between Level 1 and Level 2 fair value measurements $ 0 $ 0
Restricted cash 80,000 80,000
Financial liabilities at fair value $ 0 $ 0
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.4
INVENTORIES (Details) - USD ($)
$ in Thousands
Nov. 30, 2022
May 31, 2022
INVENTORIES (Details)    
Raw materials and sub-assemblies $ 11,963 $ 9,507
Work in process 5,826 5,461
Finished goods 183 83
Inventories $ 17,972 $ 15,051
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.4
PRODUCT WARRANTIES (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
PRODUCT WARRANTIES (Details)        
Balance at the beginning of the year $ 424 $ 505 $ 410 $ 494
Accruals for warranties issued during the period 5 95 123 257
Adjustments to previously existing warranty accruals 0 72 61 72
Consumption of reserves (118) (257) (283) (408)
Balance at the End of the year $ 311 $ 415 $ 311 $ 415
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.4
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details) - USD ($)
$ in Thousands
Nov. 30, 2022
May 31, 2022
CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details)    
Total $ 3,680 $ 2,415
Customer deposits 3,561 2,263
Deferred revenue $ 119 $ 152
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)
$ in Thousands
6 Months Ended
Nov. 30, 2022
USD ($)
Balance at the beginning of the year $ (105)
Other comprehensive loss before reclassifications (50)
Amounts reclassified out of accumulated other comprehensive loss 0
Other comprehensive loss, net of tax (155)
Balance at the ending of the year (155)
Cumulative Translation Adjustments [Member]  
Balance at the beginning of the year (105)
Other comprehensive loss before reclassifications (44)
Amounts reclassified out of accumulated other comprehensive loss 0
Other comprehensive loss, net of tax (44)
Balance at the ending of the year (149)
Unrealized Loss on Investments, Net Member  
Balance at the beginning of the year 0
Other comprehensive loss before reclassifications (6)
Amounts reclassified out of accumulated other comprehensive loss 0
Other comprehensive loss, net of tax (6)
Balance at the ending of the year $ (6)
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
INCOME TAXES        
Provision For Income Tax $ 18,000 $ 34,000 $ 32,000 $ 57,000
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES (Details) - USD ($)
$ in Thousands
6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Cash paid for amounts included in measurement of operating lease liabilities:    
Operating cash flows for operating leases $ 415 $ 408
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES (Details 1)
$ in Thousands
Nov. 30, 2022
USD ($)
LEASES (Details 1)  
Total future minimum operating lease payments $ 634
Less: imputed interest (18)
Present value of operating lease liabilities 616
2023 (excluding the first three months of 2023) 416
2024 168
2025 32
2026 $ 18
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Operating lease, weighted-average discount rate 5.38%   5.38%  
Operating lease, weighted-average remaining lease term 1 year   1 year  
Operating lease, cost $ 189,000 $ 192,000 $ 379,000 $ 385,000
Minimum [Member]        
Operating lease term 7 years   7 years  
Maximum [Member]        
Operating lease term 3 years   3 years  
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.4
BORROWING AND FINANCING ARRANGEMENTS (Details Narrative)
6 Months Ended
Nov. 30, 2022
USD ($)
Original Loan and Security Agreement  
Line of Credit, maximum borrowing $ 4,000,000.0
Variable interest rate the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%
Borrowing under line of credit $ 0
Balance available to borrow under the line of credit 6,782,000
Second Amendment To Loan And Security Agreement  
Line of Credit, maximum borrowing $ 10,000,000
Variable interest rate the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%
Revolving line maturity date Jan. 13, 2023
Second Amendment To Loan And Security Agreement | Customer Purchase Order  
Line of Credit, maximum borrowing $ 3,000,000
First Amendment to Loan and Security Agreement  
Revolving line maturity date Jan. 13, 2022
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.22.4
LONGTERM DEBT (Details Narrative) - Silicon Valley Bank - USD ($)
Jun. 12, 2021
Apr. 23, 2020
PPP loan   $ 1,679,000
Interest rate   1.00%
Total interest $ 19,000  
Recognized a gain on loan forgiveness $ 1,698,000  
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKBASED COMPENSATION (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Total stock-based compensation $ 793 $ 718 $ 1,503 $ 1,306
Cost of Sales        
Total stock-based compensation 85 76 177 158
Selling, General and Administrative        
Total stock-based compensation 507 377 971 772
Research and Development        
Total stock-based compensation $ 201 $ 265 $ 355 $ 376
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKBASED COMPENSATION (Details 1) - Stock Option - $ / shares
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Expected term (in years) 6 years 6 years 5 years 6 years
Volatility 112.45% 85.00% 116.41% 76.00%
Risk-free interest rates 4.07% 1.32% 3.10% 1.02%
Weighted-average grant date fair value $ 18.06 $ 14.16 $ 7.07 $ 2.50
XML 70 R61.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 2) - $ / shares
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Weighted-average grant date fair value $ 11.17 $ 9.57 $ 11.17 $ 9.57
Maximum | Employee Stock Purchase Plan        
Expected term (in years) 2 years 2 years 2 years 2 years
Volatility 203.00% 143.00% 203.00% 143.00%
Risk-free interest rates 4.12% 0.27% 4.12% 0.27%
Minimum | Employee Stock Purchase Plan        
Expected term (in years) 6 months 6 months 6 months 6 months
Volatility 91.00% 101.00% 91.00% 101.00%
Risk-free interest rates 3.97% 0.05% 3.97% 0.05%
XML 71 R62.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKBASED COMPENSATION (Details 3) - Stock Option and RSU Transactions [Member] - shares
shares in Thousands
3 Months Ended
Nov. 30, 2022
Aug. 31, 2022
Available shares, beginning 1,453 1,826
Options granted (5) (103)
RSUs granted (14) (276)
Options cancelled and adjusted   6
Available shares, ending 1,434 1,453
XML 72 R63.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 4) - Outstanding Options Stock Option Transactions - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Nov. 30, 2022
Aug. 31, 2022
Options outstanding, beginning (in thousands) 1,592 1,597
Options granted (in thousands) 4 103
Options cancelled (in thousands)   (6)
Options exercised (in thousands) (168) (102)
Options outstanding, ending (in thousands) 1,428 1,592
Options fully vested and expected to vest (in thousands) 1,409  
Weighted average exercise price outstanding, beginning $ 3.08 $ 2.70
Weighted average exercise price granted 21.22 8.00
Weighted average exercise price cancelled   2.41
Weighted average exercise price exercised 2.31 2.00
Weighted average exercise price outstanding, ending 3.23 $ 3.08
Weighted average exercise price fully vested and expected to vest $ 3.23  
Aggregate intrinsic value, beginning $ 18,287 $ 9,290
Aggregate intrinsic value, ending 32,614 $ 18,287
Aggregate intrinsic value for options fully vested and expected to vest $ 32,190  
XML 73 R64.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKBASED COMPENSATION (Details 5)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended
Nov. 30, 2022
USD ($)
$ / shares
shares
$1.34  
Options outstanding, ending (in thousands) | shares | shares 51
Weighted average remaining contractual life (Years) options outstanding 4 years 10 months 20 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 1.34
Option exercisable shares (in thousands) | shares 51
Weighted average remaining contractual life (Years) options exercisable 4 years 10 months 20 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 1.34
$1.64-$1.86  
Options outstanding, ending (in thousands) | shares | shares 542
Weighted average remaining contractual life (Years) options outstanding 3 years 9 months 3 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 1.71
Option exercisable shares (in thousands) | shares 385
Weighted average remaining contractual life (Years) options exercisable 3 years 7 months 9 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 1.69
$2.03-$2.40  
Options outstanding, ending (in thousands) | shares | shares 341
Weighted average remaining contractual life (Years) options outstanding 2 years 11 months 15 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 2.21
Option exercisable shares (in thousands) | shares 328
Weighted average remaining contractual life (Years) options exercisable 2 years 10 months 13 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.21
$2.76-$2.93  
Options outstanding, ending (in thousands) | shares | shares 197
Weighted average remaining contractual life (Years) options outstanding 5 years 18 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 2.91
Option exercisable shares (in thousands) | shares 65
Weighted average remaining contractual life (Years) options exercisable 3 years 10 months 20 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.88
$3.46-$3.93  
Options outstanding, ending (in thousands) | shares | shares 93
Weighted average remaining contractual life (Years) options outstanding 1 year 8 months 1 day
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 3.83
Option exercisable shares (in thousands) | shares 93
Weighted average remaining contractual life (Years) options exercisable 1 year 8 months 1 day
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 3.83
$8.00-$24.83  
Options outstanding, ending (in thousands) | shares | shares 204
Weighted average remaining contractual life (Years) options outstanding 6 years 5 months 19 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 9.52
Option exercisable shares (in thousands) | shares 23
Weighted average remaining contractual life (Years) options exercisable 6 years 4 months 17 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 10.24
$1.34-$24.83  
Options outstanding, ending (in thousands) | shares | shares 1,428
Weighted average remaining contractual life (Years) options outstanding 4 years 14 days
Weighted average exercise price outstanding, ending | $ / shares | $ / shares $ 3.23
Option exercisable shares (in thousands) | shares 945
Weighted average remaining contractual life (Years) options exercisable 3 years 3 months 25 days
Weighted average exercise price for options exercisable | $ / shares | $ / shares $ 2.36
Aggregate intrinsic value for options exercisable | | $ $ 22,412
XML 74 R65.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 6) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Employees Member        
Annual RSUs granted   1,000 151,800 120,000
Weighted average market value on the date of the grant of annual RSUs $ 0 $ 24.57 $ 8.03 $ 3.17
Annual restricted shares granted     7,500  
Weighted average market value on the date of the grant of annual restricted shares 0 0 $ 8.00 $ 0
RSUs granted in lieu of cash payment for salary reductions       89,000
Weighted average market value on the date of the grant of RSU in lieu of cash payment 0 0 $ 0 $ 2.50
PRSUs granted based on revenue target thresholds maximum     80,400 270,000
Performance restricted shares granted based on revenue target thresholds maximum     23,700  
Weighted average market value on the date of the grant of PRSUs, performance restricted shares $ 0 $ 0 $ 8.00 $ 3.41
Stock-based compensation expense $ 179,000 $ 0 $ 283,000 $ 246,000
Board Of Directors        
Annual RSUs granted 14,000 13,000 44,000 43,000
Weighted average market value on the date of the grant of annual RSUs $ 18.50 $ 19.85 $ 11.35 $ 8.02
PRSUs granted based on revenue target thresholds maximum     30,000  
Stock-based compensation expense $ 245,000 $ 0 $ 490,000 $ 0
Weighted average market value on the date of the grant of PRSUs $ 0 $ 0 $ 8.00 $ 0
XML 75 R66.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 7) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
STOCKBASED COMPENSATION (Details)        
Net RSUs and PRSUs vested 60,000 18,000 202,000 29,000
Shares withheld to settle payroll taxes 2,000   150,000  
RSUs and PRSUs unvested 394,000 237,000 394,000 237,000
Intrinsic value of unvested RSUs and PRSUs (in thousands) $ 10,272 $ 4,129 $ 10,272 $ 4,129
XML 76 R67.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKBASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
Total intrinsic values of options exercised $ 2,592,000 $ 9,133,000 $ 3,356,000 $ 11,035,000
Stock Based Compensation Costs Capitalized As part of inventory $ 101,000   $ 101,000  
Weighted average remaining contractual life of the options exercisable and expected to be exercisable     4 years 7 days 4 years 2 months 19 days
Employee Stock Purchase Plan        
ESPP purchase right granted 43,000 103,000 43,000 103,000
ESPP share issued 109,000 75,000 109,000 75,000
Unrecognized stock-based compensation $ 527,000   $ 527,000  
Weighted average period for recognition of costs     1 year  
ESPP shares available for issuance 499,000 361,000 499,000 361,000
Stock-based compensation related to the ESPP $ 216,000 $ 302,000 $ 391,000 $ 406,000
Stock Option and RSU        
Stock-based compensation expense related to stock options and RSUs 577,000 $ 416,000 1,112,000 $ 900,000
2016 Equity Incentive Plan        
Unrecognized stock-based compensation 3,999,000   $ 3,999,000  
Weighted average period for recognition of costs     2 years 2 months 12 days  
Estimated forfeitures of unvested stock based awards, amount $ 10,000   $ 10,000  
XML 77 R68.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND CONCENTRATION INFORMATION (Details) - USD ($)
$ in Thousands
Nov. 30, 2022
May 31, 2022
Property and equipment, net $ 1,263 $ 1,203
Asia    
Property and equipment, net 53 47
United States    
Property and equipment, net 1,210 1,156
Europe    
Property and equipment, net $ 0 $ 0
XML 78 R69.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND CONCENTRATION INFORMATION (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Nov. 30, 2022
Nov. 30, 2021
Nov. 30, 2022
Nov. 30, 2021
May 31, 2022
Operating lease right-of-use assets $ 561,000   $ 561,000   $ 917,000
United States [Member]          
Operating lease right-of-use assets 479,000   479,000    
Asia [Member]          
Operating lease right-of-use assets $ 82,000   $ 82,000    
Customer A [Member]          
Customers accounted for 10% or more of total revenues 79.00% 82.00% 74.00% 77.00%  
Customers B [Member]          
Customers accounted for 10% or more of total revenues 15.00%   18.00%    
Five Largest Customers [Member]          
Customers accounted for 10% or more of total revenues 98.00% 98.00% 98.00% 96.00%  
XML 79 R70.htm IDEA: XBRL DOCUMENT v3.22.4
SUBSEQUENT EVENT (Details Narrative) - SUBSEQUENT EVENTS
Dec. 05, 2022
USD ($)
Description of changes in monthly base rent The amendment increases monthly base rent from $66,385 to $88,474 effective August 1, 2023
Improvement allowance $ 282,090
Revolving line matuity date Jan. 13, 2024
Fourth amendment Lease expiry date Sep. 30, 2030
Description about amendment third agreemnet the minimum net cash at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.
XML 80 aehr_10q_htm.xml IDEA: XBRL DOCUMENT 0001040470 2022-06-01 2022-11-30 0001040470 us-gaap:SubsequentEventMember 2022-12-01 2022-12-05 0001040470 aehr:AsiasMember 2022-11-30 0001040470 aehr:USAMember 2022-11-30 0001040470 aehr:CustomersBMember 2022-09-01 2022-11-30 0001040470 aehr:CustomersBMember 2022-06-01 2022-11-30 0001040470 aehr:CustomersAMember 2021-06-01 2021-11-30 0001040470 aehr:CustomersAMember 2021-09-01 2021-11-30 0001040470 aehr:CustomersAMember 2022-09-01 2022-11-30 0001040470 aehr:CustomersAMember 2022-06-01 2022-11-30 0001040470 aehr:FiveLargestCustomersMember 2021-06-01 2021-11-30 0001040470 aehr:FiveLargestCustomersMember 2021-09-01 2021-11-30 0001040470 aehr:FiveLargestCustomersMember 2022-09-01 2022-11-30 0001040470 aehr:FiveLargestCustomersMember 2022-06-01 2022-11-30 0001040470 srt:EuropeMember 2022-05-31 0001040470 srt:EuropeMember 2022-11-30 0001040470 srt:AsiaMember 2022-05-31 0001040470 srt:AsiaMember 2022-11-30 0001040470 aehr:UnitedStateMember 2022-05-31 0001040470 aehr:UnitedStateMember 2022-11-30 0001040470 us-gaap:EmployeeStockMember 2021-11-30 0001040470 aehr:EquityIncentivePlan2016Member 2022-06-01 2022-11-30 0001040470 us-gaap:EmployeeStockMember 2022-11-30 0001040470 aehr:EquityIncentivePlan2016Member 2022-11-30 0001040470 aehr:StockOptionAndRSUMember 2021-09-01 2021-11-30 0001040470 aehr:StockOptionAndRSUMember 2021-06-01 2021-11-30 0001040470 aehr:StockOptionAndRSUMember 2022-09-01 2022-11-30 0001040470 aehr:StockOptionAndRSUMember 2022-06-01 2022-11-30 0001040470 us-gaap:EmployeeStockMember 2021-06-01 2021-11-30 0001040470 us-gaap:EmployeeStockMember 2021-09-01 2021-11-30 0001040470 us-gaap:EmployeeStockMember 2022-06-01 2022-11-30 0001040470 us-gaap:EmployeeStockMember 2022-09-01 2022-11-30 0001040470 aehr:BoardOfDirectorsMember 2021-06-01 2021-11-30 0001040470 aehr:BoardOfDirectorsMember 2021-09-01 2021-11-30 0001040470 aehr:BoardOfDirectorsMember 2022-09-01 2022-11-30 0001040470 aehr:BoardOfDirectorsMember 2022-06-01 2022-11-30 0001040470 aehr:EmployeesMember 2021-09-01 2021-11-30 0001040470 aehr:EmployeesMember 2021-06-01 2021-11-30 0001040470 aehr:EmployeesMember 2022-06-01 2022-11-30 0001040470 aehr:EmployeesMember 2022-09-01 2022-11-30 0001040470 aehr:RangeTenMember 2022-06-01 2022-11-30 0001040470 aehr:Range6Member 2022-06-01 2022-11-30 0001040470 aehr:Range5Member 2022-06-01 2022-11-30 0001040470 aehr:Range4Member 2022-06-01 2022-11-30 0001040470 aehr:Range3Member 2022-06-01 2022-11-30 0001040470 aehr:Range2Member 2022-06-01 2022-11-30 0001040470 aehr:Range1Member 2022-06-01 2022-11-30 0001040470 aehr:RangeTenMember 2022-11-30 0001040470 aehr:Range6Member 2022-11-30 0001040470 aehr:Range5Member 2022-11-30 0001040470 aehr:Range4Member 2022-11-30 0001040470 aehr:Range3Member 2022-11-30 0001040470 aehr:Range2Member 2022-11-30 0001040470 aehr:Range1Member 2022-11-30 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-11-30 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-09-01 2022-11-30 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-06-01 2022-08-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-05-31 0001040470 aehr:OutstandingOptionsStockOptionTransactionsMember 2022-08-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-11-30 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-06-01 2022-08-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-09-01 2022-11-30 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-05-31 0001040470 aehr:StockOptionAndRSUTransactionsMember 2022-08-31 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2021-06-01 2021-11-30 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2021-09-01 2021-11-30 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2022-06-01 2022-11-30 0001040470 srt:MaximumMember us-gaap:EmployeeStockMember 2022-09-01 2022-11-30 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2021-09-01 2021-11-30 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2022-09-01 2022-11-30 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2021-06-01 2021-11-30 0001040470 srt:MinimumMember us-gaap:EmployeeStockMember 2022-06-01 2022-11-30 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2021-09-01 2021-11-30 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2021-06-01 2021-11-30 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2022-09-01 2022-11-30 0001040470 us-gaap:ResearchAndDevelopmentExpenseMember 2022-06-01 2022-11-30 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2021-09-01 2021-11-30 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2021-06-01 2021-11-30 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2022-09-01 2022-11-30 0001040470 us-gaap:GeneralAndAdministrativeExpenseMember 2022-06-01 2022-11-30 0001040470 us-gaap:CostOfSalesMember 2021-09-01 2021-11-30 0001040470 us-gaap:CostOfSalesMember 2021-06-01 2021-11-30 0001040470 us-gaap:CostOfSalesMember 2022-06-01 2022-11-30 0001040470 us-gaap:CostOfSalesMember 2022-09-01 2022-11-30 0001040470 aehr:SiliconValleyBankMember 2021-06-01 2021-06-12 0001040470 aehr:SiliconValleyBankMember 2021-06-12 0001040470 aehr:SiliconValleyBankMember 2020-04-23 0001040470 aehr:FirstAmendmentToLoanAndSecurityAgreementMember 2022-06-01 2022-11-30 0001040470 aehr:SecondAmendmentToLoanAndSecurityAgreementMember 2022-06-01 2022-11-30 0001040470 aehr:OriginalLoanAndSecurityAgreementMember 2022-06-01 2022-11-30 0001040470 aehr:SecondAmendmentToLoanAndSecurityAgreementMember aehr:CustomerPurchaseOrderMember 2022-11-30 0001040470 aehr:SecondAmendmentToLoanAndSecurityAgreementMember 2022-11-30 0001040470 aehr:OriginalLoanAndSecurityAgreementMember 2022-11-30 0001040470 srt:MinimumMember 2022-11-30 0001040470 srt:MaximumMember 2022-11-30 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2022-05-31 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2022-11-30 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2022-11-30 0001040470 aehr:UnrealizedLossOnInvestmentsMember 2022-06-01 2022-11-30 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2022-06-01 2022-11-30 0001040470 aehr:CumulativeTranslationAdjustmentsMember 2022-05-31 0001040470 us-gaap:AssetsMember 2022-05-31 0001040470 us-gaap:AssetsMember 2022-11-30 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member 2022-05-31 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-05-31 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-05-31 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-05-31 0001040470 us-gaap:MoneyMarketFundsMember 2022-05-31 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member 2022-11-30 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-11-30 0001040470 aehr:UStreasurysecuritiesMember 2022-11-30 0001040470 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember 2022-11-30 0001040470 aehr:EstimatedFairValueMember 2022-11-30 0001040470 aehr:CostMember 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember aehr:CostMember 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember aehr:EstimatedFairValueMember 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember aehr:GrossUnrealizedLossMember 2022-11-30 0001040470 us-gaap:USTreasurySecuritiesMember aehr:GrossUnrealizedLossMember 2022-11-30 0001040470 aehr:GrossUnrealizedLossMember 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember aehr:CostMember 2022-11-30 0001040470 us-gaap:MoneyMarketFundsMember aehr:EstimatedFairValueMember 2022-11-30 0001040470 aehr:StockOptionsMember 2021-09-01 2021-11-30 0001040470 aehr:StockOptionsMember 2022-06-01 2022-11-30 0001040470 aehr:StockOptionsMember 2021-06-01 2021-11-30 0001040470 aehr:StockOptionsMember 2022-09-01 2022-11-30 0001040470 srt:ScenarioForecastMember 2024-05-31 0001040470 srt:ScenarioForecastMember 2023-05-31 0001040470 aehr:ServicesTransferredOverTimeMember 2021-09-01 2021-11-30 0001040470 aehr:ServicesTransferredOverTimeMember 2021-06-01 2021-11-30 0001040470 aehr:ServicesTransferredOverTimeMember 2022-09-01 2022-11-30 0001040470 aehr:ServicesTransferredOverTimeMember 2022-06-01 2022-11-30 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2021-09-01 2021-11-30 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2021-06-01 2021-11-30 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2022-09-01 2022-11-30 0001040470 aehr:ProductsAndServicesTransferredAtAPointInTimeMember 2022-06-01 2022-11-30 0001040470 aehr:EuropesMember 2022-09-01 2022-11-30 0001040470 aehr:EuropesMember 2021-06-01 2021-11-30 0001040470 aehr:EuropesMember 2021-09-01 2021-11-30 0001040470 aehr:EuropesMember 2022-06-01 2022-11-30 0001040470 srt:AsiaMember 2022-09-01 2022-11-30 0001040470 srt:AsiaMember 2021-06-01 2021-11-30 0001040470 srt:AsiaMember 2021-09-01 2021-11-30 0001040470 srt:AsiaMember 2022-06-01 2022-11-30 0001040470 aehr:USsMember 2022-09-01 2022-11-30 0001040470 aehr:USsMember 2021-06-01 2021-11-30 0001040470 aehr:USsMember 2021-09-01 2021-11-30 0001040470 aehr:USsMember 2022-06-01 2022-11-30 0001040470 aehr:TestDuringBurnInMember 2022-06-01 2022-11-30 0001040470 aehr:WaferLevelMember 2022-06-01 2022-11-30 0001040470 aehr:ServicesMember 2022-06-01 2022-11-30 0001040470 aehr:ContactorsMember 2022-06-01 2022-11-30 0001040470 aehr:SystemsMember 2022-06-01 2022-11-30 0001040470 aehr:TestDuringBurnInMember 2022-09-01 2022-11-30 0001040470 aehr:WaferLevelMember 2022-09-01 2022-11-30 0001040470 aehr:ServicesMember 2022-09-01 2022-11-30 0001040470 aehr:ContactorsMember 2022-09-01 2022-11-30 0001040470 aehr:SystemsMember 2022-09-01 2022-11-30 0001040470 aehr:TestDuringBurnInMember 2021-09-01 2021-11-30 0001040470 aehr:WaferLevelMember 2021-09-01 2021-11-30 0001040470 aehr:ServicesMember 2021-09-01 2021-11-30 0001040470 aehr:ContactorsMember 2021-09-01 2021-11-30 0001040470 aehr:SystemsMember 2021-09-01 2021-11-30 0001040470 aehr:TestDuringBurnInMember 2021-06-01 2021-11-30 0001040470 aehr:WaferLevelMember 2021-06-01 2021-11-30 0001040470 aehr:ServicesMember 2021-06-01 2021-11-30 0001040470 aehr:ContactorsMember 2021-06-01 2021-11-30 0001040470 aehr:SystemsMember 2021-06-01 2021-11-30 0001040470 us-gaap:RetainedEarningsMember 2022-09-01 2022-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-01 2022-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001040470 us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001040470 2022-08-31 0001040470 us-gaap:RetainedEarningsMember 2022-08-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-08-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001040470 us-gaap:CommonStockMember 2022-08-31 0001040470 us-gaap:RetainedEarningsMember 2022-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001040470 us-gaap:CommonStockMember 2022-11-30 0001040470 us-gaap:RetainedEarningsMember 2022-06-01 2022-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-01 2022-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-11-30 0001040470 us-gaap:CommonStockMember 2022-06-01 2022-11-30 0001040470 us-gaap:RetainedEarningsMember 2022-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001040470 us-gaap:CommonStockMember 2022-05-31 0001040470 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2021-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001040470 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001040470 2021-08-31 0001040470 us-gaap:RetainedEarningsMember 2021-08-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001040470 us-gaap:CommonStockMember 2021-08-31 0001040470 2021-11-30 0001040470 us-gaap:RetainedEarningsMember 2021-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001040470 us-gaap:CommonStockMember 2021-11-30 0001040470 us-gaap:RetainedEarningsMember 2021-06-01 2021-11-30 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-01 2021-11-30 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-11-30 0001040470 us-gaap:CommonStockMember 2021-06-01 2021-11-30 0001040470 2021-05-31 0001040470 us-gaap:RetainedEarningsMember 2021-05-31 0001040470 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-31 0001040470 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001040470 us-gaap:CommonStockMember 2021-05-31 0001040470 2021-06-01 2021-11-30 0001040470 2021-09-01 2021-11-30 0001040470 2022-09-01 2022-11-30 0001040470 2022-05-31 0001040470 2022-11-30 0001040470 2022-12-31 iso4217:USD shares iso4217:USD shares pure 0001040470 false --12-31 Q2 2023 0.01 75000000 27120000 27732000 14000 5000 0 0 0 0 0 0 0 0 80000 0 0 P3Y 0 1698000 P6M P6M P2Y P2Y 0.91 1.01 2.03 1.43 0.0397 0.0005 0.0412 0.0027 11.17 9.57 101000 43000 103000 109000 75000 0.98 10-Q true 2022-11-30 false 000-22893 AEHR TEST SYSTEMS CA 94-2424084 400 Kato Terrace Fremont CA 94539 510 623-9400 Yes Yes Non-accelerated Filer true false false Common Stock Par value of $0.01 per share AEHR NASDAQ 27759445 18874000 31484000 17710000 0 10156000 12859000 17972000 15051000 823000 613000 65535000 60007000 1263000 1203000 561000 917000 184000 201000 67543000 62328000 3949000 4195000 2566000 3610000 551000 794000 3680000 2415000 10746000 11014000 65000 212000 25000 69000 40000 44000 10876000 11339000 0.01 75000000 27732000 27120000 277000 271000 119094000 117686000 -155000 -105000 -62549000 -66863000 56667000 50989000 67543000 62328000 14815000 9611000 25486000 15257000 6904000 5092000 13094000 8457000 7911000 4519000 12392000 6800000 2875000 2489000 5400000 4442000 1551000 1313000 3049000 2634000 4426000 3802000 8449000 7076000 3485000 717000 3943000 -276000 263000 -1000 384000 -10000 0 0 0 1698000 -5000 35000 19000 58000 3743000 751000 4346000 1470000 18000 34000 32000 57000 3725000 717000 4314000 1413000 0.14 0.03 0.16 0.06 0.13 0.03 0.15 0.05 27579000 26205000 27410000 25102000 29080000 28342000 28934000 26849000 3725000 717000 4314000 1413000 -6000 0 -6000 0 1000 -44000 -44000 -80000 3720000 673000 4264000 1333000 27395000 274000 117668000 -150000 -66274000 51518000 339000 3000 654000 0 0 657000 -2000 0 -37000 0 0 -37000 0 809000 0 0 809000 0 0 0 3725000 3725000 0 0 -6000 0 -6000 0 0 1000 0 1000 27732000 277000 119094000 -155000 -62549000 56667000 27120000 271000 117686000 -105000 -66863000 50989000 761000 7000 1105000 0 0 1112000 -149000 -1000 -1215000 0 0 -1216000 0 1518000 0 0 1518000 0 0 0 4314000 4314000 0 0 -6000 0 -6000 0 0 -44000 0 -44000 27732000 277000 119094000 -155000 -62549000 56667000 24483000 245000 89668000 -64000 -75617000 14232000 663000 6000 1360000 0 0 1366000 -8000 0 -157000 0 0 -157000 1697000 17000 24013000 0 0 24030000 0 718000 0 0 718000 0 0 0 717000 717000 0 0 -44000 0 -44000 26835000 268000 115602000 -108000 -74900000 40862000 23725000 237000 87553000 -28000 -76313000 11449000 1461000 14000 2989000 0 0 3003000 -48000 0 -259000 0 0 -259000 1697000 17000 24013000 0 0 24030000 0 1306000 0 0 1306000 0 0 0 1413000 1413000 0 0 -80000 0 -80000 26835000 268000 115602000 -108000 -74900000 40862000 4314000 1413000 1503000 1306000 24000 0 191000 149000 64000 0 0 1698000 2618000 -2284000 3094000 4212000 -196000 -60000 -210000 512000 -1045000 104000 1221000 9970000 4000 11000 5266000 5211000 17652000 0 99000 132000 -17751000 -132000 0 1400000 1112000 3003000 1216000 259000 0 24030000 -104000 25374000 -21000 -4000 -12610000 30449000 31564000 4662000 18954000 35111000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 2022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended November 30, 2022.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The accompanying financial information has been prepared by Aehr Test Systems, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the opinion of management, the unaudited condensed consolidated financial statements for the interim periods presented have been prepared on a basis consistent with the May 31, 2022 audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the condensed consolidated financial position and results of operations as of and for such periods indicated. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2022. Results for the interim periods presented herein are not necessarily indicative of results which may be reported for any other interim period or for the entire fiscal year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PRINCIPLES OF CONSOLIDATION. The condensed consolidated financial statements include the accounts of Aehr Test Systems and its subsidiaries (collectively, the “Company”). All significant intercompany balances have been eliminated in consolidation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">ACCOUNTING ESTIMATES. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used to account for sales and revenue allowances, the allowance for doubtful accounts, inventory valuations, income taxes, stock-based compensation expenses, and product warranties, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. The Company’s significant accounting policies are disclosed in the Company’s Annual Report on Form 10-K for the year ended May 31, 2022. There have been no significant changes in the Company’s significant accounting policies during the three and six months ended November 30, 2022.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2. RECENT ACCOUNTING PRONOUNCEMENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting Standards Not Yet Adopted</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis, with early adoption in or after fiscal 2021 permitted. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting Standards Not Yet Adopted</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), that requires measurement and recognition of expected credit losses for financial assets held based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Due to a subsequent ASU in November 2019, the accounting standard will be effective for the Company beginning in the first quarter of fiscal 2024 on a modified retrospective basis, with early adoption in or after fiscal 2021 permitted. The Company does not expect a material impact of this accounting standard on its consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. REVENUE</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue recognition</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company recognizes revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by following a five-step process: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue when or as the Company satisfies a performance obligation, as further described below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Performance obligations include sales of systems, contactors, spare parts, and services, as well as installation and training services included in customer contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A contract’s transaction price is allocated to each distinct performance obligation. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled. The Company generally does not grant return privileges, except for defective products during the warranty period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis. Standalone selling prices are based on multiple factors including, but not limited to historical discounting trends for products and services and pricing practices in different geographies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Revenue for systems and spares are recognized at a point in time, which is generally upon shipment or delivery. Revenue from services is recognized over time as services are completed or ratably over the contractual period of generally one year or less.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company has elected the practical expedient to not assess whether a contract has a significant financing component as the Company’s standard payment terms are less than one year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company sells its products primarily through a direct sales force. In certain international markets, the Company sells its products through independent distributors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Disaggregation of revenue </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following tables show revenues by major product categories. Within each product category, contract terms, conditions and economic factors affecting the nature, amount, timing and uncertainty around revenue recognition and cash flow are substantially similar.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s revenues by product category are as follows (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Type of good / service:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Systems</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,754</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Contactors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,607</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,101</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,042</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">808</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">767</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,891</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,582</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product lines:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Wafer-level </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,107</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Test During Burn-In</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">414</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">504</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">763</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,007</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geographic region:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,555</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,418</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,216</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,716</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,853</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at the point in time when control transfers to customers. The following presents revenue based on timing of recognition (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Timing of revenue recognition:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Products and services transferred at a point in time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,427</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,270</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,681</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,560</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Services transferred over time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">341</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">805</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Contract balances</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the Condensed Consolidated Balance Sheets at the end of each reporting period as a component of deferred revenue. Contract liabilities as of November 30, 2022 and May 31, 2022 were $3,705,000 and $2,484,000, respectively. During the three and six months ended November 30, 2022, the Company recognized $44,000 and $2,115,000, respectively, of revenues that were included in contract liabilities as of May 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Remaining performance obligations</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On November 30, 2022, the Company had $135,000 of remaining performance obligations, which were comprised of deferred service contracts and extended warranty contracts not yet delivered. The Company expects to recognize approximately 49% of its remaining performance obligations as revenue in the remainder of fiscal 2023, and an additional 51% in fiscal 2024 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Costs to obtain or fulfill a contract</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company generally expenses sales commissions when incurred as a component of selling, general and administrative expense as the amortization period is typically less than one year. Additionally, the majority of the Company’s cost of fulfillment as a manufacturer of products is classified as inventory and fixed assets, which are accounted for under the respective guidance for those asset types. Other costs of contract fulfillment are immaterial due to the nature of the Company’s products and their respective manufacturing process.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s revenues by product category are as follows (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Type of good / service:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Systems</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,754</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Contactors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,607</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,101</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,042</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">808</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">767</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,891</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,582</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product lines:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Wafer-level </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,107</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,723</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Test During Burn-In</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">414</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">504</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">763</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,007</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following presents information about the Company’s operations in different geographic areas. Net sales are based upon ship-to location (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geographic region:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,555</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,418</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,401</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,216</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,716</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,853</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">With the exception of the amount of service contracts and extended warranties, the Company’s product category revenues are recognized at the point in time when control transfers to customers. The following presents revenue based on timing of recognition (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Timing of revenue recognition:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Products and services transferred at a point in time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,427</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,270</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,681</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,560</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Services transferred over time</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">388</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">341</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">805</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">697</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,815</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,611</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,486</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,257</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 7400000 3754000 16494000 7633000 6607000 5090000 7101000 6042000 808000 767000 1891000 1582000 14401000 9107000 24723000 14250000 414000 504000 763000 1007000 14815000 9611000 25486000 15257000 2555000 895000 5418000 1401000 12216000 8716000 20024000 13853000 44000 0 44000 3000 14815000 9611000 25486000 15257000 14427000 9270000 24681000 14560000 388000 341000 805000 697000 14815000 9611000 25486000 15257000 3705000 2484000 44000 2115000 135000 0.49 0.51 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. EARNINGS PER SHARE</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Basic earnings per share is determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined using the weighted average number of common shares and potential common shares (representing the dilutive effect of stock options, restricted shares, restricted stock units (“RSUs”), Performance RSUs (“PRSUs”) and Amended and Restated 2006 Employee Stock Purchase Plan (“ESPP”) shares) outstanding during the period using the treasury stock method.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents the computation of basic and diluted net income per share (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td colspan="7" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Numerator: Net income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,725</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,314</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,413</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for basic net income per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Weighted average shares outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,579</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,205</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,410</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,102</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares used in basic net income per share calculation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,579</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect of dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,501</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,524</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,747</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for diluted net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,342</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,934</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,849</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.03</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.16</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.06</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Diluted net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.13</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.03</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.15</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For the purpose of computing diluted earnings per share, weighted average potential common shares do not include stock options with an exercise price greater than the average fair value of the Company’s common stock for the period, as the effect would be anti-dilutive. In the three and six months ended November 30, 2022, stock options to purchase 14,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive. In the three and six months ended November 30, 2021, stock options to purchase 5,000 shares of common stock were outstanding, but were not included in the computation of diluted net income per share, because the inclusion of such shares would be anti-dilutive.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents the computation of basic and diluted net income per share (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td colspan="7" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Numerator: Net income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,725</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">717</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,314</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,413</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for basic net income per share:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Weighted average shares outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,579</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,205</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,410</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,102</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares used in basic net income per share calculation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,579</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,102</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect of dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,501</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,137</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,524</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,747</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Denominator for diluted net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,080</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,342</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,934</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,849</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.03</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.16</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.06</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Diluted net income per share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.13</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.03</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.15</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3725000 717000 4314000 1413000 27579000 26205000 27410000 25102000 27579000 26205000 27410000 25102000 1501000 2137000 1524000 1747000 29080000 28342000 28934000 26849000 0.14 0.03 0.16 0.06 0.13 0.03 0.15 0.05 14000 5000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. CASH, CASH EQUIVALENTS AND INVESTMENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,673</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,673</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,228</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,228</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,973</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,973</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,874</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,874</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Short-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,716</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,710</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,670</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,664</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Long-term investments are included in other assets on the accompanying condensed consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Unrealized gains and temporary losses on investments classified as available-for-sale are included within accumulated other comprehensive loss, net of any related tax effect. Upon realization, those amounts are reclassified from accumulated other comprehensive loss to results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The unrealized loss of $6,000 as of November 30, 2022 is not considered other-than-temporary, and has been in an unrealized loss position for less than a year.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s cash, cash equivalents and investments by security type at November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cost</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Gross Unrealized Loss</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Estimated Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,673</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,673</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash equivalents:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,228</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,228</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,973</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,973</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,874</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,874</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Short-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,716</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,710</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term investments:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total cash, cash equivalents and investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,670</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,664</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3673000 3673000 11228000 11228000 3973000 3973000 15201000 15201000 18874000 18874000 17716000 6000 17710000 80000 80000 36670000 6000 36664000 6000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6. FAIR VALUE OF FINANCIAL INSTRUMENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s financial instruments are measured at fair value consistent with authoritative guidance. This authoritative guidance defines fair value, establishes a framework for using fair value to measure assets and liabilities, and disclosures required related to fair value measurements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The guidance establishes a fair value hierarchy based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Level 1 - instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Level 2 - instrument valuations are obtained from readily-available pricing sources for comparable instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Level 3 - instrument valuations are obtained without observable market values and require a high level of judgment to determine the fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,308</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,308</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,683</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,683</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32,991</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32,991</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Included in money market funds as of November 30, 2022 and May 31, 2022 is $80,000 restricted cash representing a security deposit for the Company’s United States manufacturing and office space lease which is included in other assets in the consolidated balance sheets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no financial liabilities measured at fair value as of November 30, 2022 and May 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no transfers between Level 1 and Level 2 fair value measurements during the three months ended November 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The carrying amounts of financial instruments including cash equivalents, accounts receivable, accounts payable and certain other accrued liabilities, approximate fair value due to their short maturities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,308</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,308</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">U.S. treasury securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,683</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21,683</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32,991</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">32,991</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of May 31, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Balance as of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 1</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 2</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Level 3</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">28,609</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 11308000 11308000 0 0 21683000 21683000 0 0 32991000 32991000 0 0 28609000 28609000 0 0 28609000 28609000 0 0 80000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">7. TRADE AND OTHER ACCOUNTS RECEIVABLE, NET</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Trade accounts receivable represents customer trade receivables. As of November 30, 2022 and May 31, 2022, there were no allowances for doubtful accounts. Trade accounts receivable is derived from the sale of products throughout the world to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers and burn-in and test service companies. Other accounts receivable represents non-customer trade related receivables that are derived from the sale of raw materials to our subcontractors. The Company’s allowance for doubtful accounts is based upon historical experience and review of trade receivables by aging category to identify specific customers with known disputes or collection issues. Uncollectible receivables are recorded as bad debt expense when all efforts to collect have been exhausted and recoveries are recognized when they are received.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8. INVENTORIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Inventories are comprised of the following (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Raw materials and sub-assemblies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,963</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,507</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Work in process</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finished goods</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">83</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,972</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,051</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Inventories are comprised of the following (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Raw materials and sub-assemblies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,963</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,507</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Work in process</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,461</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finished goods</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">83</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,972</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,051</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 11963000 9507000 5826000 5461000 183000 83000 17972000 15051000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9. PRODUCT WARRANTIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company provides for the estimated cost of product warranties at the time revenues are recognized on the products shipped. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The standard warranty period is one year for systems and ninety days for parts and service.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following is a summary of changes in the Company’s liability for product warranties during the three and six months ended November 30, 2022 and 2021 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the beginning of the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">424</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accruals for warranties issued during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">257</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustments to previously existing warranty accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consumption of reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(118</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(257</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(283</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(408</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the end of the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">311</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">311</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The accrued warranty balance is included in accrued expenses on the accompanying condensed consolidated balance sheets.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following is a summary of changes in the Company’s liability for product warranties during the three and six months ended November 30, 2022 and 2021 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the beginning of the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">424</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">505</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">494</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accruals for warranties issued during the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">257</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustments to previously existing warranty accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consumption of reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(118</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(257</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(283</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(408</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at the end of the period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">311</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">311</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 424000 505000 410000 494000 5000 95000 123000 257000 0 72000 61000 72000 118000 257000 283000 408000 311000 415000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10. CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Customer deposits and deferred revenue, short-term (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,561</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">119</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,680</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Customer deposits and deferred revenue, short-term (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Customer deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,561</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">119</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,680</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,415</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 3561000 2263000 119000 152000 3680000 2415000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">11. ACCUMULATED OTHER COMPREHENSIVE LOSS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cumulative Translation Adjustments</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unrealized Loss on Investments, Net</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(44</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(50</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Amounts reclassified out of accumulated other comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Other comprehensive loss, net of tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(149</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Changes in the components of accumulated other comprehensive loss, net of tax, were as follows (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cumulative Translation Adjustments</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unrealized Loss on Investments, Net</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(105</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Other comprehensive loss before reclassifications</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(44</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(50</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Amounts reclassified out of accumulated other comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Other comprehensive loss, net of tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(149</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(155</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -105000 0 -105000 -44000 -6000 -50000 0 0 0 -44000 -6000 -155000 -149000 -6000 -155000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12. INCOME TAXES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company is subject to U.S federal and state and foreign income taxes as a corporation. The Company’s tax provision and the resulting effective tax rate for the interim period is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter. The Company recorded a provision for income tax of $18,000 and $32,000 for the three and six months ended November 30, 2022 which consisted primarily of foreign withholding taxes and foreign income taxes. The Company recorded a provision for income tax of $34,000 and $57,000 for the three and six months ended November 30, 2021 which consisted primarily of foreign withholding taxes and foreign income taxes. The income tax provision was not significant due to available net operating loss and research and development credit carryforwards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Income taxes have been provided using the liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and net operating loss and tax credit carryforwards measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse, or the carryforwards are utilized. Valuation allowances are established when it is determined that it is more likely than not that such assets will not be realized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since fiscal 2009, a full valuation allowance was established against all deferred tax assets, as management determined that it is more likely than not that certain deferred tax assets will not be realized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company accounts for uncertain tax positions consistent with authoritative guidance. The guidance prescribes a “more likely than not” recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company does not expect any material change in its unrecognized tax benefits over the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income taxes.</p> 18000 32000 34000 57000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">13. LEASES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company has only operating leases for real estate including corporate offices, warehouse space and certain equipment. A lease with an initial term of 12 months or less is generally not recorded on the condensed consolidated balance sheets, unless the arrangement includes an option to purchase the underlying asset, or renew the arrangement that the Company is reasonably certain to exercise (short-term leases). The Company recognizes lease expense on a straight-line basis over the lease term for short-term leases that the Company does not record on its balance sheets. The Company’s operating leases have remaining lease terms of 7 months to 3 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The weighted average remaining lease term for the Company’s operating leases was 1.0 years at November 30, 2022 and the weighted-average discount rate was 5.38%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s operating lease cost was $189,000 and $379,000 for the three and six months ended November 30, 2022, respectively. The Company’s operating lease cost was $192,000 and $385,000 for the three and six months ended November 30, 2021, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for amounts included in the measurement of operating lease liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Operating cash flows for operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">415</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents the maturities of the Company’s operating lease liabilities as of November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fiscal year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Operating Leases</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023 (excluding the first six months of 2023)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">634</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">616</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> P7Y P1Y 0.0538 189000 379000 192000 385000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents supplemental cash flow information related to the Company’s operating leases (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for amounts included in the measurement of operating lease liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:20pt">Operating cash flows for operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">415</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 415000 408000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table presents the maturities of the Company’s operating lease liabilities as of November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fiscal year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Operating Leases</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023 (excluding the first six months of 2023)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">416</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">168</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum operating lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">634</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: imputed interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Present value of operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">616</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 416000 168000 32000 18000 634000 18000 616000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">14. BORROWING AND FINANCING ARRANGEMENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On January 16, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Pursuant to the Loan Agreement, the Company may borrow up to (a) the lesser of (i) the revolving line of $4.0 million or (ii) the amount available under the borrowing base minus (b) the outstanding principal balance of any advances, under a revolving line of credit which is collateralized by all the Company’s assets except intellectual property. The borrowing base is 80% of eligible accounts, as determined by SVB from the Company’s most recent borrowing base statement; provided, however, SVB has the right to decrease the foregoing percentage in its good faith business judgment to mitigate the impact of certain events or conditions, which may adversely affect the collateral or its value. Subject to an event of default, the principal amount outstanding under the revolving line of credit will accrue interest at a floating per annum rate equal to the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75%. Interest is payable monthly on the last calendar day of each month and the outstanding principal amount, the unpaid interest and all other obligations are due on the maturity date, which is 364 days from the effective date of January 13, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On January 14, 2021, the Company entered into the First Amendment to Loan and Security Agreement (the “Amendment”) with SVB. The Amendment, among other things, extended the Revolving Line Maturity Date to July 14, 2021; provided, however, that if the Company achieved specified operating metrics on a consolidated basis on or prior to May 31, 2021 the Amended Revolving Line Maturity Date would be extended to January 13, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On January 11, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (the “Second Amendment”) with SVB. The Second Amendment, among other things, (A) increased the available amount of the line up to the lesser of (i) $10 million or (ii) the available amount under the borrowing base, under a revolving line of credit, (B) allowed for borrowing up to $3 million of the available balance based upon eligible customer purchase orders, (C) reduced the interest rate for account advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75%, and (D) extended the maturity date to January 13, 2023. See note “18. SUBSEQUENT EVENTS” for the renewal of this Loan and Security Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At November 30, 2022, the Company had not drawn against the credit facility and was in compliance with all covenants related to obligations to meet reporting requirements. The balance available to borrow under the line at November 30, 2022 was $6,782,000. There are no financial covenants in the agreement.</p> 4000000.0 the greater of (a) the prime rate plus an additional percentage of up to 1%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 4.75% 2022-01-13 10000000 3000000 the greater of (a) prime rate plus an additional percentage up to 1.0%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.25%, reduces the interest rate for purchase order advances under the line to the greater of (a) prime rate plus an additional percentage up to 1.5%, which additional percentage depends on the Company’s adjusted quick ratio, and (b) 3.75% 2023-01-13 6782000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15. LONG-TERM DEBT</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On April 23, 2020, the Company obtained the Paycheck Protection Program Loan (the “PPP Loan”) in the aggregate amount of $1,679,000 from SVB. The PPP Loan was evidenced by a promissory note dated April 23, 2020 (the “Note”) that matured on April 23, 2022 and bore interest at a rate of 1% per annum, payable monthly commencing on November 23, 2020. The PPP Loan proceeds were used for payroll, health care benefits, rent and utilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. On June 12, 2021, the Company received confirmation from SVB that on June 4, 2021, the Small Business Administration approved the Company’s PPP Loan forgiveness application for the entire PPP Loan balance of $1,679,000 and interest totaling $19,000, and the Company recognized a gain on loan forgiveness of $1,698,000.</p> 1679000 0.01 19000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">16. STOCK-BASED COMPENSATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Stock-based compensation expense consists of expenses for stock options, RSUs, PRSUs, restricted shares, performance restricted shares and ESPP purchase rights. Stock-based compensation expense for stock options and ESPP purchase rights is measured at each grant date, based on the fair value of the award using the Black-Scholes option valuation model, and is recognized as expense over the employee’s requisite service period. This model was developed for use in estimating the value of publicly traded options that have no vesting restrictions and are fully transferable. The Company’s employee stock options have characteristics significantly different from those of publicly traded options. For RSUs and restricted shares, stock-based compensation cost is based on the fair value of the Company’s common stock at the grant date. All of the Company’s stock-based compensation is accounted for as an equity instrument. See Note 11 in the Company’s Annual Report on Form 10-K for fiscal 2022 filed on August 26, 2022 for further information regarding the 2016 Equity Incentive Plan (the “2016 Plan”) and the ESPP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2022 and 2021 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">177</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">158</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">507</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">377</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">971</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">772</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">265</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">355</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">376</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">793</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">718</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,503</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,306</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of November 30, 2022, there were $101,000 stock-based compensation expenses capitalized as part of inventory. As of November 30, 2021, there were no stock-based compensation expenses capitalized as part of inventory.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $577,000 and $416,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to stock options, RSUs and restricted shares of $1,112,000 and $900,000, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of November 30, 2022, the total compensation expense related to unvested stock-based awards under the 2016 Plan, but not yet recognized, was approximately $3,999,000, which is net of estimated forfeitures of $10,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 2.2 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the three months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $216,000 and $302,000, respectively. During the six months ended November 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the ESPP of $391,000 and $406,000, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of November 30, 2022, the total compensation expense related to purchase rights under the ESPP but not yet recognized was approximately $527,000. This expense will be amortized on a straight-line basis over a weighted average period of approximately 1.0 year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Valuation Assumptions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Valuation and Amortization Method. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model and a single option award approach. The fair value under the single option approach is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Expected Term. The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior as evidenced by changes to the terms of its stock-based awards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Volatility. Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, which matches the expected term of most of the option grants, to estimate expected volatility. Volatility for each of the ESPP’s four time periods of six months, twelve months, eighteen months, and twenty-four months is calculated separately and included in the overall stock-based compensation expense recorded.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes option valuation model on the implied yield in effect at the time of option grant on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock awards including the ESPP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112.45</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116.41</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.07</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.02</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2022 and 2021 were estimated using the following assumptions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three and Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three and Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5-2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5-2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91%-203</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">101%-143</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.97%-4.12</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.05%-0.27</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.57</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">During the three and six months ended November 30, 2022, ESPP purchase rights of 43,000 were granted. During the three and six months ended November 30, 2021, ESPP purchase rights of 103,000 were granted. Total ESPP shares issued during the three and six months ended November 30, 2022 and 2021 were 109,000 and 75,000 shares, respectively. As of November 30, 2022 and 2021, there were 499,000 and 361,000 ESPP shares available for issuance, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">The following tables summarize the Company’s stock option and RSU transactions during the three and six months ended November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Available</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(103</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(276</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options cancelled and adjusted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, August 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,434</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the stock option transactions during the three and six months ended November 30, 2022 (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Intrinsic</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,290</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(102</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, August 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,287</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(168</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,428</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,614</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options fully vested and expected to vest at November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,409</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,190</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The options outstanding and exercisable at November 30, 2022 were in the following exercise price ranges (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Outstanding</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Exercisable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at November 30, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at November 30, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Range of Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prices</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Outstanding Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td class="hdcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Exercisable Shares</p></td><td/><td/><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate Intrinsic Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">51</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:6%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                      51</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.64-$1.86</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">542</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.71</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">385</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.61</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.03-$2.40</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">341</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.96</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.21</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">328</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.87</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.21</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.76-$2.93</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">197</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.05</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.91</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.89</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$3.46-$3.93</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$8.00-$24.83</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">204</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.47</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">23</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.34-$24.83</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,428</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.04</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.23</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">945</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.32</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.36</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">22,412</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The total intrinsic value of options exercised during the three and six months ended November 30, 2022 was $2,592,000 and $3,356,000, respectively. The total intrinsic value of options exercised during the three and six months ended November 30, 2021 was $9,133,000 and $11,035,000, respectively. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2022 was 4.02 years. The weighted average remaining contractual life of the options exercisable and expected to be exercisable at November 30, 2021 was 4.22 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and six months ended November 30, 2022 and 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of annual RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24.57</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual restricted shares granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of annual restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted in lieu of cash payment for salary reductions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of RSU in lieu of cash payment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PRSUs granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">270,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Performance restricted shares granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of PRSUs, performance restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Members of Board of Directors:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PRSUs granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">490,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PRSUs were granted to key officers and members of Board of Directors based upon revenue target thresholds for fiscal 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the RSUs and PRSUs vested and unvested during the three and six months ended November 30, 2022 and 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net RSUs and PRSUs vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares withheld to settle payroll taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs unvested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">237,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">237,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Intrinsic value of unvested RSUs and PRSUs (in thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,272</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,129</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,272</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,129</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the stock-based compensation expense for the three and six months ended November 30, 2022 and 2021 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation in the form of stock options, RSUs, restricted shares and ESPP purchase rights, included in:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">177</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">158</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">507</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">377</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">971</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">772</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">265</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">355</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">376</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">793</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">718</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,503</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,306</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 85000 76000 177000 158000 507000 377000 971000 772000 201000 265000 355000 376000 793000 718000 1503000 1306000 101000 577000 416000 1112000 900000 3999000 10000 P2Y2M12D 216000 302000 391000 406000 527000 P1Y <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Fair Value. The fair value of the Company’s stock options granted to employees for the three and six months ended November 30, 2022 and 2021 were estimated using the following weighted average assumptions in the Black-Scholes option valuation model:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112.45</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116.41</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.07</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.02</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> P6Y P6Y P5Y P6Y 1.1245 0.85 1.1641 0.76 0.0407 0.0132 0.0310 0.0102 18.06 14.16 7.07 2.50 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The fair values of the ESPP purchase rights granted for the three and six months ended November 30, 2022 and 2021 were estimated using the following assumptions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three and Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three and Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30, 2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (in years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5-2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.5-2.0</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91%-203</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">101%-143</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.97%-4.12</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.05%-0.27</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average grant date fair value</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.57</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> P0Y6M P2Y P0Y6M P2Y 0.91 2.03 1.01 1.43 0.0397 0.0412 0.0005 0.0027 11.17 9.57 43000 103000 109000 75000 499000 361000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">The following tables summarize the Company’s stock option and RSU transactions during the three and six months ended November 30, 2022 (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Available</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(103</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(276</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options cancelled and adjusted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, August 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,453</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance, November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,434</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1826000 103000 276000 6000 1453000 5000 14000 1434000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the stock option transactions during the three and six months ended November 30, 2022 (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Intrinsic</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.70</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,290</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(102</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, August 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,287</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(168</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balances, November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,428</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,614</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options fully vested and expected to vest at November 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,409</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,190</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1597000 2.70 9290000 103000 8.00 6000 2.41 102000 2.00 1592000 3.08 18287000 4000 21.22 168000 2.31 1428000 3.23 32614000 1409000 3.23 32190000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The options outstanding and exercisable at November 30, 2022 were in the following exercise price ranges (in thousands, except per share data):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Outstanding</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Exercisable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at November 30, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">at November 30, 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Range of Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prices</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Outstanding Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td class="hdcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number Exercisable Shares</p></td><td/><td/><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Remaining Contractual Life (Years)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Aggregate Intrinsic Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td>1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">51</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:6%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">                      51</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.64-$1.86</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">542</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.76</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.71</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">385</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.61</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.69</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.03-$2.40</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">341</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.96</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.21</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">328</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.87</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.21</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$2.76-$2.93</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">197</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.05</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.91</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.89</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$3.46-$3.93</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.67</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$8.00-$24.83</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">204</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.47</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">23</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.38</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$1.34-$24.83</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,428</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.04</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.23</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">945</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.32</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.36</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">22,412</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 51000 P4Y10M20D 1.34 51000 P4Y10M20D 1.34 542000 P3Y9M3D 1.71 385000 P3Y7M9D 1.69 341000 P2Y11M15D 2.21 328000 P2Y10M13D 2.21 197000 P5Y18D 2.91 65000 P3Y10M20D 2.88 93000 P1Y8M1D 3.83 93000 P1Y8M1D 3.83 204000 P6Y5M19D 9.52 23000 P6Y4M17D 10.24 1428000 P4Y14D 3.23 945000 P3Y3M25D 2.36 22412000 2592000 3356000 9133000 11035000 P4Y7D P4Y2M19D <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes RSUs, PRSUs, restricted shares and performance restricted shares granted to employees and members of the Company’s Board of Directors during the three and six months ended November 30, 2022 and 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of annual RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24.57</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.03</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Annual restricted shares granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of annual restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted in lieu of cash payment for salary reductions</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of RSU in lieu of cash payment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PRSUs granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">270,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Performance restricted shares granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of PRSUs, performance restricted shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">179,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Members of Board of Directors:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of RSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PRSUs granted based on revenue target thresholds maximum</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average market value on the date of the grant of PRSUs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">490,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1000 151800 120000 0 24.57 8.03 3.17 7500 0 0 8.00 0 89000 0 0 0 2.50 80400 270000 23700 0 0 8.00 3.41 179000000 0 283000000 246000000 14000 13000 44000 43000 18.50 19.85 11.35 8.02 30000 0 0 8.00 0 245000000 0 490000000 0 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table summarizes the RSUs and PRSUs vested and unvested during the three and six months ended November 30, 2022 and 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Three Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Six Months Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net RSUs and PRSUs vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">202,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares withheld to settle payroll taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs and PRSUs unvested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">237,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">237,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Intrinsic value of unvested RSUs and PRSUs (in thousands)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,272</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,129</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,272</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,129</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 60000 18000 202000 29000 2000 150000 394000 237000 394000 237000 10272000 4129000 10272000 4129000 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">17. SEGMENT AND CONCENTRATION INFORMATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company has only one reportable segment. The information for revenue category by type, product line, geography and timing of revenue recognition, is summarized in Note “3. REVENUE.”</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,156</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,263</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of November 30, 2022, the operating lease right-of-use assets of $479,000 and $82,000 are allocated in the United States and Asia, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no revenues through distributors for the three and six months ended November 30, 2022 and 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Sales to the Company’s five largest customers accounted for approximately 98% of its net sales for both the three and six months ended November 30, 2022. Two customers accounted for approximately 79% and 15% of the Company’s net sales in the three months ended November 30, 2022. Two customers accounted for approximately 74% and 18% of the Company’s net sales in the six months ended November 30, 2022. Sales to the Company’s five largest customers accounted for approximately 98% and 96% of its net sales in the three and six months ended November 30, 2021, respectively. One customer accounted for approximately 82% of the Company’s net sales in the three months ended November 30, 2021. One customer accounted for approximately 77% of the Company’s net sales in the six months ended November 30, 2021. No other customers represented more than 10% of the Company’s net sales in the three and six months ended November 30, 2022 and 2021.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Property and equipment information is based on the physical location of the assets. The following table presents property and equipment information for geographic areas (in thousands):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">November 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,210</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,156</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Asia</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Europe</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,263</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,203</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 1210000 1156000 53000 47000 0 0 1263000 1203000 479000 82000 0.98 0.79 0.15 0.74 0.18 0.98 0.96 0.82 0.77 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">18. SUBSEQUENT EVENTS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On December 5, 2022, the Company entered into a Fourth Amendment to the lease agreement for the Company’s United States manufacturing and office facilities. The amendment extends the term of the lease for a period of eighty-six (86) calendar months, commencing on August 1, 2023 and expiring on September 30, 2030 (the “Expiration Date”) with an option for the Company to further extend the lease for one additional period of five (5) years after the Expiration Date. The amendment increases monthly base rent from $66,385 to $88,474 effective August 1, 2023, and an annual increase in monthly base rent of 4 percent throughout the remainder of the lease term. The amendment provides for two months of rent abatement, and an improvement allowance of up to $282,090.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On January 10, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement (the “Third Amendment”) with SVB. The Third Amendment, among other things, extends the Revolving Line Maturity Date to January 13, 2024, provided, however, that (i) if the Company submits a fiscal year 2024 plan of record to that is generally acceptable to SVB, and (ii) the minimum net cash at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025.</p> 2030-09-30 The amendment increases monthly base rent from $66,385 to $88,474 effective August 1, 2023 282090 2024-01-13 the minimum net cash at the end of November 30, 2023 is at least $20.0 million, the Amended Revolving Line Maturity Date would be extended to January 13, 2025. EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 226 264 1 false 60 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://aehr.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://aehr.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) Statements 5 false false R6.htm 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited) Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited) Statements 6 false false R7.htm 000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 7 false false R8.htm 000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES Sheet http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES Notes 8 false false R9.htm 000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://aehr.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 000010 - Disclosure - REVENUE Sheet http://aehr.com/role/REVENUE REVENUE Notes 10 false false R11.htm 000011 - Disclosure - EARNINGS PER SHARE Sheet http://aehr.com/role/EarningsPerShare EARNINGS PER SHARE Notes 11 false false R12.htm 000012 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS Sheet http://aehr.com/role/CashCashEquivalentsAndInvestments CASH, CASH EQUIVALENTS AND INVESTMENTS Notes 12 false false R13.htm 000013 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://aehr.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 13 false false R14.htm 000014 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET Sheet http://aehr.com/role/TradeAndOtherAccountsReceivableNet TRADE AND OTHER ACCOUNTS RECEIVABLE, NET Notes 14 false false R15.htm 000015 - Disclosure - INVENTORIES Sheet http://aehr.com/role/INVENTORIES INVENTORIES Notes 15 false false R16.htm 000016 - Disclosure - PRODUCT WARRANTIES Sheet http://aehr.com/role/ProductWarranties PRODUCT WARRANTIES Notes 16 false false R17.htm 000017 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM Sheet http://aehr.com/role/CustomerDepositsAndDeferredRevenueShortterm CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM Notes 17 false false R18.htm 000018 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLoss ACCUMULATED OTHER COMPREHENSIVE LOSS Notes 18 false false R19.htm 000019 - Disclosure - INCOME TAXES Sheet http://aehr.com/role/IncomeTaxes INCOME TAXES Notes 19 false false R20.htm 000020 - Disclosure - LEASES Sheet http://aehr.com/role/LEASES LEASES Notes 20 false false R21.htm 000021 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS Sheet http://aehr.com/role/BorrowingAndFinancingArrangements BORROWING AND FINANCING ARRANGEMENTS Notes 21 false false R22.htm 000022 - Disclosure - LONG-TERM DEBT Sheet http://aehr.com/role/LongTermDebt LONG-TERM DEBT Notes 22 false false R23.htm 000023 - Disclosure - STOCK-BASED COMPENSATION Sheet http://aehr.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 23 false false R24.htm 000024 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION Sheet http://aehr.com/role/SegmentAndConcentrationInformation SEGMENT AND CONCENTRATION INFORMATION Notes 24 false false R25.htm 000025 - Disclosure - SUBSEQUENT EVENTS Sheet http://aehr.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 25 false false R26.htm 000026 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies) Sheet http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies) Policies 26 false false R27.htm 000027 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://aehr.com/role/RecentAccountingPronouncementsPolicies RECENT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 27 false false R28.htm 000028 - Disclosure - REVENUE (Tables) Sheet http://aehr.com/role/RevenueTables REVENUE (Tables) Tables http://aehr.com/role/REVENUE 28 false false R29.htm 000029 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://aehr.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://aehr.com/role/EarningsPerShare 29 false false R30.htm 000030 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Tables http://aehr.com/role/CashCashEquivalentsAndInvestments 30 false false R31.htm 000031 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://aehr.com/role/FairValueOfFinancialInstruments 31 false false R32.htm 000032 - Disclosure - INVENTORIES (Tables) Sheet http://aehr.com/role/InventoriesTables INVENTORIES (Tables) Tables http://aehr.com/role/INVENTORIES 32 false false R33.htm 000033 - Disclosure - PRODUCT WARRANTIES (Tables) Sheet http://aehr.com/role/ProductWarrantiesTables PRODUCT WARRANTIES (Tables) Tables http://aehr.com/role/ProductWarranties 33 false false R34.htm 000034 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables) Sheet http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermTables CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables) Tables http://aehr.com/role/CustomerDepositsAndDeferredRevenueShortterm 34 false false R35.htm 000035 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLossTables ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables http://aehr.com/role/AccumulatedOtherComprehensiveLoss 35 false false R36.htm 000036 - Disclosure - LEASES (Tables) Sheet http://aehr.com/role/LeasesTables LEASES (Tables) Tables http://aehr.com/role/LEASES 36 false false R37.htm 000037 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://aehr.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://aehr.com/role/StockBasedCompensation 37 false false R38.htm 000038 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://aehr.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables 38 false false R39.htm 000039 - Disclosure - REVENUE (Details) Sheet http://aehr.com/role/RevenueDetails REVENUE (Details) Details http://aehr.com/role/RevenueTables 39 false false R40.htm 000040 - Disclosure - REVENUE (Details 1) Sheet http://aehr.com/role/RevenueDetails1 REVENUE (Details 1) Details http://aehr.com/role/RevenueTables 40 false false R41.htm 000041 - Disclosure - REVENUE (Details 2) Sheet http://aehr.com/role/RevenueDetails2 REVENUE (Details 2) Details http://aehr.com/role/RevenueTables 41 false false R42.htm 000042 - Disclosure - REVENUE (Details Narrative) Sheet http://aehr.com/role/RevenueDetailsNarrative REVENUE (Details Narrative) Details http://aehr.com/role/RevenueTables 42 false false R43.htm 000043 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://aehr.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://aehr.com/role/EarningsPerShareTables 43 false false R44.htm 000044 - Disclosure - EARNINGS PER SHARE (Details Narrative) Sheet http://aehr.com/role/EarningsPerShareDetailsNarrative EARNINGS PER SHARE (Details Narrative) Details http://aehr.com/role/EarningsPerShareTables 44 false false R45.htm 000045 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails CASH, CASH EQUIVALENTS AND INVESTMENTS (Details) Details http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables 45 false false R46.htm 000046 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) Sheet http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative) Details http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables 46 false false R47.htm 000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://aehr.com/role/FairValueOfFinancialInstrumentsTables 47 false false R48.htm 000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) Sheet http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) Details http://aehr.com/role/FairValueOfFinancialInstrumentsTables 48 false false R49.htm 000049 - Disclosure - INVENTORIES (Details) Sheet http://aehr.com/role/InventoriesDetails INVENTORIES (Details) Details http://aehr.com/role/InventoriesTables 49 false false R50.htm 000050 - Disclosure - PRODUCT WARRANTIES (Details) Sheet http://aehr.com/role/ProductWarrantiesDetails PRODUCT WARRANTIES (Details) Details http://aehr.com/role/ProductWarrantiesTables 50 false false R51.htm 000051 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details) Sheet http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermDetails CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details) Details http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermTables 51 false false R52.htm 000052 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details http://aehr.com/role/AccumulatedOtherComprehensiveLossTables 52 false false R53.htm 000053 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://aehr.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://aehr.com/role/IncomeTaxes 53 false false R54.htm 000054 - Disclosure - LEASES (Details) Sheet http://aehr.com/role/LeasesDetails LEASES (Details) Details http://aehr.com/role/LeasesTables 54 false false R55.htm 000055 - Disclosure - LEASES (Details 1) Sheet http://aehr.com/role/LeasesDetails1 LEASES (Details 1) Details http://aehr.com/role/LeasesTables 55 false false R56.htm 000056 - Disclosure - LEASES (Details Narrative) Sheet http://aehr.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://aehr.com/role/LeasesTables 56 false false R57.htm 000057 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) Sheet http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative BORROWING AND FINANCING ARRANGEMENTS (Details Narrative) Details http://aehr.com/role/BorrowingAndFinancingArrangements 57 false false R58.htm 000058 - Disclosure - LONGTERM DEBT (Details Narrative) Sheet http://aehr.com/role/LongtermDebtDetailsNarrative LONGTERM DEBT (Details Narrative) Details 58 false false R59.htm 000059 - Disclosure - STOCKBASED COMPENSATION (Details) Sheet http://aehr.com/role/StockbasedCompensationDetails STOCKBASED COMPENSATION (Details) Details 59 false false R60.htm 000060 - Disclosure - STOCKBASED COMPENSATION (Details 1) Sheet http://aehr.com/role/StockbasedCompensationDetails1 STOCKBASED COMPENSATION (Details 1) Details 60 false false R61.htm 000061 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://aehr.com/role/StockBasedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://aehr.com/role/StockBasedCompensationTables 61 false false R62.htm 000062 - Disclosure - STOCKBASED COMPENSATION (Details 3) Sheet http://aehr.com/role/StockbasedCompensationDetails3 STOCKBASED COMPENSATION (Details 3) Details 62 false false R63.htm 000063 - Disclosure - STOCK-BASED COMPENSATION (Details 4) Sheet http://aehr.com/role/StockBasedCompensationDetails4 STOCK-BASED COMPENSATION (Details 4) Details http://aehr.com/role/StockBasedCompensationTables 63 false false R64.htm 000064 - Disclosure - STOCKBASED COMPENSATION (Details 5) Sheet http://aehr.com/role/StockbasedCompensationDetails5 STOCKBASED COMPENSATION (Details 5) Details 64 false false R65.htm 000065 - Disclosure - STOCK-BASED COMPENSATION (Details 6) Sheet http://aehr.com/role/StockBasedCompensationDetails6 STOCK-BASED COMPENSATION (Details 6) Details http://aehr.com/role/StockBasedCompensationTables 65 false false R66.htm 000066 - Disclosure - STOCK-BASED COMPENSATION (Details 7) Sheet http://aehr.com/role/StockBasedCompensationDetails7 STOCK-BASED COMPENSATION (Details 7) Details http://aehr.com/role/StockBasedCompensationTables 66 false false R67.htm 000067 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) Sheet http://aehr.com/role/StockbasedCompensationDetailsNarrative STOCKBASED COMPENSATION (Details Narrative) Details 67 false false R68.htm 000068 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details) Sheet http://aehr.com/role/SegmentAndConcentrationInformationDetails SEGMENT AND CONCENTRATION INFORMATION (Details) Details http://aehr.com/role/SegmentAndConcentrationInformation 68 false false R69.htm 000069 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details Narrative) Sheet http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative SEGMENT AND CONCENTRATION INFORMATION (Details Narrative) Details http://aehr.com/role/SegmentAndConcentrationInformation 69 false false R70.htm 000070 - Disclosure - SUBSEQUENT EVENT (Details Narrative) Sheet http://aehr.com/role/SubsequentEventDetailsNarrative SUBSEQUENT EVENT (Details Narrative) Details http://aehr.com/role/SubsequentEvents 70 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 40 fact(s) appearing in ix:hidden were eligible for transformation: aehr:FairValueAssetsLevel1ToLevel2TransfersAmount1, aehr:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriod, aehr:StockBasedCompensationCostsCapitalizedAsPartOfInventory, us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:CashEquivalentsAtCarryingValue, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:ConcentrationRiskPercentage1, us-gaap:DebtInstrumentDecreaseForgiveness, us-gaap:FinancialLiabilitiesFairValueDisclosure, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:LongTermInvestments, us-gaap:ProceedsFromLinesOfCredit, us-gaap:RestrictedCashNoncurrent, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans - aehr_10q.htm 1 aehr_10q.htm aehr-20221130.xsd aehr-20221130_cal.xml aehr-20221130_def.xml aehr-20221130_lab.xml aehr-20221130_pre.xml aehr_ex311.htm aehr_ex312.htm aehr_ex32.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aehr_10q.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 777, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 226, "dts": { "calculationLink": { "local": [ "aehr-20221130_cal.xml" ] }, "definitionLink": { "local": [ "aehr-20221130_def.xml" ] }, "inline": { "local": [ "aehr_10q.htm" ] }, "labelLink": { "local": [ "aehr-20221130_lab.xml" ] }, "presentationLink": { "local": [ "aehr-20221130_pre.xml" ] }, "schema": { "local": [ "aehr-20221130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 416, "entityCount": 1, "hidden": { "http://aehr.com/20221130": 5, "http://fasb.org/us-gaap/2022": 35, "http://xbrl.sec.gov/dei/2022": 5, "total": 45 }, "keyCustom": 40, "keyStandard": 224, "memberCustom": 40, "memberStandard": 20, "nsprefix": "aehr", "nsuri": "http://aehr.com/20221130", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aehr.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - REVENUE", "menuCat": "Notes", "order": "10", "role": "http://aehr.com/role/REVENUE", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - EARNINGS PER SHARE", "menuCat": "Notes", "order": "11", "role": "http://aehr.com/role/EarningsPerShare", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS", "menuCat": "Notes", "order": "12", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestments", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "menuCat": "Notes", "order": "13", "role": "http://aehr.com/role/FairValueOfFinancialInstruments", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - TRADE AND OTHER ACCOUNTS RECEIVABLE, NET", "menuCat": "Notes", "order": "14", "role": "http://aehr.com/role/TradeAndOtherAccountsReceivableNet", "shortName": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - INVENTORIES", "menuCat": "Notes", "order": "15", "role": "http://aehr.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - PRODUCT WARRANTIES", "menuCat": "Notes", "order": "16", "role": "http://aehr.com/role/ProductWarranties", "shortName": "PRODUCT WARRANTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM", "menuCat": "Notes", "order": "17", "role": "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShortterm", "shortName": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS", "menuCat": "Notes", "order": "18", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "19", "role": "http://aehr.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://aehr.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - LEASES", "menuCat": "Notes", "order": "20", "role": "http://aehr.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS", "menuCat": "Notes", "order": "21", "role": "http://aehr.com/role/BorrowingAndFinancingArrangements", "shortName": "BORROWING AND FINANCING ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - LONG-TERM DEBT", "menuCat": "Notes", "order": "22", "role": "http://aehr.com/role/LongTermDebt", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "23", "role": "http://aehr.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION", "menuCat": "Notes", "order": "24", "role": "http://aehr.com/role/SegmentAndConcentrationInformation", "shortName": "SEGMENT AND CONCENTRATION INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "25", "role": "http://aehr.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "26", "role": "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Policies)", "menuCat": "Policies", "order": "27", "role": "http://aehr.com/role/RecentAccountingPronouncementsPolicies", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - REVENUE (Tables)", "menuCat": "Tables", "order": "28", "role": "http://aehr.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - EARNINGS PER SHARE (Tables)", "menuCat": "Tables", "order": "29", "role": "http://aehr.com/role/EarningsPerShareTables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "menuCat": "Tables", "order": "30", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "menuCat": "Tables", "order": "31", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - INVENTORIES (Tables)", "menuCat": "Tables", "order": "32", "role": "http://aehr.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - PRODUCT WARRANTIES (Tables)", "menuCat": "Tables", "order": "33", "role": "http://aehr.com/role/ProductWarrantiesTables", "shortName": "PRODUCT WARRANTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:CustomerDepositsAndDeferredRevenueShortTermTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables)", "menuCat": "Tables", "order": "34", "role": "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermTables", "shortName": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:CustomerDepositsAndDeferredRevenueShortTermTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "menuCat": "Tables", "order": "35", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "36", "role": "http://aehr.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "37", "role": "http://aehr.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - SEGMENT INFORMATION (Tables)", "menuCat": "Tables", "order": "38", "role": "http://aehr.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - REVENUE (Details)", "menuCat": "Details", "order": "39", "role": "http://aehr.com/role/RevenueDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_aehr_ContactorsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)", "menuCat": "Statements", "order": "4", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - REVENUE (Details 1)", "menuCat": "Details", "order": "40", "role": "http://aehr.com/role/RevenueDetails1", "shortName": "REVENUE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_srt_AsiaMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - REVENUE (Details 2)", "menuCat": "Details", "order": "41", "role": "http://aehr.com/role/RevenueDetails2", "shortName": "REVENUE (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_aehr_ProductsAndServicesTransferredAtAPointInTimeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - REVENUE (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://aehr.com/role/RevenueDetailsNarrative", "shortName": "REVENUE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-05-31", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - EARNINGS PER SHARE (Details)", "menuCat": "Details", "order": "43", "role": "http://aehr.com/role/EarningsPerShareDetails", "shortName": "EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30_aehr_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - EARNINGS PER SHARE (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://aehr.com/role/EarningsPerShareDetailsNarrative", "shortName": "EARNINGS PER SHARE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30_aehr_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details)", "menuCat": "Details", "order": "45", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_CostMember", "decimals": "-3", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_GrossUnrealizedLossMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "shortName": "CASH, CASH EQUIVALENTS AND INVESTMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_GrossUnrealizedLossMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_us-gaap_MoneyMarketFundsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "menuCat": "Details", "order": "47", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_us-gaap_MoneyMarketFundsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - INVENTORIES (Details)", "menuCat": "Details", "order": "49", "role": "http://aehr.com/role/InventoriesDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)", "menuCat": "Statements", "order": "5", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-08-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - PRODUCT WARRANTIES (Details)", "menuCat": "Details", "order": "50", "role": "http://aehr.com/role/ProductWarrantiesDetails", "shortName": "PRODUCT WARRANTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-08-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:CustomerDepositsAndDeferredRevenueShortTermTableTextBlock", "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "aehr:CustomerDepositsAndDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details)", "menuCat": "Details", "order": "51", "role": "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermDetails", "shortName": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:CustomerDepositsAndDeferredRevenueShortTermTableTextBlock", "aehr:CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "aehr:CustomerDepositsAndDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-05-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "menuCat": "Details", "order": "52", "role": "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "aehr:ProvisionForIncomeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "53", "role": "http://aehr.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "aehr:ProvisionForIncomeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - LEASES (Details)", "menuCat": "Details", "order": "54", "role": "http://aehr.com/role/LeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - LEASES (Details 1)", "menuCat": "Details", "order": "55", "role": "http://aehr.com/role/LeasesDetails1", "shortName": "LEASES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - LEASES (Details Narrative)", "menuCat": "Details", "order": "56", "role": "http://aehr.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_OriginalLoanAndSecurityAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - BORROWING AND FINANCING ARRANGEMENTS (Details Narrative)", "menuCat": "Details", "order": "57", "role": "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "shortName": "BORROWING AND FINANCING ARRANGEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_OriginalLoanAndSecurityAgreementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2020-04-23_aehr_SiliconValleyBankMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - LONGTERM DEBT (Details Narrative)", "menuCat": "Details", "order": "58", "role": "http://aehr.com/role/LongtermDebtDetailsNarrative", "shortName": "LONGTERM DEBT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2020-04-23_aehr_SiliconValleyBankMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - STOCKBASED COMPENSATION (Details)", "menuCat": "Details", "order": "59", "role": "http://aehr.com/role/StockbasedCompensationDetails", "shortName": "STOCKBASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited)", "menuCat": "Statements", "order": "6", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_aehr_StockOptionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - STOCKBASED COMPENSATION (Details 1)", "menuCat": "Details", "order": "60", "role": "http://aehr.com/role/StockbasedCompensationDetails1", "shortName": "STOCKBASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_aehr_StockOptionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - STOCK-BASED COMPENSATION (Details 2)", "menuCat": "Details", "order": "61", "role": "http://aehr.com/role/StockBasedCompensationDetails2", "shortName": "STOCK-BASED COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-08-31_aehr_StockOptionAndRSUTransactionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - STOCKBASED COMPENSATION (Details 3)", "menuCat": "Details", "order": "62", "role": "http://aehr.com/role/StockbasedCompensationDetails3", "shortName": "STOCKBASED COMPENSATION (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-05-31_aehr_StockOptionAndRSUTransactionsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-08-31_aehr_OutstandingOptionsStockOptionTransactionsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000063 - Disclosure - STOCK-BASED COMPENSATION (Details 4)", "menuCat": "Details", "order": "63", "role": "http://aehr.com/role/StockBasedCompensationDetails4", "shortName": "STOCK-BASED COMPENSATION (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-05-31_aehr_OutstandingOptionsStockOptionTransactionsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_Range1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000064 - Disclosure - STOCKBASED COMPENSATION (Details 5)", "menuCat": "Details", "order": "64", "role": "http://aehr.com/role/StockbasedCompensationDetails5", "shortName": "STOCKBASED COMPENSATION (Details 5)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_aehr_Range1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:RsusPrsusRestrictedSharesAndPerformanceRestrictedSharesGrantedtabletextblock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30_aehr_EmployeesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000065 - Disclosure - STOCK-BASED COMPENSATION (Details 6)", "menuCat": "Details", "order": "65", "role": "http://aehr.com/role/StockBasedCompensationDetails6", "shortName": "STOCK-BASED COMPENSATION (Details 6)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:RsusPrsusRestrictedSharesAndPerformanceRestrictedSharesGrantedtabletextblock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2021-09-01to2021-11-30_aehr_EmployeesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:RsusAndPrsusVestedAndUnvestedDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000066 - Disclosure - STOCK-BASED COMPENSATION (Details 7)", "menuCat": "Details", "order": "66", "role": "http://aehr.com/role/StockBasedCompensationDetails7", "shortName": "STOCK-BASED COMPENSATION (Details 7)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "aehr:RsusAndPrsusVestedAndUnvestedDuringPeriodTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000067 - Disclosure - STOCKBASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "67", "role": "http://aehr.com/role/StockbasedCompensationDetailsNarrative", "shortName": "STOCKBASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000068 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details)", "menuCat": "Details", "order": "68", "role": "http://aehr.com/role/SegmentAndConcentrationInformationDetails", "shortName": "SEGMENT AND CONCENTRATION INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30_srt_AsiaMember", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000069 - Disclosure - SEGMENT AND CONCENTRATION INFORMATION (Details Narrative)", "menuCat": "Details", "order": "69", "role": "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative", "shortName": "SEGMENT AND CONCENTRATION INFORMATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-09-01to2022-11-30_aehr_CustomersAMember", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)", "menuCat": "Statements", "order": "7", "role": "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-12-01to2022-12-05_us-gaap_SubsequentEventMember", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:DescriptionOfChangesInMonthlyBaseRent", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - SUBSEQUENT EVENT (Details Narrative)", "menuCat": "Details", "order": "70", "role": "http://aehr.com/role/SubsequentEventDetailsNarrative", "shortName": "SUBSEQUENT EVENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-12-01to2022-12-05_us-gaap_SubsequentEventMember", "decimals": null, "first": true, "lang": "en-US", "name": "aehr:DescriptionOfChangesInMonthlyBaseRent", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "menuCat": "Notes", "order": "9", "role": "http://aehr.com/role/RecentAccountingPronouncements", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "aehr_10q.htm", "contextRef": "From2022-06-01to2022-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "aehr_AccumulatedOtherComprehensiveLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "AccumulatedOtherComprehensiveLossAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_AmountsReclassifiedOutOfAoci": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amounts reclassified out of accumulated other comprehensive loss" } } }, "localname": "AmountsReclassifiedOutOfAoci", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "aehr_AnnualRestrictedSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual restricted shares granted" } } }, "localname": "AnnualRestrictedSharesGranted", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_AsiasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "localname": "AsiasMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Of Directors" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "domainItemType" }, "aehr_ContactorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contactors" } } }, "localname": "ContactorsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_CostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost [Member]" } } }, "localname": "CostMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "domainItemType" }, "aehr_CumulativeTranslationAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative Translation Adjustments [Member]" } } }, "localname": "CumulativeTranslationAdjustmentsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "aehr_CustomerDepositsAndDeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "CustomerDepositsAndDeferredRevenue", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermDetails" ], "xbrltype": "monetaryItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTerm": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Customer deposits and deferred revenue, short-term" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTerm", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTermAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "CUSTOMER DEPOSITS AND DEFERRED REVENUE, SHORT-TERM" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTermDisclosureTextBlock", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShortterm" ], "xbrltype": "textBlockItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTermTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Customer deposits and deferred revenue" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTermTableTextBlock", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermTables" ], "xbrltype": "textBlockItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShortTermTablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Tables)" } } }, "localname": "CustomerDepositsAndDeferredRevenueShortTermTablesAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_CustomerDepositsAndDeferredRevenueShorttermDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CUSTOMER DEPOSITS AND DEFERRED REVENUE SHORTTERM (Details)" } } }, "localname": "CustomerDepositsAndDeferredRevenueShorttermDetailsAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_CustomerPurchaseOrderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Purchase Order" } } }, "localname": "CustomerPurchaseOrderMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_CustomersAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer A [Member]" } } }, "localname": "CustomersAMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_CustomersBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customers B [Member]" } } }, "localname": "CustomersBMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_DescriptionAboutAmendmentAgreemnet": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description about amendment third agreemnet" } } }, "localname": "DescriptionAboutAmendmentAgreemnet", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "aehr_DescriptionOfChangesInMonthlyBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of changes in monthly base rent" } } }, "localname": "DescriptionOfChangesInMonthlyBaseRent", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "aehr_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employees Member" } } }, "localname": "EmployeesMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "domainItemType" }, "aehr_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2016 Equity Incentive Plan" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_EstimatedFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Estimated Fair Value [Member]" } } }, "localname": "EstimatedFairValueMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "domainItemType" }, "aehr_EstimatedForfeituresOfUnvestedStockBasedAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Estimated forfeitures of unvested stock based awards, amount" } } }, "localname": "EstimatedForfeituresOfUnvestedStockBasedAwards", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_EuropesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe" } } }, "localname": "EuropesMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails1" ], "xbrltype": "domainItemType" }, "aehr_FairValueAssetsLevel1ToLevel2TransfersAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Transfer between Level 1 and Level 2 fair value measurements" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_FirstAmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Amendment to Loan and Security Agreement" } } }, "localname": "FirstAmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_FiveLargestCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Five Largest Customers [Member]" } } }, "localname": "FiveLargestCustomersMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_GainFromForgivenessOfPppLoan": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain from forgiveness of PPP loan", "negatedLabel": "Gain from forgiveness of PPP loan" } } }, "localname": "GainFromForgivenessOfPppLoan", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_GrossUnrealizedLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Unrealized Loss", "verboseLabel": "Gross Unrealized Loss" } } }, "localname": "GrossUnrealizedLossMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_IncreaseDecreaseInCustomerDepositsAndDeferredRevenue": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Customer deposits and deferred revenue" } } }, "localname": "IncreaseDecreaseInCustomerDepositsAndDeferredRevenue", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_IncreaseDecreaseInPrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Prepaid expenses and other assets]", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherAssets", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_IncreaseDecreaseInTradeAndOtherAccountsReceivable": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Trade and other accounts receivable" } } }, "localname": "IncreaseDecreaseInTradeAndOtherAccountsReceivable", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_NetCashUsedInProvidedByFinancingActivities": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Net cash (used in) provided by financing activities]", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashUsedInProvidedByFinancingActivities", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_NetIncomePerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income per share" } } }, "localname": "NetIncomePerShareAbstract", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "aehr_OriginalLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Original Loan and Security Agreement" } } }, "localname": "OriginalLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_OutstandingOptionsStockOptionTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Options Stock Option Transactions" } } }, "localname": "OutstandingOptionsStockOptionTransactionsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "domainItemType" }, "aehr_PerformanceRestrictedSharesGrantedBasedOnRevenueTargetThresholdsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Performance restricted shares granted based on revenue target thresholds maximum" } } }, "localname": "PerformanceRestrictedSharesGrantedBasedOnRevenueTargetThresholdsMaximum", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_ProceedsFromPublicOfferingsNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from public offerings, net of issuance costs, amount" } } }, "localname": "ProceedsFromPublicOfferingsNetOfIssuanceCostsAmount", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "aehr_ProceedsFromPublicOfferingsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from public offerings, net of issuance costs, shares" } } }, "localname": "ProceedsFromPublicOfferingsNetOfIssuanceCostsShares", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "aehr_ProductsAndServicesTransferredAtAPointInTimeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Products and Services Transferred at a Point in Time" } } }, "localname": "ProductsAndServicesTransferredAtAPointInTimeMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "aehr_ProvisionForIncomeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Provision For Income Tax" } } }, "localname": "ProvisionForIncomeTax", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_PrsusGrantedBasedOnRevenueTargetThresholdsMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PRSUs granted based on revenue target thresholds maximum" } } }, "localname": "PrsusGrantedBasedOnRevenueTargetThresholdsMaximum", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_Range1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.34" } } }, "localname": "Range1Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.64-$1.86" } } }, "localname": "Range2Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$2.03-$2.40" } } }, "localname": "Range3Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$2.76-$2.93" } } }, "localname": "Range4Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$3.46-$3.93" } } }, "localname": "Range5Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_Range6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$8.00-$24.83" } } }, "localname": "Range6Member", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RangeTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$1.34-$24.83" } } }, "localname": "RangeTenMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "aehr_RentImprovementAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Improvement allowance" } } }, "localname": "RentImprovementAllowance", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_RestrictedStockSharesIssuedNetOfSharesForTaxWithholding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares repurchased for tax withholdings on vesting of restricted stock units, shares" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholding", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "aehr_RsusAndPrsusVestedAndUnvestedDuringPeriodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs and PRSUs vested and unvested during period" } } }, "localname": "RsusAndPrsusVestedAndUnvestedDuringPeriodTableTextBlock", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "aehr_RsusGrantedInLieuOfCashPaymentForSalaryReductions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs granted in lieu of cash payment for salary reductions" } } }, "localname": "RsusGrantedInLieuOfCashPaymentForSalaryReductions", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "aehr_RsusPrsusRestrictedSharesAndPerformanceRestrictedSharesGrantedtabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs, PRSUs, restricted shares and performance restricted shares granted" } } }, "localname": "RsusPrsusRestrictedSharesAndPerformanceRestrictedSharesGrantedtabletextblock", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "aehr_SecondAmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Amendment To Loan And Security Agreement" } } }, "localname": "SecondAmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_SegmentAndConcentrationInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT AND CONCENTRATION INFORMATION" } } }, "localname": "SegmentAndConcentrationInformationAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_SegmentAndConcentrationInformationDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT AND CONCENTRATION INFORMATION (Details)" } } }, "localname": "SegmentAndConcentrationInformationDetailsAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_SegmentAndConcentrationInformationDetailsNarrativeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT AND CONCENTRATION INFORMATION (Details Narrative)" } } }, "localname": "SegmentAndConcentrationInformationDetailsNarrativeAbstract", "nsuri": "http://aehr.com/20221130", "xbrltype": "stringItemType" }, "aehr_ServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Services" } } }, "localname": "ServicesMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_ServicesTransferredOverTimeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Services Transferred over Time" } } }, "localname": "ServicesTransferredOverTimeMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[RSUs granted]", "negatedLabel": "RSUs granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRSUsGrantsInPeriodGross", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RSUs and PRSUs unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardEmployeeStockPPurchasePlanNumberSharesAvailableForGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ESPP shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardEmployeeStockPPurchasePlanNumberSharesAvailableForGrant", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of RSU in lieu of cash payment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ESPP purchase right granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriod", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "aehr_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "aehr_SharebasedCompensationArrangementBySharebasedPaymentsAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intrinsic value of unvested RSUs and PRSUs (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentsAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails7" ], "xbrltype": "monetaryItemType" }, "aehr_SharesUsedInBasicNetIncomePerShareCalculation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares used in basic net income per share calculation" } } }, "localname": "SharesUsedInBasicNetIncomePerShareCalculation", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "aehr_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silicon Valley Bank" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_StockBasedCompensationCostsCapitalizedAsPartOfInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock Based Compensation Costs Capitalized As part of inventory" } } }, "localname": "StockBasedCompensationCostsCapitalizedAsPartOfInventory", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_StockBasedCompensationRelatedToEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation related to the ESPP" } } }, "localname": "StockBasedCompensationRelatedToEmployeeStockPurchasePlan", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_StockOptionAndRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option and RSU" } } }, "localname": "StockOptionAndRSUMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_StockOptionAndRSUTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option and RSU Transactions [Member]" } } }, "localname": "StockOptionAndRSUTransactionsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails3" ], "xbrltype": "domainItemType" }, "aehr_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option" } } }, "localname": "StockOptionsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/EarningsPerShareDetailsNarrative", "http://aehr.com/role/StockbasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "aehr_StockbasedCompensationExpenseRelatedToStockOptionsAndRestrictedShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation expense related to stock options and RSUs" } } }, "localname": "StockbasedCompensationExpenseRelatedToStockOptionsAndRestrictedShares", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_SystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Systems" } } }, "localname": "SystemsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_TestDuringBurnInMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Test During Burn-In" } } }, "localname": "TestDuringBurnInMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_TotalInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total interest" } } }, "localname": "TotalInterest", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "aehr_USAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "localname": "USAMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "aehr_USsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States" } } }, "localname": "USsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails1" ], "xbrltype": "domainItemType" }, "aehr_UStreasurysecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U.S. treasury securities [Member]" } } }, "localname": "UStreasurysecuritiesMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "aehr_UnitedStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[United States]", "verboseLabel": "United States" } } }, "localname": "UnitedStateMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "domainItemType" }, "aehr_UnrealizedLossOnInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrealized Loss on Investments, Net Member" } } }, "localname": "UnrealizedLossOnInvestmentsMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "aehr_WaferLevelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Wafer-Level" } } }, "localname": "WaferLevelMember", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfAnnualRestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of annual restricted shares" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfAnnualRestrictedShares", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of PRSUs" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsus", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "aehr_WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsusPerformanceRestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average market value on the date of the grant of PRSUs, performance restricted shares" } } }, "localname": "WeightedAverageMarketValueOnTheDateOfTheGrantOfPrsusPerformanceRestrictedShares", "nsuri": "http://aehr.com/20221130", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "verboseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r222", "r468", "r515", "r561" ], "lang": { "en-us": { "role": { "label": "Major Customers Axis" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r248", "r249", "r250", "r251", "r301", "r411", "r426", "r449", "r450", "r465", "r473", "r481", "r513", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r248", "r249", "r250", "r251", "r301", "r411", "r426", "r449", "r450", "r465", "r473", "r481", "r513", "r552", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r222", "r468", "r515", "r561" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r218", "r412", "r466", "r479", "r509", "r510", "r515", "r560" ], "lang": { "en-us": { "role": { "label": "Product Or Service Axis" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r218", "r412", "r466", "r479", "r509", "r510", "r515", "r560" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r248", "r249", "r250", "r251", "r292", "r301", "r327", "r328", "r329", "r410", "r411", "r426", "r449", "r450", "r465", "r473", "r481", "r508", "r513", "r553", "r554", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r248", "r249", "r250", "r251", "r292", "r301", "r327", "r328", "r329", "r410", "r411", "r426", "r449", "r450", "r465", "r473", "r481", "r508", "r513", "r553", "r554", "r555", "r556", "r557" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r302", "r504" ], "lang": { "en-us": { "role": { "label": "Scenario Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r170", "r302", "r488", "r504" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r219", "r220", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r467", "r480", "r515" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r219", "r220", "r437", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r467", "r480", "r515" ], "lang": { "en-us": { "role": { "label": "Statement Geographical Axis" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r170", "r302", "r488", "r489", "r504" ], "lang": { "en-us": { "role": { "label": "Statement Scenario Axis" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Trade and other accounts receivable, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r478" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r45" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "[Accretion (Amortization) of Discounts and Premiums, Investments]", "negatedLabel": "Accretion of investment discount" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r25", "r26", "r128", "r421", "r431", "r434" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss", "periodEndLabel": "Balance at the ending of the year", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r22", "r26", "r88", "r402", "r427", "r428", "r495", "r496", "r497", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r336", "r337", "r338", "r501", "r502", "r503", "r543" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r82", "r83", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Options not included in the computation of diluted net income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r96", "r109", "r127", "r150", "r202", "r208", "r214", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r359", "r363", "r375", "r478", "r511", "r512", "r550" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r122", "r130", "r150", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r359", "r363", "r375", "r478", "r511", "r512", "r550" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails6", "http://aehr.com/role/StockbasedCompensationDetails1", "http://aehr.com/role/StockbasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r435", "r436", "r478", "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH, CASH EQUIVALENTS AND INVESTMENTS" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r46", "r124", "r451" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "verboseLabel": "CASH, CASH EQUIVALENTS AND INVESTMENTS" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Total cash, cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r41", "r46", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period(1)", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period(1)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r41", "r94" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r501", "r502", "r543" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r69" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r478" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value: Authorized: 75,000 shares; Issued and outstanding: 27,732 shares and 27,120 shares at November 30, 2022 and May 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r27", "r134", "r136", "r142", "r417", "r423" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r35", "r141", "r416", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "verboseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r51", "r52", "r92", "r93", "r222", "r439", "r562" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type Axis" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r51", "r52", "r92", "r93", "r222" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Customers accounted for 10% or more of total revenues" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r51", "r52", "r92", "r93", "r222", "r439" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r87", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "PRINCIPLES OF CONSOLIDATION" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r275", "r276", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Recognition of contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r32", "r150", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r375", "r511" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerDepositsCurrent": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.", "label": "Customer deposits" } } }, "localname": "CustomerDepositsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BORROWING AND FINANCING ARRANGEMENTS" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r68", "r149", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "BORROWING AND FINANCING ARRANGEMENTS:" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Recognized a gain on loan forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r18", "r261" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Variable interest rate" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r226", "r232", "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Unrealized loss" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CustomerDepositsAndDeferredRevenueShorttermDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r492" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred revenue, long-term" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r44", "r59" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r304", "r332", "r333", "r335", "r339", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r143", "r162", "r163", "r164", "r165", "r166", "r173", "r175", "r177", "r178", "r179", "r183", "r367", "r368", "r418", "r424", "r458" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic", "verboseLabel": "Basic net income per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r143", "r162", "r163", "r164", "r165", "r166", "r175", "r177", "r178", "r179", "r183", "r367", "r368", "r418", "r424", "r458" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted", "verboseLabel": "Diluted net income per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r381" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average period for recognition of costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock Purchase Plan", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Information by name of employee stock ownership plan.", "label": "Employee Stock Ownership Plan E S O P Disclosures By Plan Axis" } } }, "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r69", "r118", "r137", "r138", "r139", "r153", "r154", "r155", "r159", "r167", "r169", "r185", "r228", "r274", "r336", "r337", "r338", "r344", "r345", "r366", "r383", "r384", "r385", "r386", "r387", "r388", "r402", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r89", "r91" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r269", "r294", "r295", "r296", "r297", "r298", "r299", "r373", "r407", "r408", "r409", "r463", "r464", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r269", "r294", "r299", "r373", "r407", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r269", "r294", "r299", "r373", "r408", "r463", "r464", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r269", "r294", "r295", "r296", "r297", "r298", "r299", "r373", "r409", "r463", "r464", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r269", "r294", "r295", "r296", "r297", "r298", "r299", "r407", "r408", "r409", "r463", "r464", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial liabilities at fair value" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "Selling, General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r31", "r150", "r202", "r207", "r213", "r216", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r375", "r460", "r511" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r28", "r95", "r104", "r115", "r202", "r207", "r213", "r216", "r419", "r460" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Income before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r243", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location Axis" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r151", "r341", "r342", "r343", "r349", "r351", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r152", "r168", "r169", "r200", "r340", "r350", "r353", "r425" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "[Income Tax Expense (Benefit)]", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r43" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r43" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r43" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r43" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r106" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVENTORIES" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r58", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r129", "r452", "r478" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets", "http://aehr.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVENTORIES (Details)" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r58", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials and sub-assemblies" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r58", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investment securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Supplemental cash flow information related to leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Fourth amendment Lease expiry date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in measurement of operating lease liabilities:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Maturity of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total future minimum operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2023 (excluding the first three months of 2023)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r150", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r360", "r363", "r364", "r375", "r459", "r511", "r550", "r551" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r98", "r111", "r478", "r500", "r507", "r544" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r123", "r150", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r360", "r363", "r364", "r375", "r478", "r511", "r550", "r551" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r13", "r499" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Line Of Credit Facility Axis" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Revolving line maturity date", "verboseLabel": "Revolving line matuity date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r13", "r499" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit, maximum borrowing" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Balance available to borrow under the line of credit" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "verboseLabel": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/TradeAndOtherAccountsReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r1", "r97", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "PPP loan" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongtermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Property and equipment by geographic region" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "verboseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term investments:" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "PRODUCT WARRANTIES (Details)" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r41", "r42", "r45" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r29", "r45", "r105", "r114", "r121", "r133", "r135", "r139", "r150", "r158", "r162", "r163", "r164", "r165", "r168", "r169", "r176", "r202", "r207", "r213", "r216", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r368", "r375", "r460", "r511" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r119", "r156", "r157", "r160", "r161", "r170", "r171", "r172", "r224", "r225", "r229", "r230", "r346", "r347", "r348", "r365", "r369", "r370", "r371", "r376", "r377", "r378", "r390", "r391", "r401", "r403", "r413", "r414", "r415", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r202", "r207", "r213", "r216", "r460" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r395", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease, cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES (Details 1)" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r393" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r393" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r394", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r392" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets", "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r398", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease, weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r397", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease, weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r126" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r21", "r23", "r379", "r380", "r382" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Net change in cumulative translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in other comprehensive income." } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r24", "r137" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other comprehensive loss before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r24", "r137", "r141", "r340", "r352", "r354", "r383", "r386", "r388", "r416", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r131", "r132" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net change in unrealized loss on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r103", "r113", "r493" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Short-term investments" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r145" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "aehr_NetCashUsedInProvidedByFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]", "negatedLabel": "Shares repurchased for tax withholdings on vesting of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r37" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "[Payments to Acquire Investments]", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r36" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment." } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/RevenueDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/RevenueDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r494" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r38" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "aehr_NetCashUsedInProvidedByFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance of common stock from public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r38" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "aehr_NetCashUsedInProvidedByFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock under employee plans" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r39", "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Borrowing under line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PRODUCT WARRANTIES" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r64", "r65", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "[Standard and Extended Product Warranty Accrual]", "periodEndLabel": "Balance at the End of the year", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "[Standard and Extended Product Warranty Accrual, Decrease for Payments]", "negatedLabel": "Consumption of reserves" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties.", "label": "Adjustments to previously existing warranty accruals" } } }, "localname": "ProductWarrantyAccrualPreexistingIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Accruals for warranties issued during the period" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarrantiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "verboseLabel": "PRODUCT WARRANTIES" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarranties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r121", "r133", "r135", "r146", "r150", "r158", "r168", "r169", "r202", "r207", "r213", "r216", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r358", "r361", "r362", "r368", "r375", "r419", "r460", "r475", "r476", "r497", "r511" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r60", "r112", "r420", "r478" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets", "http://aehr.com/role/SegmentAndConcentrationInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r144", "r231" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TRADE AND OTHER ACCOUNTS RECEIVABLE, NET" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r40", "r499" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "aehr_NetCashUsedInProvidedByFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "[Repayments of Lines of Credit]", "negatedLabel": "Line of credit repayments, net" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r86", "r116", "r558" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r438", "r491", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Shares repurchased for tax withholdings on vesting of restricted stock units, amount" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r70", "r110", "r430", "r434", "r478" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r118", "r153", "r154", "r155", "r159", "r167", "r169", "r228", "r336", "r337", "r338", "r344", "r345", "r366", "r427", "r429" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r193", "r194", "r206", "r211", "r212", "r218", "r219", "r222", "r286", "r287", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net Sales", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/REVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Remaining performance obligation revenue recognition" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r140", "r150", "r193", "r194", "r206", "r211", "r212", "r218", "r219", "r222", "r227", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r375", "r419", "r511" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r26", "r545", "r546" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Changes in the components of accumulated other comprehensive loss, net of tax" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, cash equivalents and investments by security type" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Compensation costs related to the Company's stock-based compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair value by hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r9", "r10", "r11" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Liability for product warranties" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/ProductWarrantiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r72", "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Stock option and RSU transactions" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r71", "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock option transactions" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair value assumptions of the ESPP purchase rights" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Fair value assumptions for Option Valuation Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r190", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r246", "r247", "r462", "r560" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION (Tables)" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r202", "r205", "r210", "r214", "r215", "r216", "r217", "r218", "r221", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT AND CONCENTRATION INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r43" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKBASED COMPENSATION (Details)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted average market value on the date of the grant of annual RSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Net RSUs and PRSUs vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility", "verboseLabel": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rates", "verboseLabel": "Risk-free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant]", "periodEndLabel": "Available shares, ending", "periodStartLabel": "Available shares, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Option exercisable shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price for options exercisable | $ / shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Total intrinsic values of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted average exercise price cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Options cancelled and adjusted", "negatedLabel": "Options cancelled (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockbasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross]", "negatedLabel": "Options granted", "verboseLabel": "Options granted (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockbasedCompensationDetails3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value]", "verboseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value]", "periodEndLabel": "Aggregate intrinsic value, ending", "periodStartLabel": "Aggregate intrinsic value, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Options outstanding, ending (in thousands)", "periodStartLabel": "Options outstanding, beginning (in thousands)", "verboseLabel": "Options outstanding, ending (in thousands) | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price outstanding, ending", "periodStartLabel": "Weighted average exercise price outstanding, beginning", "verboseLabel": "Weighted average exercise price outstanding, ending | $ / shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Aggregate intrinsic value for options fully vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options fully vested and expected to vest (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average exercise price fully vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails6", "http://aehr.com/role/StockbasedCompensationDetails1", "http://aehr.com/role/StockbasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value for options exercisable |" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life (Years) options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life (Years) options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetails5" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average remaining contractual life of the options exercisable and expected to be exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares withheld to settle payroll taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails7" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r99", "r100", "r108", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r120", "r190", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r246", "r247", "r462", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r69", "r118", "r137", "r138", "r139", "r153", "r154", "r155", "r159", "r167", "r169", "r185", "r228", "r274", "r336", "r337", "r338", "r344", "r345", "r366", "r383", "r384", "r385", "r386", "r387", "r388", "r402", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://aehr.com/role/EarningsPerShareDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/LongtermDebtDetailsNarrative", "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2", "http://aehr.com/role/RevenueDetailsNarrative", "http://aehr.com/role/SegmentAndConcentrationInformationDetails", "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails6", "http://aehr.com/role/StockbasedCompensationDetails", "http://aehr.com/role/StockbasedCompensationDetails1", "http://aehr.com/role/StockbasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetails5", "http://aehr.com/role/StockbasedCompensationDetailsNarrative", "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY (unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r153", "r154", "r155", "r185", "r412" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/AccumulatedOtherComprehensiveLossDetails", "http://aehr.com/role/BorrowingAndFinancingArrangementsDetailsNarrative", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetailsNarrative", "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://aehr.com/role/EarningsPerShareDetailsNarrative", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails", "http://aehr.com/role/LeasesDetailsNarrative", "http://aehr.com/role/LongtermDebtDetailsNarrative", "http://aehr.com/role/RevenueDetails", "http://aehr.com/role/RevenueDetails1", "http://aehr.com/role/RevenueDetails2", "http://aehr.com/role/RevenueDetailsNarrative", "http://aehr.com/role/SegmentAndConcentrationInformationDetails", "http://aehr.com/role/SegmentAndConcentrationInformationDetailsNarrative", "http://aehr.com/role/StockBasedCompensationDetails2", "http://aehr.com/role/StockBasedCompensationDetails4", "http://aehr.com/role/StockBasedCompensationDetails6", "http://aehr.com/role/StockbasedCompensationDetails", "http://aehr.com/role/StockbasedCompensationDetails1", "http://aehr.com/role/StockbasedCompensationDetails3", "http://aehr.com/role/StockbasedCompensationDetails5", "http://aehr.com/role/StockbasedCompensationDetailsNarrative", "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r2", "r3", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "ESPP share issued" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Annual RSUs granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r2", "r3", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock under employee plans, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r2", "r3", "r69", "r70", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]", "negatedLabel": "Options exercised (in thousands)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails4" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r2", "r3", "r70", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock under employee plans, amount" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "[Stock or Unit Option Plan Expense]", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/StockBasedCompensationDetails6" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r57", "r478", "r500", "r507", "r544" ], "calculation": { "http://aehr.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets", "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r389", "r405" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r389", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r389", "r405" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r404", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r469", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing Of Transfer Of Good Or Service Axis" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r469", "r515" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/RevenueDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r457", "r470", "r472", "r559" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "verboseLabel": "U.S. treasury securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CashCashEquivalentsAndInvestmentsDetails", "http://aehr.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Net unrealized loss on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r53", "r54", "r55", "r186", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "ACCOUNTING ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/BasisOfPresentationAndSummaryOfSignificantAcccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Effect of dilutive securities" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r174", "r179" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "[Weighted Average Number of Shares Outstanding, Diluted]", "terseLabel": "Denominator for diluted net income per share", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "[Weighted Average Number of Shares Issued, Basic]", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r173", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Denominator for basic net income per share: weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aehr.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(4))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "https://asc.fasb.org/topic&trid=2155896", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 88 0001654954-23-000431-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-000431-xbrl.zip M4$L#!!0 ( -V +5:_GM<341, ./5 1 865H5Z(H:BJ+?>[NB>#0.N;F(I8,%TSW[:4!D!VC8V M(]E5Q?[Z2\DOV,A&MJD9,W>>B.DR5J:V]HPI(Z[S^:)S M>76A8<=R%\19?;[P60LQBY +C7G(62#;=?#GBQUF%W_[Y;_^\NF_6ZU?N].A MUGY=Q73UWNZ-DM?:T=]9/&G^, M-FB-#%/K^HPXF#%MYMH^%X7]K T@R=5-^]5[,M43L2=0?%K:AD)(GWP.< M0S9&K.R'0$&J?OQJK;,I>4F*E#C/F'G9Q$$9D'=N6E>=UDTG8G+PBK>P7/M\ M:%/7QNV0+.9"Q&+93Q)%AR;R=EO,,NTC2E+DS-O2'-M 29(T)?3+321RI_WK MXW FFLI%W%:@.621=SY\^- 6I1&I1)EN6+SX"7I77#.4DB/TQ.$]W4K1+PY M"HGOVD%ABI1DDMX'I"1NN*[O>#2OW0:%:4P\>@1R*(W1H%X>>G%1JN:%1P\8 M4O5#<9L71@,P9KV"3F.ZPG?(7[S.]LM M<99N^!-N\$[RD>-E@ITT?C&?#N2*Q%;,NW*S#N M)!':@8+IAKDP4?M[O(YH/0;(VQQR)C*^F42%R#^6=@1AQ! M,1[UC=',Z/.KV7@XZ.LF_.CJ0WW4,[395\,P9PU4Q:&:P"3,\=;8(Z!-4=S2 M3$H0;ZJ J+U+/>6G!M2CH,;V9>/E>(NI4(#-'>0OB)A6Y2*KXE3">UL,WID) M?QZ-$4 [?M#&$V.JFP,@T-[YT;,:D(N#W',WH/\::,@SAJC&W>"ARTHCKJQ& M"?]=%?A[X\?)U/@*=(-OAC88P6]#>S<VA4GN808R,UZZ]@(#=^,TG MWJYL4SA6@[(5W%=I!;.O.C2"\;!O3&>:\8_YP/QG@WZUT0"Q]8/MOI3O_S*C M$NOWE7J\/ONJ/0S'WYL!/Q/B+F($\)@D5-2=Q6-O3I"!KT3(-0(YAJ-$:/ M)Q3@]OG_?)[WC&P^>("K&(@0!\"1C-S.F\P2F%D4K3 T#/&WAK3T#LS[JNAUSS9>(2] *8" M=$JD;@^1,J=ZWQ#]9VQ^A:$N].4SX=NA?W6'QL_:R# ;N"*X^#@S,L=3F'X& MN"1O* &X.P0@P=W8.+(QS$P7ON5]1Y1"P!''*/)MI;WO#^T-,]3^O&=JW_7I M%,**QNQ)Q^XSS]U@VL=;EQ'AKOMXB2G%BRE^QHZ/9VN7>AZFF]#%EV!00O5> M#H=?^?I)NX/PNB"_^(>_4N3>CIH_:ZS,C'?7/,4 M!A*I.TKS2S'X<#SZTN+^%EQQMPD,8D///-?Z(;:VP*6'@+%VZ24*BIE/" M(X73,^/+HTB)C\1Z%D^/!SL5P#4_C*>/#59IK/PGAG_S03WC>>\SI+M*'*2H M>C;OSHQ_S#D4/$IH_,$;K16^X9IAX;7#:RF&?Y.U0^U=)$&SD%QP&3&-?D%: M);Q2W*]:5FR0RT1.Y%M,G@J. 4K>4N(@A?)1@N5=4$-C[-QEQZ35<\J4YI>" M>7D)LD&B_%ID$IJBQ"JL;J3L0+%UR0:_L@N42?2*D2JQD]()!18K&^ R,I=\ M;NY2\,))D.3;2D"D!$-B2:PQO'IM+&G^O$(E"%*B05XG:[ X9<$LY8=*LRGQ MDS(191?/&G3+KZ(E,2U*K$12RF4465%KT)/SWABQ]."8NJ/$0W>R#-Y16OPV;Q]^;'&MT]@\Q^;763:_5MM< M"M,EFU\W-L^Q^8B'?Q[,.[-LOR]48B!%YA(&<64-%KG)X=1@GU>HQ$(*T+/2 MPXT#* C&00]14BGAD>+O(_ TO:9*(C_5C0I3*X&3PNVBJ?RFKU6%\*#SE6=3 M@BK%[B5!;7IH^:6:5/\L2*L$4@K]"RW6-%VS&G8'';,LDQ)-*6E0!LVF3QY? MA4OUOXS[2G0RWB9(K,,U?4JY$)="(+=4A<.=E&W(6HIKX#AA+2X]E2S/IX10 M2EZ47XUK "Z]')>"M3"U$DPI"U)L0:X!\,C+;MD3CF,$2IBD!$GR9;AF%J%> M*DUUG_0MI?&E]$>T6-KT@J/&[F186[T@<2N%+I3E][1B%$C(I=\!?0XW?0FVP M46[0>3K@$]VI(9(_F:#J1'<-0L4ZT7V!3G2O1DC^F(*R$]TW$!6# MZ'T!B-ZK(9+2#VJ(WC<0%1OG#J+6@K1*R+)?8CB&6!/)5OFX3SJJ+4RNQ"_W MA8>CG_IIXMT3,#SLB>7YE*C*>8M2J#9]5/U1IQPP%40JY-[+&8V#3S[]/P6) M_\/=U10O-7%R[$YDA'TQX[9CDX(WSH M6J*B(RS\5ROB:_%;K,3 GWI7 MXGG9ATIG/90=8XE^B/99Y?'IL]B+/3_)$_^J*L'^C.E"#X_(^46)1Q8X>;H( MX$G.4<#(@?_ FUOG_B11JHE148:42?&KM2X#04POKJJ"( Y(#P>_]A)97@N_ M;FWD(,^ENP?X7NJT[KNY$NBXA2_617HO2TMA7U$+ZZJ&-]G%< 'IA5"VX3] MHVHJBE >_DP1RK8 J3%5;WS5](Y5.$EM?D<6 -O!T:T\BN=S^'\5W$!OBE-C MN-R%]]R'+,2V^7=$/E]XU.=!!$A./CX%9\I_OK" B7C1;9C.$W=ABJ@CF#U# M41"$! 0;%T9P1'<##V\X&5C(?V(>\7QNGR_4];<1*0&2?+6_(.(\4'?S /8C M(#-F_%/(V^W014ZDIX*FJF(+/TA]_4Z:C; 7[,2.7H?6H1HJY@Z!6L<(#G1" M84E:1[4RP$6$[U^)]Z:GV - MSXT4K"6T!M8,GG*KVA+H6Q@O&V][$?[*)-5Y"]^*ON NYN0J\D?5,%QZ7G@OSE+3(&]=Y'D;BLG.=OH'4> &_YN*;(WC1]_D$8!+(D]E"JK/7 MKWH 33#2\1-<+&DZW]NO%T4*EV6J=T(8?[DB\-A#Z+1VQW3%WVN8VS@,>G,X MG>M$*I9E.L^PM+C'?P/_7I>2 0A\0FHCQLB2X,78A]FZ[EHD4D]!W)YF@ MG7@+47]!=#'>C@>NMU:#K, 9"=,[V*1SP%4;TJ'+3&1T1_ M8"_XO)1CKC%OF.,E7 AY89C.5"92]:TJJ[?Y\UED",_ &1+LCY<\" T;)(SR M,Q@)Z6Z*^9>$>/].3C_+,M:+?O6AC7\6T-LEOCLF4C'F&CEU#;:_@T3UMD,1 MQH3M2:@[=N*SX^@*>^8:F@#/;;-']$HV_F8_(RG/6'.J6!FLEC/ FU7WIQJ< M!>Y'=*\X3!>HMMZ.4D6?4VQ1N\*5)U),.4B.W#!=,O(W3YB>/'6K\L0S\(G2 MJT6RJD_E/9"^6E&Q4PIB+0K!$K%$2XLMD+)V;2*<9^":_7*>6 #LH2V! );\ M![HQFR#*%PC#+VWN8I-69C]3<[QM4/H[Q;KU=^;,]P3#!<0I%A\B-%U!%740 M9Y'G-]^JLO-L408P;;@*$*@L,?"#L.-EE#W?]Y]@6(]L4IJKHO+GFEHR-EO; MW6$L-)U,?&JM@68"Z@3N+%R/>49$J U6$CWD#<*=R@]6]LA,6[]EAY04CCM/ M6JN$4L?'\4+\Y]GM^IA9E(CA8KSLK3GN,'P^NHZWMG==\?K,OKD4):XZZ+[5 M]B['&VRVU'T6!;IMNR_!>S;1_JW<\K/'2']R?4^'XH40'293>".VJTL Y5/6 MBTZ)9?3#'8;56,]K[Z'R"\2'2I=A."]5U:]F'^I:BN.\E"V[.T3"^90*_I2F M2'P[O:(MLFLX+V,4_CY!^;[P?T;U^%7\RC;(JN$LC!&V9Y@AP:-=RAYQD&3: M=Q:IJ/)FH(6[0<0Y3=(9IL_$PK*B?A-M%0,7IGOZ MQ"7\@&63;+"D2!7FLQ@S$E*.GS'-5*X ;;VZ)+)GLO 9A37W4X]OR_?ICF$+ M!A&^$SVCX^83U6MK8A/+=;XAV\:[+G)^R ;/HZC7Z@X1N44(R61CRV6UROK M@T2^O,R\:%(MMY!C1+5*'TNCR_,FJ>@\).WF2]H]"TGG,]F8B7NURJ8S@N3F MF;I;+\HN\S)F\/N;M4HG-B7.'1CLQ6(BSPU)PAZAJ7=6%Z_C1/N?Y E>+DF] M7FS'H#!CLI"^7_/H)#*(,,R+>5?P/H:^^+;\=A)' Z< MX9>5M+7J,J9D11QD\V\ B(F_F*GM@K0]D$D*%66H.3* V=LB7H0PW<+JE>8\ M"^\?K?B-Z0+3W(E )E7-LT3*O"HPE64\E]B.;XR8S<78ABQEL)=/7>^8X7M\ MH9Q_6R(,2A,R']6M-&>M>D[Y.G-'4B)]NWX)K[,EO#X?"6^R);PY'PEOLR6\ M/1\)[[(EO#L?">^S);P_'PE-+.?!#POJC4;";3P96>;#DEKE[+I\Y^.R3RC. M7EW*(S@O/ZSVO6&ULW5UM?E.WI);X^5\OBT![(C3VH_#S2??T M_8E&0B^:^>']YY,T[KBQY_LG6IRXXS:OUM^9Q/6N_T_/3]3V^_OW9C MH(I"3@-_[+[]90#]:=%<\UC/G/1]]ZQ[<=9[WSM_:^1$\^39I41SJ??@)\1+ M4NH&VHS$_GVH 7!MR= G3?^'IPT>7+IP'RE9N"%C2M.?DM.WOOK1XROU[Q\2 M[9WW@\8>HYF=D3'1KM/8#TD<:TX4I Q*_*-FAMZII@>!9C.*6+-)3.@3F:VZ M"_SPOY_8/W? GP:"#N-/+['_^>0A21X_G9T]/S^?/I^?1O0>^ &^?KD=.MX# MX.KX(1.X1T[65*R7/+KNQX\?S_A?UTV%EB]W-%@_X_QL#0>:Q_ZGF#]N&'E< MN @RK; %^]99-^NP7W6ZOOU[UN-DM='L,W87SP&P-S9 M'D\,9R0$.X0/<13X,V;)UV[ U. \$)+$Y7"P/:C'.@9W"),'DOB>&]0'GMN= M$BZ8B"&0SXQN^IG[P>CDE$W^HUZ<8/-T'T?$C=%799EQN( MKCX\8$PA.H4)-WX]G#GI8N'25Y G!$E_#HX=)KKG>5$:)A KQX#1\TGIH'>0 MSNMR:!./\ >L^Z=1"!^]I6S+6,!1U\9H?#-&4Z,4S':SND\U7!H"2_&84.XW M98\O:E_;H\"ZV?_,89_<@ D6S,0,GTB6 M;1I.&:BU[8TG/A/W MI5S7.4WK/GUHZ$ZYH6^WJAWA(TJC9QBWP0Y6HPY\9O9[CPN!Z YJ2R<*[R=@ ME0-R5SI"Y;6M^WPGB;S_\N4&9GY@>SQC*4,BIZJ-B=PS&8/H(3=DJU1"^- 5NQ&<5Z,PURID_IY !MR(@H&C4-72'#P'!2'IX3L MB/DHTB+W[5!Y;HK#7[&;VKD0@8P""2VOK9I<"(<'0WN@O"B3Q2"QE= =**H- M2.+Z 3:L[;0^+(9N-1!=-2AZU5#TU* 8L=$R 8>MAD8@.W3F@327$C)%J-!" MP](KSY&0XJS:S[%PHP6^=X>*\SVD_*OUW>XL#>D3*&*E"$M]!D>M9IZ,G?3@ MJ)7*\;R6',^/(L>+6G*\.(H<+VO)\?(HKHV#\4 OCAZ/H&CV.5^M% M_5XA=G2OVM'1D.,EOW>/!]X%K0P<1UZ,TG,#CR7ZP.(0OF^U)R\)"6>;ZD$& M&%-DG?@):_A^^5]7ZVS*^C,?63&] 1.ZY%7;VEU6@@Y=3IV!W@.T;V65\+EO MC0;&R#$&[)-C#]X)7P:=^Y=]Y$=3^B=D2")U[_A!L"5O_K%;WH< PO]E++*ZG7? M@7M' O[$WU;M=IJ=-8"4+3\Q)]M9A4KZ8+"OD&GS)9)B#I#DVYQE;$BGGA;1 M&:&?3][2)9=Z6Y8C'D=8M3B+V6X]ZZ;C@TVLZ>:-J*N6W/:I9K]N]9JHM16UL MM\(HX*)1!>1QU1Z9CREY=/V9\<)RM4T!+&XT1A%C-'39J(8JR* ]BEO7**_A M;FJ58S"T\D"*(\C\VH!\5PB_2SB8"C*/3*HDE! MU[;)U&3LOK(XC,Y%=MNCS*>KS'R*15^0@N3SVQY; IPT);,J)B4A06E'W1)% M%>W(N6Z/@K:#Q!KQ:ZF6RNA0JE*W3(%6%8[_@^E+7(IFO_D-6?HRR9PFS*B$ M=5&I!Y1RU"UAE"NG,D=MU;!UR4ZQ1>6U;62?,EHLHI"C*=N2%%JBC$;=2DJQN'?W( MX;(_EZ+.9 MSQAV@['KS\RP[S[ZB1MD@$LF7PA:U#ZQNB46M*;P83 M]T4ZBZ[6$4JKZE8^\%K=3T+M4;'-BHU",EL?Y,HP!.F.[_F27 Y#BU*DND42 MM"+QTH*R92UHI3J?I)8>\H:PY5V),TE'#Y\]DN MDT/XWD2!7OZUH9EJO?-]JO6T=UO]_G"\ZD/L1:(9#B]P'#H3^'%KC( [ZT:S MQH:M3TQHH+U+U[W_T$25XA<*T6Q,H[DL+FPU:B:H\0FZ9-:[:=%LG6&./(7 MM,U+>\)//XHAJUGADTVNMIHU6S!8+N]=F-X)6FTQ]O97?;L/GV^ M\?%$@HC7UI0JKX2LV=I(K,Y0O+='56]L;2:@B$$BV[C9JD<)_AW%Y WG>^?[ MZI:T\0P56V1[(M"&B1M@%/)AP)L"Y$T&?$WF$2690_W&"PQO(&8_=.FK":+B M)4= "5(,N%P20DDL+7I7^-!FJQJ/(,\B*\NQQ]:,8FL>EAA7_E!R,**(HMFZ MR.,KN$QVJBM(OKA^R'B] 9%!4L/>DV/-QX^/P\@-<_3':.0D#1=2'E&#Y;)H MFZ/RA6]@+MH>54I3PS*ZAJL?&QB648)LC^)A0,%DF#O-&BZ;S 4M#)_J5=\: M+;XQL;*S:QAOI,M[A00-5UGB-5O(K#3+;G0=?:_7.F76G2_W67?N6[=CV_@* M[<+M\Q6S, %FW< M0_8%P,)E39;W.J%N&+O>ZM9__FTI=9:M,92' M-[OF7MU@CJB1]IOA-*3$#?P_R.QK%+#7EJZYLT*'>, :WT4^I.W5?V*S2_&' M,[A#R;ZUV_-57Z28R2BN]LDHG*\Z)!36<CF;\9VI.?MW*)!K9NI>\:C'# M[X>],BC=^:K=#*WOC>_ CR:%[\C*V>4M:-]L[E);1W(QM"?[ MX!RRE[%#CC6(TKMDG@;K8[U29Y)0-9L%',*]2D72'@4.""0OGN^NLF%]$='$ M_Z/$Z:1$S>[-UU8?0B#MT1ZDFY0=^QN0Y4\SS-SA+UV*DY$UNXU?6X,HH;0H MY(EX=RY&J*)(@;39$@8%RBP03IN=4KQ*H:)*!>IF2P_4:+5 1*HWG44LY8?V M"S:C]^NJV2J#_76Y/\=_&H_-[-3M-Q87==)P88(Z!RZ6V/]G\8BZ0H)ZCKEG M+4A3.1"S'L)EF\FWK?G C]]NJ1Q3LO#318RZ>GC?_IJO,JCGE_7D>#B#0,?: M"75GFZMC5ZG=YBY2=* M[:?Y*H.#AEFDW(Z?/,DN!49K4]Y)PS<_'5J5&(FU M:*@N8'\YG-3;$%IRLN%L\VX^V4C#>JC203.'XQY7 M4K?F0Q]R=&O>AWFR_/*,0I*F+N"J*NE<\RL519N&%AIYA,QXE:\9QRF[J8"7 M5Y9?380@;>KBL8.H$2V:]BS^K <^F_!K6R;1Q'WY[BT$53=Y$I\WBIJ-KC^8SQ MG==PV9 M4=\#\UV]IFO[%YF6RXH]<3;G!>F,'\3U'MB+@VUP!0,DX$EB^K%Q M-'Q+6C-B%XO+JT[B][\12F%5?8ME*9M[["]+A07GC,LU=5:;'T$6D_6Y3'7W3^RMMG[L!5&<4@)?KG7'Y"7<8]MPC-&$W[^F MZ:.!YDQO;W7[5U[.;GX9F3=F7Q]--+W?[UO3T<0ZH.>\E67/;^C S\BUWX$UL?&%S8UN0K M6,O*RQSN=:",ZZ'QHS8R)DIX8/H=32R;#SXBV,M=L%OM%>"!P6F6>LEW]C+S M,,D??+M7NZA@-!I,^Q/MNV[;,+:J H=\J4N2?:E+!O8'P>^FSL2Z!94/C+'E MF"N7&Q@WAFT;@_6@!L.'94\FAGVKA"GIE=1;AT4RK CA#XQV>CL=\B--2S/> M/@S.#H&K,>!-W5$>4"&4K4ZE3_1?%!G)T-"=7&?J"5%KW50!BNN(TNB931W" MV68:P9SJOC#N]X0H=FW9MO6=Q7MFF*N1E7UC;O9%8>P?1N$]>S?2@-SE#:(] M(80-K=&7#O,1<)]K-4,E7\8N7L3,H!,B%+AY_]\=2!'YZ;_;,3@%SP_5X"3W M3,/L5?-1R%*_Y1TD9CB/Z*(0LQ"6'./++4_Z1OS$(DL EY<*@PO=6/:M0@;2 MNYC\GK(K$Y^*3%4(3,[TVH'DA2%FPZ8BNZPUCY#,)WI"2#O(?$)[MWZFFJ.R M\JF%C%\A%I9-,=2SP@/XA+\(.P^Q$/+6X?G=DD8-K-W)1S$^(=*)4Q"U4$OG M(H78SX7(B)N1J.6G9&I2S(T01A$3%+6L9,Y!%<,68FHFUU<+3TCZBT$*H55, M_15;.7X.4,R%$&RKS@34\E@Z)2CF3(C+F(F!6F[X^Q$ED(70NTS+U8+*3R:+ M00KQLBBE5 Q[F5MF4F?Q1+=J50P[8NWJ"7(PY*YVKH+XB.@:P M;@ZRBZ(ESC=D6O<8V'IYV(0 )V#K'0/;B,4+=@E^'D8AF@D8W\B/D[D56^&% M$-3R4C>E!ED 5BIA(8A)4*L6=FGN*9&^$+*PR:=2C6 YDJI("&T565.MMI(4 M6Z(T(1ZB,V; M1ZAU@JD5)9;L/*2X$LA-._@4I4#;R&3*KAP\G@DU9;N\V"8$((I9M_G M>-8;A??):B\(PXT01-G>T-O6T-%@\QG^W>X,7^*$0N3D4_R\&;Y2KY3BSO/2 M*R&6E@%7Y;;YBRJ2F>R5$#Z+EU443VVE8C_/PRZ$QU*QGS<@]HL\Z.@-T@WV MBP;$?IF'7=PH+1/[90-BO\J#+FZ:EHK]J@'L'_*P"X&V'/N'!DQ&%IFN\A=Q M92RHCE&EI0+%\>JJ<'U76C&@.GIA.9(J2@S%E5A3KK;M @D$1Q_$&+U3+U$, M?E6CS?YA5O_/_P%02P,$% @ W8 M5I(!A.-8)@ 88L" !4 !A96AR M+3(P,C(Q,3,P7V1E9BYX;6SM?6MSVSB6]O>MVO^@S7[8[JIQ'-NQGYU$53D,2)1+I!THGGUR_ BT21! A>0 VW]JW)[8!\#D7 <' MYQS\]>\_MYO!$X">[3J_O3EY^^[- #B6N["=U6]O N_(]"S;?C/P?--9F!O7 M ;^]>0;>F[__[;__ZZ__'Y^^.SW;-9JY2_^'"<' A-;:]H'E!]#<#!; LU?. $?1 1]'FC_9PVN MUB;L ?V8P.AKK\\%EX-D.\+S! MS-T$&(KWE\'(L=X.M,UF,,4]O,$4> ^@44\W,9VOG_&_WE ] T0HQWO\T_/ M_NW-VO)/TPJ,4]3OY M].G3_=D+D=VZ5B@' MAB\,B"WP3T=)LR/\JZ.3TZ.SD[<_O<4;Q+C!(&(==#=@"I8#_+_WT]'NFR98 MP[>6NSW&?S@>NDA]$<:PRQJ"Y6]O< ,T[NGIR%BIF/_HO7'<]8&H\ AHKIW3MFL$"+P*(6*8QCPG M@)89=PMN7:]%XE@_P)W2&5J.P=K=+-#>H/\9V/YS>T0RC,U?DJ:WOMZX/]J4 M'7'(IM2@C=A&'YA M)$Y?JC\FK.8!=NM"9\1/]%^:B_1Q'9\S;(L-W!\M*U. M$$;+!J6+7BN#-Z5P"BP0?B 9'[H.^J<5\;:,!+;>C3'J7_7QO5X*YK!9TZ_J M)G002=X$P'#>E'V>U+[QC$+:C?\_GK!/Y@8S%JG)R'D"GL\D).8!FB*]-FWX MU=P$P%A>V\B6M&QS,T*6&PR8<#)V;XIR#LT%0 PPT*8,8]7UL"(CYCQLP!CX M94#91VB*=31&*CTWIB-]5@:JH&G3KZ/9O @L_YL)(5J$&%8T8H?& ).@(PM%_KH;+4MG0W5AVJ*'JE(L TV>-L*5>; MUL!61AEFY@$:ZUMH^,S-G^6R+FC:].NWNC8K5_3#5HUW>!="]P=:MY$>Q*L. M^C?6WQ7;%L@\0&/NN,YJCK3R"CR4KE!%;9M^?^:[UO?0,X'5#^E>:+&4(:'W M:HP)K#"/$>N1;8A-D>B ,G*6+MRRX6,>H3'6X,$#?P;H$_H3BV*1V@NU:3NQ M;;NU<5E)JC9*<\SA7C3'!@4#M(+&;=N_;%#HO;C;PFP@*P[#V2YFPUQID.9V M %YR7(@4F@T=L4/K-B@;GI)N'=JCC!I9=T#NMBD;_HK#-+:% +(H&*$5M>5C M"['A8>G;DEV4LF(8L97T:VE7NP*^:6]8M[5,ZW8QG%0#<<('Q6DU%*=\4(SQ M:NFC"5L-3:Y;VY8'H[J4=..$BIEIK/VYVTB,[*PZ3E>XF1E>>T#.]AXC_ZN- MT@UF9M[7'*Y%NY61R^0>K5NNC(C*^G5HN[*N%+5'Y&Z],E)0=9P6_:Q59Q9# MUW:L:T;6%39N%4&IB5;$] M9$]IC'."J3-7A*5SAJTWGW,RZZ&'K3=7/IXUXN-9)WQ\WXB/[SOAXWDC/IYW MPL>+1GR\Z 3CAT88/W0B:^9UO-HH_.\*65?WJ@-UAIR=\[5';/D6M#)PMNYD ME":T$J!%3=-?)\1K)V'@.%#[/ 2U1D- *W@ 1PM[B\\,^-(X_E":$[M1;,<_ M1DV/XS;'A0/P1KW[U-'"W9IV1<4_R-<'",. ON/\+O:@X=6BK/AB-T<_ZX)=;8S;[ M53@36))#4O1?U*%_]D5#Y!NW5_IT-M#_>3^:_^N [H9+Y-+T'L(-(O".5J;Y M&*V38.-[R6_V"V;\BS]V-"#F@A'ZIU>PB\0-/FT6[BKOQ%%[A :1, MF ?*1Q)D,2T[N8H14 ;457R"(0F&T)RG0/+'JS)IT'0M(QP"/;%0SA06RA\G M.?#(+ MH@-'J;38AU!,D)&-CZO> MR/."_?FTP*8^:"6>\>PGH0/@,:\%[2_A7G?@&: =8O)M56)[ ?Q$T04R/]*# MJP#BO#, ;7<1Z4?X7V)V)4$Z50=337Q5Z4O./5+)-PR>;4F\U+'4ERZ5O.3@ M5$NX^?MG_!MD!W@^M*W0?XH0I9?J,?!C3ZIW[<*Y^?.;[:_Q>H+0%L@-#U=[ M-!4DUXC 6';GHJR] ]A[+4MC/X1,<>[5&TT%$3OYT:90)#<\5*V15)!9;>)B>7T0)B]MB]/O MVY!7,M*+E%="7"ROCZ(<4_\.DHQZE^"A"34K%P0X!+$@T M29!CZ=Z!P-S8_P&+&\0M3(SA%-0ES*M$:4>%9%M*2R*DG0-*8-P>8]G55)S0 MAUIQ4MKLR^#ZUOC&/3:LG2*L*7H_XEA0V\-1* $$Z(=+;38*B9I,]1DB,(QY M&VAC1//]W9TV_5<8Z&8^N1T-M/!]HP^'0N!_/1^.;P00Q:!B6=&R?=,;B MK2G:/F5IF^I#/4*\ SPUQNC?PTB67&!GRKSN\9V\R^.+V[8/@UCN-87G)(M' MUZ9CQ*798*)/HV X+J%^S 5?4UA/LUCQ'/Q+-!-QI-Y7[3:C;7Q<*3=(NBS^?2>&_0*I6%3Z-]GT<^G MVI4>LMJ8?T&J$D^P63CAD"@N;_6_#,;ZG <)185D4UC/LU@/VK@ M*FT*9VX#BT.PY]KO?#0D4ZQV#^4TMU:.9=E-$Y+;8JH8_5Q*KUO)-$9;;C5G. 5R)*:S^FT*_D<:<^&[7/1I4V&]6#?DHT MZ*>]6- /?\0;J@'C>WM"XBEJ6MQ2C5Q3(GP>Z:5L',?V0 S%(V8P[G$7-1>; M5DKD*8GU123PR"3MB/\R9)"V((,.DD8)T7Q#] G30JW)Z5&X7;Z9P"M[NC8? MGL%IF#Y'Q8W"[?3"%&YL$W MRY0DL'(./#]*O+@,H#-RJ PE-5:(K202FF4^DB;[LX=-4?I0F:I#^ MNUB71.DD3&EM&G7"U%8=CWH W<<2YVVFC0JZF(&D_/R/3G[M[Y2 MGIQW)Z3\Y+\.3,[2V:EL8RS.9> F@L;UQW41;=$?=FZJS&T:L* M18+=0248R]P6C-VEW(C+(U9CC2DR5!Q)O)E92XTSAJ *P5%X,_106#P-U@JN? M]X>TUW!(RS_"F3JLY5*+U7??^T-8?VJ0]M+'>AE/FOED&@3$WK8O.Q8P'C;VJN1% M#<;N"HF/D2*QCZ(P@42_Q'5GS!7E[%-YH)* M>Q25K]FEYW=0:8?%M9$KYD$!W7LY>B^' EZ."N+1?IAP,44H MQB[X8KGXH:MT-EB]RGC$))1D*QR!=2+?B?<\>V%O0FP M_3D#5@!M7&LONE$$B^C&W MI;4Z*0>U7)T_UF*=?6VU_O3S@DX_KS/%6M3#8Z\TQ5JMC':);/-&*=9G75[< M5I#*%68F6%P"!_W#Q_@OG_%_<3R8/T13>A56>::O2)4&46K!JD29!#4,,KA8 MYAJABQ2K7 WM+)B1! IYY-8+$I=$JR1'D:77T_..JU!2PENB$HY2Q+00=OZ\ M.R&--UFV6@VNOX&NY^W?HL1UWJD,I+17@9\4^ E[V\T&]WQ[BTOJ[]Z4H">& M$YNKP%PR^H2W@N(*[EP'/-^9\#OPKP-G0=;PN .IO1Q"H&Y&F36:1$DBD'JU M+!L+Y'XV1U/0"^#SWG]6)A1:'_4$0Z,F$8Z@,IE9[R B"<)GVUG%K[Z3!%36 M3[R0V(/=2D@1&ZV8/(W']&9V86.%1%&(7VQP(=8.^C10BL,18+&1?Q@#?K"P MP=+#T%TQH3!0E(WMZUYJ^;ND\"4LYO6IRAB*R8^5K.2H+"HNI(JXE!<,5007 MS^9]H3L%KP\7KMPALRF0\@3_$ O-;NOWFCB)AB+VM^X)LW=WTN7S>_?.+#2!BU?HY?!N.;@6S]E?*/F8E2K I ME[HFQ3=!41I"'G"9I5=Q&"GL[FIJ2Q(O&\&"P[U$2%DB<[\[20NKOU-ON8YN MBS>F5Q*T2>FBZJ*"[-6-'2;ZI,EBGLRM?U&VU;U8RTFJT3H[>#P)]"HU2\X=1:AV=?#. M4>\*K^4*%S7=7ZDK_$(I=DNTDC5RA7^0=,GI,Y5:SU02.<'Z3*7*F4H?7H"X M)%HE.\I4^BCI>KHS7T.CU M=)B=EP?+43N)OLFKYQ$AF?1&)R<(IJN1*?-*@ M"^FPE412X71:S991.2 _D9B@F.XB;3JM,\M.)91GR[/L-"LS04'C1=C.ZLCL M[.7+["PKLWHAX\2'E_TXF\DKS^>*GC8F=Q O!):GF\MN]L68SN?Z](XOD9IE!=M@@^LK&/X: M0%QC$H(U=J(\ 1S)22$M]PZ?-AS>W]W?:G-$AS'_@F@<&G>3J?Y%'\]&7_7! MK3'K8R7[6,F7%2N9GS8C!TTO-'FLJ!HP]4J"K;=2=Q%L) F.DBP#6>;B9NTO MQ?5$%16M*$Q)PB&[$:=$UQ?<12JN)OPP,D@0KO 5ZDU$S^+?07R5;1UQU-(PG5);%0< MBK"61F\V>/L/(JT+D&9IKF43EE%Z%Q7D4$Z%V*)1- 6I/7E>TBQ)3X>.GW^, M0" @,55>YY[ G(T'AIW^F"N_:YWYI.]!:9'=73FWGR\U;49;^?F :J3(EBY M9UDRL 8G_(%1I9LK490%V)<@ZEV-\KL:/>BG1(-^VHL%_?#'%#\E1O AHK^G M_JR&D_ 0,P\O( M#B4?5!%XG9])2_]TALXH9F:WO*RDK9?"=L;-36-9O"S M"DVZ;\!>K7VPT)[0;U=A* @^ T[17A$_*T\Y654>2:6C5F7B!/N<:'BG /,F M^2,NB'I24ZR%([T4L182)[;\^"%>_$(,J^"BMLJ*)H(OUN=T"SP/@$-<6"N, MY1!9'-"T*,)@Z:N0<%C($>-\NG0A='\@3)JSB(,'T;]3;SVS."URY>4NC>G4 M^#8:WX1A8''T(/X)![G=Z'U5Y=ZEH9Q+HX)X7F'R MG.T,ER)8:.@[BW"E=6N)H_(H*LBE,E%<'L1-4K4F ;36I@<,_)&2.&%*#_&, M+UF'#Z.!*90T>R*7P.UK&WI^T]E0=1#Q,BF?#%5I$OQ>+O8P&,LA! O;OS9Q MJ17_.;Y"VOFZAN8C^HO_3/$_5AI%O!C9/9&5"!-[*8.7B7T>\PC9)1!XX:T1 M7D2H)?%*.BHDL%):Q-ZP3*!K ;#PKA&!F!0O42Z*8X#<12&Y4*@0?.U2,,-W M5W,-ET#:. K)KBII8I^.+4*K_WRT892]@VBF7$X6P!;KE3F4\Q6P M<-E5_,SP"AWL'. Q>S,+NZH@$G9JQ$3"SGS7^OZ L"QPBC@R42*/ CG%.5=Q MQ06-)-BB,\@]:Q"4J2(SP/44ET>&]97"J\6(R3KHSES-R4OR)0T%2\ M#<>DD1FA%1 B^%Q_@ZQ(:&XT9Z$MMHB'R-0,;T_TG]BH(V?VQ_T9NZLI+4;B M!.=83X$'$"_686WR)[!Q'S&!C/)CZJRF])A(2V0GZ)RK;<)QP6*V-B&XS!ZG M8K!D\;'V%R]!]O*+C"2)>3R">NPMJJ%UD7O#H.S=]F8C[CWX4D[.EP%JPIBWR^)L7IN5!S MPY+)]%O[@H82&*DB(P0TVES8^KIJ:\>:'V/2:5DFR'N>#._P6]:>B-G J#M+C(5_\(_XIR+'9$D MXZAS&"JHEAC."(RNR=$9.PA/B]R,N3=&0S?C$-K[&7L_H[1^QKXF?LM^ MQ-==$U_6YP5D<%?5JXDO:VTW??NX<9\!B)PL/QP O;4=5N[09\9DOT=ZE\_X ME_2[B5J#J;'B-*%0<# 8'3/^WS+/,_L(4MQ'--#I2N).$RZX#%UW,I9A"18F MYP[JVO6OY:A9H:[=J546(5;86+R_H.KR0)L>[=2EZQ_S(3SF4[/RG#AO M<&O.O*;>T)?LSA/%&PENQ/IKUA=ZS?H2KKWZ:U9!"UJ-:U;5-M;^FE5B7:-> ML\J477Y6=/]U6CG,_JR__NJOOZ2]_NK#[/LP^S[,O@^SEU6#)'*:O^HP>X1J M.KN?(SH\TZH4=T_N*8$%W'T@/ID=,D3FUS'RQP'&;RS#OWK:$[)Z\19[[<+0 M+\;AD%7Z10DTB_O9JI0)$G@@6W.XWD"75HR-R\=>@Q+1Z.=1V+ V4+1F,JI$ MW?A=^F=44 8^E"OJ XPU&RV'2V#[.)8AH8O?,E+X,14TAR?]$D:VOR_R[)U5 MCVQ_W[OV>M=>[]KK77NOT#'3N_9ZUU[OVE/6M6<$ON>;SL)V5K'QEO)1,;OY M*H\B@3' MV&=VF^KK5^#A.'UGL8ND=O&O.K16V!&HI$B=,256OPLUU2]%4"9G))EA$VA; M''-ZF &\(N5CYDFL>Q\DU3WB294E9ZDM_6L3Q$O2P3;Y$NOA1TGUD-UDC!;\ M^%EXWIK)%]9+TE6^G(JU]Y.DVELV41-J1"^D%7&\)/ULF36RW_TUMIW%+*A- M<;TDC>7,JD2#%?78I>@<.3ZT'<^V.-D=A0N)2BD:YU<^H[35"H(5 M8G17*M< TBM2R09<2E3V7**DX?.BT,+WE9.&S_O(PCZR\"5$%A8O#W'.2N"O M76C_!RSNT=1+)TGA\ ID]!]8/;1*O-2UJ.''E(IRY,(!*2/=F&C*4U0OT*WA MQZ2(E.0X$]M30C(/!9>"55T))0JV5%H1.WCQG!"Q&8(XH89C'C:1X!#!;]*D M0RT/R6[VT#F-^:?ES#]]GYW,/\LRO]6WBL)/O"]G M_OO7R?SW6>;7BY.B,?^\G/GGKY/YYUGFG[?._(MRYE^\3N9?9)E?+T2+QOPY M<,K9GVKTN@20(CP1@:R12GWNB!S.=CES1W*^=(9BR:6A?%. .8]^/T1',VA: M?F!N50L^]8KT MJ8!Z"9)F&BS4*8(8%VH>ST(T :.:]G7-G^0E+N57-C&[*C, U?2P"YY(D-'5 MSG0[C$?J9@G,?5,U#>/$AFRJE@15YBZ*0L'.JU>9N^ACP?I8L)<0"]97F9/- MSI*^1I@DL5-]E3EE-4BBP*?75V4N>?Z67D4NUTH"FY:CWJH1"XH#HK#M:\9XI\-")".?/A,U"@LM*J=4<3P)% M:*7>$85$"2Y%ZWAB]#\#VW\>.8BN()P/AK\&<+XV'6F>FFX?HDKJ* _7>#SN MH3E.8&Y2TRJ<9N'7"VNNX4XE?500+@,9C2X2"=S."/G.A-^!'TK7<.9K@.5M M+-$_0A#&LA@A02HMC:V*]%HBM]&E'RD.S@L2-1HYMS8(C.70]-;QXG#MPIFY M,>'S%"R"J)PP*52N^CBJ2*\&:8VNOUI\VLCK:MNN^S00+X"JZ)9,/&MT;T90 MV@G<3YZ0!L.9@B?@!&!NPA7PYZBWMW8W"^_._&EO@RU!MVJ,HXH*U""M4=U MDJ0 7+IP:SH6()@9C>37UNC*2+4M@AO5YFO'M LUE$)0.T9>^5=4D7WKA NN M<'>82(#KJ#@>]?:SN+T*XBLAH=E]6XNSL<4IIX9@ZE.7\WA+$+KQH2ATXZ)Z MZ,:'7W=$M0V=5(!H;$):<,&UVKJ3L43K>O=R%E<*+>7^0?O,='9/ M#6@CMI; K])11!N1!5R*I2577Q8":S\!#._TW0F]DDY)G]NYWM#\]%&*'#]*LV;F- WEB/G"2%WX3-MYZTSF@JR;D2@!%5M&B3B M$MYLD*IL1)L855!'"=G&(^JU?D!68=A5ZZ%RA*^HH$%<"!=<"(>6_W%@R$T" M:*T146$IQI+8B3H#JJ 36D46U1FAPS )]L"Q9H\=M$>'*YP6&>]T*[*;MUC MU_\7\*? '(!;&E8K@1%DVH:Q?&O\+M**90USAZW2.R MAD=D;X,8\X/%.+T:1W7HHB5;>S+M#;;<$#7A]MQ^?D!='"IHFB#6\(@K+CZN M3L'&# U]XMY>Z7C/,IPR[./AU!RKEZ_>PLY\M&+REL942 M;'-RN<0;ZYYO;S& U+OKQO(^WL/V*AGM9J3[E(J#J"*XJG2)BBZ.+CV1T@S= M\"H'A@HV/YP-MC,-TQT/T[VD4ISL:7QO3N\.8 MW3Y2MX_4E392UX-^2C3HI[U8T ][D=P =P7-Q[5MF1M"G!5J3VFN1B05G08> MD;ME HC4((V%&"R#P9.;BXU^HC,V+P0R'3P"UCH2@@SA26T)0EC\:(FL-,\V MB8$0J$'Z[P*-++J.Y\201LVE)-D]HAS;:T@SJ'%!!>T4X2(!/8\B8B4JJ@?0 M?22S&34Y;*$(@W.X$]8*"L*98"S0#\,KL>6/([D>,2EC4.1RB[O1>ZEP+&,B M)!NL(MDQC)HU^:G9>:S/H>Q/9NJ?S.[,?[MP&'B^NP70(Q_)BMHI M]\OG\@1O:B,@6];SX"$2RV+(+37$WI=;#$EI2 A0BH A,:16"PV92 MK'I,NI45QB$=2?R40LR7:#5K+(#T"O:QTY3=:_L)W.(:BIZ_LT6ICE]:![$. MRM+S0=H#3",C68E:=:SO+7TJ>_/-Q+L:&>R0-&OS)"0,;;6J_>XSEVP,O52? MH9=9AK::PG,_HZMFZN_B65BX8QQ<\1FR 39HN@7YHKVGBN]EP0B8'5'TPD1^PJ.@8X%")>SN@6F!Z8XZ=!8WGM M\SS:?5I)-X6$4T))-H6XHQNUX,$#?P8(OHZ3F1FNSSZ\RUV?W5_.]'_>XQLT M_2O^;W]3UM^4*7135D4\A].EW"U-[*"6"X9$A>A*DGE<:)+U- S.]D["N! )@R@1C)X5$E"8\\VCY"]RF$J6TV[@_\ M,@B!\>3FJO":3('80D88-!(^! O;OS8M>V/[S_K/1SLZT.(')RBG>*;.*DBH M"CV-:O(TEQ<^R;(+J+"U2A(I)(#',Y&IQ5![< -?0_ 6X51=00"V3J'')+.* M$CNJP'%66K(U:DA>D_CW^#\X3?AO_P]02P,$% @ W8 M5J%>-ADK7@ M6-4$ !4 !A96AR+3(P,C(Q,3,P7VQA8BYX;6SMO?MSXSB2,/C[1=S_@.O; MB^F.L+OU?O3M[!>R+5<[UF5Y)+E[YSHN)B 2M+DMDQJ2O"'/MUWGK]_U?^Q]!Y!CN*;M//_U MNZ-_"7W#MK\#?@ =$^Y=!_WUNP_D?_>__NU__]_^]?^XO/R/J_4]N'&-XRMR M G#M(1@@$WRS@Q= ?OH*_0!YEY(O!KAY@=XK/'CH%3I$*+!X"WZ,:5V[AP_/?GX)P/?&#X!\!MQ= M/BRWX.KHVP[R?;!Q]T?"BG\![ASC1[#8[\&:8/A@C7SDO2$S)+>WG3]^)O_9 M8?D 'FC'__G=M__ZW4L0''[^Z:=OW[[]^&WXH^L]8WFP7/_Q]7YCO&"^+FV' M#+B!OHNP")4BO/Y\/O^)_AJ!YB#?=]X^^L;PIX@=#.[;/_OT<_>N00=7 UP M(]H0E M^F\O'K**6=E[WD\$_R<'/1-%(Y^9D\_T)^0S_V?XS_=PA_;? 0+YM+[C2C5/ MT0J1?A)DM1[Q1^39KKETHJ^T)&B6K"CSK7Y^$T O:#3D>7S) FS= .X;L9[$ ME,ST VHVVB<\V:.,K3YJ-LH)S Z8#O(,UQ[:HC'=DW^ZQW]*,8C> ^28R(Q8 M) 1*+"ZE3PT[I1S3=HT4U3VQW:Z7E]O'5"E%'QD_/KMO/YG()MOF@/SADOR! MBHS_\H]K%SL BYT?>- ((DI4B+]^5_#[3VF&"-S"B[C"6W"%8"'$3X:+-[A# M<+E/FD3+ !OJ(".8K! MY$QX&8O1O!?!:##])6QEM8"!@A,L(, *=.$:.^S82[[#)NG]W]$'5ZH_(W#::[ M@)WL+,='9 (C=6H7^+,F^?3M'CX7,)_Y7<[D%C(5S6[J1PVFMXB?[/S&,( M29W@ZZ/G$>9LWX#[OR/HX?,@"9L4N2E<4$D^706KL7O'@=- &2I8RSE]#!PP M>$ 0 ,8 !$7!IK]YA?M]%,GB;EP9*)D;?B&#Z>T^!:*!1O"YXFSU%#2.)ZK0 M@A>TWU^[KP?H\/V^-)!4'2A@+Z,""0A]-"#/%$\!""0(017,__(5><^V\_S% M<[\%+U6*P(&6J1&E#*=5HQ!4&QTIXXZC+!$*8#@*U2;[Q#9>A]Q$B 82DY6\:7%1SGE ,G][19R&3V MV)D"TD!!ROCB'D09L$IG]-;>(^\:?_O9]?C;3P9*IO4H9#!M-%(@&J@"GRN. MB:"@(()58AC8V8CIXRW^MZ(MI016KH'@,ILU$CE #;2CBC>NL0B/KZ'-H"@* M586H8?DOKZZSB9PC3\V+Q / MRNH8T+PE[/CPW:I2)*F^J@#[&8^U!$,#51)FDN>]4DQ 40'#!0ED)0;H;T?H M!,:H!@\/.RHN3[SH./;))6N4CWR MH)*OU3BLYJ[8,G ::0B'-?[56PRO0D=.GOG#\76'/*[!3(+(/NVD6G<##6Z/)3\*IP)*I&4("I)6E M%$4;_1'ADJ-2*50:5D,@1 8$6X&>;>'[G8D-G6W9+)^[PM!PX67J5@73::WB M &NC3^7\<30)(X$TECI3M3!-/"I^^#_WMH/Z7&$+866J3@FS:;4I -1&9?B\ M<=0EA(S_EZ" OCI=N<9_7'E;]YM3)6,24H&>Y!DMU)(3F&XZDN.L0D,(/%AY M@&"HTP^Z-:Z\1\]]LQV#[^_PP!5H"H?E0G7)P.JF,\7L52@.\V:PYD1HZK3G MT?4#N/]_[$.IKUP,K$!S"MDMU)L4I&Y:4\1E['Q3,$#A5)Q%-L@X>ECE^H/=U@[V16LZ#R)GSGFL17.>_5V#.>>P ME)WS" Q@.$ !I<[YUH/D4F?S\;ISBZ3(_"YGM@N9BJ8Z]:,&\US$3W:20QC M@)0LZN6[\8)90IP7B,5@!&L!KHBP!XWZ!WCD*1!&"68MJ@\%O1W5(ZC M?_D,X8%I$-H'?O0O)U4*_^$?]+Q*KOA6UJWM0,>PL9/CLJL^SK/V>JC=JU@3 M48BZU<$C<_L/8SPVYX9"#6S.<>Y4LGJX63YLEC< _VFSNK^[66SQ7ZX6]XN' MZR78_+)<;C>*57/A^RCP*Y0P"R1/W8K92RI6&H).R-RT^A,=5*B,M]P#SL&A]F\BF0 Z6R@B3&8S+31E%(6>2\W(47]6;'F7$/_9>&8 MY'^6_SS:;W"/>?,7P37TO _LT?\*]\>L.UT35YYFU1(FJ6E"B'1:S?EH-)QH MH'D-6,YI(L9E5>S(']")BF*=7 4OR-N\N%ZP1=[KG?.&_(!LZ-FT; %X>;I7 MR712W[C =,(&Y@#-H 8Z)LAF[B!(,"ZQ1_\*[!..ZBW2,$@6C8_7#!5KC0R$ M]7VW1_X#"HK/B#5Q)6ZA=81);:DBB'1V>Z8Q' PT4,(&+!=%IQ"U="ZA &!( M$G@QK0O@(-7'3;+ '$SV \O%&8PTB#R%*V(MJ5?)W]E!^O YRVI) M!&DCU;;JT4,':)O+]P-R?!0I?LK7Y$@KA"E/;6H(DM0F 30VE=/IS#(U4++: M#&=U+R0 $*/@)XR5D3HO\#53UHFM\J1&)9U-QF@PE30U0:)H:O4Q+W65NSV<;@'I 7?#QB+@-L M9LC)[T"\:[['4(XB\M9'UP#LMEN-(/(J+,)\ZCIX(+:#>"2]>Z/.*_:+'1);RF!SS-I1L>!U9RP(?';"[8DP6D4S4>3@;S MH0Y:5;L#FE\5Z^*E:5,YT1I&*@9F'8Z*^M$AOA2Z)L%F@3@0M#KVK/@.G#OB1,!_E M.E6%I"KVPF.?'WS)8M"YFUA3>(XBR/C.3UT;O7M:8B M$:VKB\MR^0;3R5QEJ/D\KO-.&",$S) 2C3^;(2W@,6)B2BG5,M%D^Z3.XDF-Y6N[6\FKWK/+?@U)RMC)EMLE()2^#E*5\E MTTFEXP*'5X)PIL4]DR";N4J;.==$%\VBMV )^UMVOY8"DWQ/6 M#<#! .IPL"_GKOAB4LAGDN."5/@>[)IU8EG0TM!=37-7[*=JZ9]6BZ;((Q51 MA\%(@V57R%29\ZG:YZQ]@ZG'G66]6\J*&[ZA-9M/=7@[),IG_O$0]%"(]Q>: M%!=\J+XB2K0:*'T/F0.3^/21PV+JE6,&AL4@=B,XU"&SK9R[?--[VL/!)^ 7 MX%]Z/_;ZX ]\$90?P:+8_#B>O9_(?-G,!U?]'H]X--&#_\WN/-]$NZG"?:G MI@\_@\'T8CH!2!:0L&^P@\P[+-_N, N MJG] M)+%OLVN1XUNIDR35CV ^T=HFW?.-3S8>+].##3O)D4 4>)=E; 8J4NK M2BP6KA\.1XE*G IOKVKRF[O&BO$!>4ER:3O 8"14:Z%A'%^/>Q@@]BJ&])G$ M%AXY/EXCI-KY*[IW??*6;V5MX3O_%:EWJ4T$S-RPUB%!-6%J]DPM8I5G M,5]P&QL1B]X_)5-88K7GRQJJ,]1AARGC+1>02 +_!3!PL @"S]X= Y(O!@(7 M/,**2S(YL:#"C-V* %$A#C-B<#K09YG78[DRLDB/6AH: ='9K#DZ.B7--U;( M85\#XR'.:5ELDZH?0U =YDP<";$96WFTX*%)8R:/I%P/7B+5(18^II*8594@ MG# 6#XW=$(U[4&G65F.&RX-=<9A+'SUD351/0;?J@:,&1J87.%'.5 M59('% ?[I5G/5V[?K"R0IZY]C4%(W/+*F NO4&REM^% M_ "X5I4^=#C07SS7]Q\]URJ^N$G\S,+MX\'0V.D2+.1REQUG"@@.%%+QLBL8 M<+Y4,I=<34W0(=>PB*=<.([-/8-2'82+WSV$-3^K6G&4P"MXS\)CNO =2Q:8 M!>YW1G^G0]J8()O\=RO1NV_5288;M,?DGK\@!W.V7SCFPGRU'9L(0[+)0O%X M-V2"R!)O'6N)D[J)%,)D]71[LYZA@Z?0A.=\_S1*XP(\,RKTR@&FZ"@_6_@( M#^\+?7G\AO8NK5=9KID5.#)/(0+,IX\F)0@L8#^U9G,=U*\&JUFMBU##-^ Q MLA(?-F?,A3:F4,#!R)+UQJW2GZW@L?BVV\WM2;HY.:+2*G5JQ'5&AP0U/F;!9N?F6JQE2S:9BJD0P7Y,MY*EFZD/@3^!]6G6-IW%?D!8RJT*F7=9WC@ M,J\GREE.WT\4P[(+IA4Y&-@%X276B1)B."T.5 ;.XY+3?ZZOL.%.3S5SX M%&.R//C(]AC=-4;&'GR\> Z;MJXEA\QJY DUUJH9#]7>8&+P0(& MN^ETJ,.M6!U>BZLRQ$8JM%H5MJKS6VZR"9.%=.TZ6)XC%FD5NW)7""^1\/W2 M%KXC?_D>>-#U3-N!WL==@%YIK7R,B;^YIZ/!+#+_IKR3S[$*#?W);B8K$E'I M4TN3EN.;[RCU:&<,X'MTH%;N;G6N=/)F0GY.RI]FM6K1I$"*D+F#4.KXPSR1 MTZ?!Z=O1&@[AZ>FC!(/##A!GB%G2G.E2L'-.Q:.ACL.K^#G3.% M<- SR3VO-MX5O'(,KVZFECLY8C++-W%G:U-?A]O\2@9Y9@&C1+%-\'V(518D MZ7 ^\ &\/#:5 F"7S8.>9(DU%0!2PHK5;(;QY2XD*R>2W^Z4UI^ MJ0Z/?+L!L./&$> M4X#%K/I0$,WTY<;>'P/NXS(NM#J=R3!*RW)9Q#\YD MO3G$#.U<'Y4=E)HQK^-F5G<*&PZ$-@:H3:W4HI1>?8YSI[B(! AI $:$W/&& MQH?1N0"4DIK@"D?.<%L7>MI][ :&"0 MNE;=@0YIYHT9;V"E$G0N0/@%U>ER\2/RE<7")0O'+*AV6EEUOB85F:4"&PF8 MKB-8BP3+M866,5&95=4*\XUJ"%ROOCZNE[]@N+M?E^#N ?]]";Z_7VTV/X@5 M%= LX-V?3:&LVVV!';:$0VTO06K64ZZP-HVI:5M N\SZ-"3%-*/7&TUUL$*M M"%&<@)^!Z^!_?4-^0)P4Y:^-. -TZWK8O7=8)U+C8^M! MQ\?VR78=[$[1O[% 9S1N[2W85K^L?NUV,) BR[C%SX95MJ:]OLXKNC.!RQ=W MN,N3G3@X?01 \S^/E0N\0VTL&* R+2H!9WDQ4%! M8*+$I9=,Q%P=(ZE8IQ%.A1&?.%*E6$P**0!IIJT1*A!JM910L[1YU0P.\$2;6J79\*I7^ES6CY M#FD63DF=^C23G.+T#(@M?(3&/1W*<"#M<7SIQ8XXJR7M?0GNY9T#KC]+>]]RQ1/'U^I&LD0A19%9/M>D M/T)3'92S&=ME#5/9G6-QE(->/2JO9YIN#ENJJ#Q@=1U[^2I8#,EJ9XQ&EFEI MH&\B/)8IUXW*;KP5;9UR;9+0;C ?RLJ+.= ;">SZ>D%9*)S/9#ZW'?_50%%W M'=6'K>HF8*HZ?]76"QT@2*:0(DW?WJY638.=2E)[J#=3-"<8M8C MP\Z_<#(7# 6+XNVT_Q M(-!VKFTH?2DAY3HO(*: RI=0"=O_C(VQ#I5LSN7_3(5OP\QSZFVLD1]XMD'> M;60;>]*+:_8/MZZWA>^_V<'+"\MURXS3>:0DU>HX4]2XDD=#.LRW'O1[AV972X&3QZKH&0 M22M!/AYW>]M8618B^QU[91!M6Z3+(7/TLNK>G(RD3> ,$>,-H $-]D1L@B9C MY<;_;.ZSZAT19&4\#Y0D5N"09OR>Q(Y\'H,0;L?"MZ''"[J>SAZIB(R.>IP6 ML9D>,QIA)]RA,5=IJMOAOB4]UB(&LS@EBV]=SOTB7;-3+<9X=2H1L@]R:SZ\_*O'&6,X3I2^MNO\F2-W=C[)EHX%G)E3:? M,8:=J$M*FKY_C&A_EC?5H_G V$DK*XN\NB^J8_ZT?5%=]HI6].W/28<;ODT[ M]V/JGZ.U,UPB+]#.^U+8J7V.!CK<<\N0,;OR0KK " ESWIMG/&LQ)*W4 0%2&I\!0K;R8;6$.E0T[46LT76O^GS99VNZ$>[N363Y46Q M>^.E4]JA@<]BX\0-72_MQ^8$#F6=.,4&OX)1W:_LXY=?U]!_N=V[WWSQEWH% M*$H>Z'%9Y[S+R\&S;LRSX=C0XUI=E--F):86FU_ [?WJMXU&C^_P[D!D??3< M-]M$YM7'$SZ>W3EQG]0%]H+>6"6-V/_W*WH3/AF9/5@UV@6)I M//:T/=?G1YLKD8"_+7_9'<8()'UZ-'RVR=@OK]VF0' MS0F'V)K05Z1;EP06'HU24:^NVLU5U_UDE0?-.AY 3-._DFRQ7<3J?CG78 M-.5*FW]O%G^=+&0O^B:]#(L:J[KT;X0U< @_#'8?=;=C>8\&A#,SU6=?BF=8 M\K,0D05-/0XX CR*WMIHTE^2+C0?\W/K>C?N<1=8Q_W",,@1O\09*4&1ZIY4 MLIYQ6+CP[&)].AW-=*CO)LYI00H PZ0)6F:(B^T70U:L;#?H@ VP#<.+@<4K M<;?^J\R"E6+(4S4!QI.:5@(>5I Q#"W>+@HSFFO2D$ $T#%)5#!&57)BQ>O# M0U2.!">DIK_/5!^+]^BA5_OXZE=<;32CQ$XK77X8[O3/9S<8*3FG^?I/@#T?J8*#5]$5D2 M2(@)RWU82O,)R=TFR27$3L.S_88J!&:Q^D$?==]8L=J4 MU>0V.X\$DP57K1,NFPQ^CJ^[M["!\.;A#[W^11U_=14!6+J8$OM0=\ M/:$R7>'%D-FY"^ZLO@ZO+AJRG;L2H%65?5)6.1%^H 2HL=G;<&?OVPA%<%+/ M\W)L/6B2!C(T 2@ZAJR1@>RW@H*338E(2CMO+%YL.6M38)[TM#=1^O:Y#=ZS MRDJ1J5JZM$).=,PD8;:0@)*S0%Y,LC,[> G8J-#W*44(ZP1-9[O.:V^)>_8U M.,Z]W3T!:K?Y%[S=07]YG/XSX<6*684M_:3=I^B2W)' M1":P^1@H=$2ZULR^RBOZLYC.V9I*7513URDO7^11/<(/7O7S2B26GHSFXY&L M.M<".38UN2X((C)/\<"@M7-$.!-7=Q34.B2M:5]?AQHV-5@5=4YB-0PI:&0V MO"/>UT^'?>&YR^"%>?6]OK2^M$V-1RGC19<0&#[> '2T'YP9;# 6RJU(F\K8 M?5"YJ2WA=]P@"WD>,M<(G\!R M+^#/H*/,0Q87LL1/KB;"7)=YSYBJK&?=$ONY '.(#\R0 /6=S9 $\!@-7>TI MRQ/726^KXS>SUM?3<1QO/!2Y:R21"J#P\=SJ3X M6Y"BB13'9M=%V!$:R;KEJNP]V93YPBZB(DFWG^:-U]D#IN>;KA8TN*]#CD@3 MG@L?D-"'6X\)K?V>4,(NX \@)@9.U%2_$^'(S=)56GBD6$I(N4(+B"F@V"54 MV N$_GPWUV&K/9?_JD>*=D1(_2-%^!'58C+^>;0]5)'A5@;/"F#V1U,=9XEQF;]_"='(TZD045WR(U<6 M; +Q9AQ\/&+F WQ.)F4N#@1$:+ZXV&Q$XA#1HB !% M!'2S(973W'BHE-J73K57ARZ"37@6LD01G0M *5U0]8V)J3%.XE[9>3XI"_Y- MD3&0==O?-%Q0R3PW7'!D9ZU"3_33G+3.'BP]3U8M:*\6I5Z;\%PW5! 3TS]4 M<&L[T#%:"!64$E*NT )B"BAV"17V6*7?-P>&ODHNS']5J,"*""D/%:S1(704 M5M:][2#\/]<>,NW":>4"LZC@9-K3(<&S)K?9N2*@M'L3A26]/4(JM$Z\\KXU M%=,E.@9R.]"TIF,#'0*) BSF=KP3#M$MBD7^P/!4[VW)A@M1==@M[X-AUVE5IS1PM4:T(_3633=G MNG4]\3(Z36FQW/\A'%D[?;:V=H3ILIN5:HMVIN:T--XJXF3*%\M AXI4YTO MBZA= $P*)&A= $KJDM("(118>!YYL%P16%.VO=^1[BIPGVZO5&/7X>"KW>Y+ MA:K:]@N1V5%A;D$MJA(U9+NA&U#4+(O3*TO^^\7PA,[.Y:=S>L$)/3G_-5'9 M,.X&PXFLU&QNS/@LSKD!X^^/4<@MF6E6%)WH)%N[_B0V&PUIF=GRM'*@,FVL M,<.%@>":FJAZ-UUB4V@$*VOY;M"2)&OL7ZP<,A3D_Y/;M#>X9ZY'Y!B3'Q:. MF?Z'!"3'W'?R)7D[=(<#E=S+._@,R[0V>U#I.P=I F97)?L@V>51^$G@X6_2 M@Q]9K!=LR:(3/7J1G#@(DM^51 S.&A76>S"?D1\604^./QNB(G64RP&;R%[? M,+5)@E1I>PW:E1:Z:3*W*7^6UJ,H0XIEJKDSCFA MU]04T#O:Q! M;/L?W;UM"+2B*D&06H2]@NU,H74.-#,)YG0TU:&BL2B?N4ZQB\T=;=CYN%YN ME@_;Q?9N]0 6#S=@\_3UZV+]=_+;YN[+P]WMW?7B80L6U]?7JZ>'[=W#%_"X MNK^[OEMNE%BN*^C;I+ X'DF\9**N&!O[V;$MVR"/$G)#LD7OP=6>DW9S#CTV MQI.!.9>5#BU0N*D]@20KC13KU8;ZM#C@,BV@=BM'AS<$K0B1[\.-B=(&!@FR M='-/$ 8GRB B#7XGQ &EKOIRZ0%]2\CNN0[^HT&32$@]H[ &?ES?C\+8CF$? M]@+/#EJ@+/,=0FL#D7Z8<#99=IY'U@CJD!+2ND#99;5>7B_9KA)O*NO5 _[S M-6M KNC18&.I2ZUK&W3I<$X- XUD71X*^"?M"]:>GNAN6*M$GKD'I9D(="W'Q7['!]<8C9F!E<,2YSR8V+]0,^G6S XW(--K\LUFJVK2SSI?: "\R.9+/AH"?+EQ#8F 2Y M/6=BE"SRJEVH!%[=,C]#KW386*HYS*E1B$%RL=C#/)TVCO ".W-M7;%]5"') MS7>I9C^;HL#'H+,X1O/95(>J+W5XS>46+#:_7 #R7[#\V]/=KXM[$O2B]W1W M#[\N-UMUP=)BL4BK[KWK'RM,A#!R6!1S,-AI%/9LR'W;DZO0M)1,<].Q4F]P MNM%=;2U0&<>%E:9H##&3\@9.5'3:$&^A[?T*]T=T8J]J.RQ'D:>;(JPGU;$, MGLYG#_7& QU>G(ESFE6_V\7=&F#[^+0D:2FW=P^+A^N[Q3TVDYOM^DG='E@D M4:GM*$6@8S"?[?#_T6>OJ\%QJ[.FS$Q4;6@5.&H-Q9G*I\-F)<9E3M=SGRM$2:EB5 M";T+0"G2\QVE"1)$-3W@D5K>#B;[<6*O8EIIS"CN0Z3#[_BD\!JK>H12@'CI5:D##XLD#:;2ZNC)-3]6Y3A1E.C:KE7 M[6OE*$H7_'GZI<-F),1DOI=LB*3IGO+HN>;1"'Z#I,8FJ0DF'CP40Y5:QE)8 ME$P%RTH\.K_6M+?KZ?!JLC['N;J5Z]7-T_46_+98KQ\00?7M^EK@1MD(<]#9ICDN'EQO6"+O%?.5M6(&)<[;4"#%:^' M:#Y76;VJ'>YSU[9/F^WJZW(-;I:/J\U=F%QPL[Q=KM?+&Q!F:8/-+ZOU=KM< M?U6MNM5FLQ6*^BETA:%M@1Q3%&O0F\FJR]*&FE<*TDSC+YC*7W:F\PO#.+X> M:8\ &E$CO0 \](("V2.'!Y MTE,%#JLV,IN-=QI=$-5CNMWYDY.<)SB3-<=%:BI>5\JHPVE#F-'<-I9$! P3 M?$]LSP_TSD:GL!GC;@O?:US%E&#(C,Q6,IX.S'+!61+W8&QTWZ)>*#@KR&@^ MWH\MW!)L%_^A["XFQWE%K)P/SXP[G _G&F73B3/<;&Y4+?CJRY@R%*5+_CP% MTV&7$6(R?QE#]Q32=$S/VYA[4N"ZZMXE"R0Q*Z60O52Z20J"Q;/-H3G3H8]= M&6^Y5)'E8J-H/[A'OH_0ZH \2(J5,*[+JT.=R@72!\W. !RU.Q&;T'(W\C][1G1(C))HKUL^H-TG6>Z6T&%K#*H2T$E9ELS68#**VO:>GN5\EA;N-;/7RA5T+@9GFEZI7'B>F*7/8"0"J>.1\,#8W2 M3P4X;3H1TA=O]5N*0E@UR[>A_FCAN99REW_+X#Q?$G! X+5R4^/=;&4EV\&' M[>.O29-K6DQF1YJ\1\WEJ]S9,XE*=%!:$3_EQYQ%D?5Q0<,9DA42+G5W6I0E MNR0VV]7UOU]>+3;+&WIKN7S8T X/2C8U84&ODH*6^[/GD607]X.>L9/E]PIL ME*W*=+Y"Z&4@RU6CW9'4TD3*71LZ. %MR9%;"@3GDB*!$ LL2$KO,RW$W7TN M[P8]DP^1BCQ$04A54B+7G6.YWBMK6U*2'58'6U)Z6'V!XOPP<506!AB@/E2Y M>9_%=$X3EU^^TNX&#\0H/Y!.!VO6B.GNX7:U_JINRPXE7*.#ZY$0L&"820"- MM0696FBG46W1VGRW/)-2]MH:&3NF1TKIPY[7QU><[K(<$&,K.D%_^:X M\]$_CYC5Y9O L9-#N#XP?Y;.D%BF.QB:#J:&AH9@2:L_XG[O I.?J-! M5-"[M5M=UL'RU&27VWGU1.""=5?] +^'_ZN/-WOM.C[FR:3'?S'5+$>1^02G MFO7T\QL^/+N6F YFEJPKZ#(-%.$8_^2C ME;7T _L5!LCG")X%DJ=,Q>PEU2<-P:XMAH.!I4,UF3+>"MX'1AOENK+"*R984T!7(51#!E9J1("Y,)N^@&I%%*Q":3'38N+.99G?D7&V0FCOV_A@@4TA+&U.3Z"R>)W#* M>VQ&BET10S29ZO":HA4AN&T0#\@#/B&FC9J3SE39'GN.&5>2(L5G_8"E"-73 M^.:$52C_N<-0O Z:4J7:-!E-!U"'UKYMRU/4)>T"&*1%&DJT2"-U]>T31;#[ M #XRCIX=? BJ#9+*&Z]L_!]1$?DWH8[>V^3NKI?$209!.;*61/F/6P&:(2V MYFIJY1LJ%E:+@U.\QEKX '-5#&,PMK1:;JV+5MC^Z8VV?\*KZ\5&'I;XY4.; ME167/K_& N(_U5PT5>@JUH.82,6J7H[+C&S/'&K11JH9U[G 7$B%'!#LD [6 M?6T4-%,7.5J>'S45592,"H6M)V*QXHK18/54)B::R+VZ1F<)H2R_^;CT>FRK-LFS*<6QL; M?,^H_Z"%AO-,\KG$--7P0O-\'B76E:K?'QLJO8PV92CS.:)/ #/\!CV5FN%7 MM(M9EI9@9J7K2#'4FMY)0ZHJG)6S!J#8=VE$DJ5 C)#1TR);O4UA2I?+"WD. MZ&-7'6#J ),[N X-WN ?X>G;P*7]$HU4N=X]_O %<%! @ /XKKJ !:G>15Y+ M"JT6+K3DTHI\AG,U%O.@K,GK8&Y,5?;TJ,5D/@G[<-C3FT^X9R%%:^]^PPH9 MOS'$1IOI8.""/:W0IES1\O7FXN/"5QC0B*>@$C:@I+9BH*"@564$*\BPNCFC MF8ED%; L5^PS!<@J?81##*<;EQ^DR@WVIXBA-F[*\O6P=S\0VB#OS3;0Z35Z M\KWZ8D_9""^8#??9L?\+F8_(LUWVB+W&Y6O;WU-R/=O-H'$N<-O]&(M"PYV) M=$A?D"1F47."B"9V?3!BT@@WUDB(\;99PKH+$ MXAOTS UA>W4@G/KDXH*-G^\?7]F_U3QXM/,1%8NUS>$I7J%M?(&=@ZT>-'0H M[-2E;"477_!$@<9FV1= _ 7PU3717O.%%QLR,D:/>%9>,,0C%KFS57C6%_59 MDBT,7)WU><;G6/JG8>R&>EWO=2RHX,HE(0.\@RXWCX_@$'X.>/;S2Z"/V\MQ M+XS ?JM_95B/F-H%)RYNU5JJIL3Z'.[03K/4J>8RY$(<9$GAKUY M H$',4F#+@;-%3ZYC[>J_"*$]5D(XL-09U%44V6'E)XYTJ+<=-ORE"X6G19) ML3DXU=.[^BC>6",'&/GXX+APS.7[ 1DD'=DE_[0Z!GZ ;8+M/-/?D&?8/ATN MH06FF"F)BU.+X4\M;*4_?4+R2="9D D"K!$.UZR0[OT)>4_=#$H<4I$ MF\39P]/=!$Y4=I[I6*S<>]K-$WENR/['B^FQ!R\L<^)P^F !Q#/[9F?KB4A, M1B*V#T_T>0$R;XXD?9J%=*OSA!J3DKA*SA UM2 :T&'%6^?0G*M,XVQ/@B(U MI\I,-1TP8O0?CB%E8%+21-LQ;=6>9J8F9E6]2"ZXNDJEI?4B.;!AD_+IH*>% M1R/$):\\;J(8;DOIE*VT=[FWW_""HD]3KCZ^(!>;[\.+;2P\!,5BS'6)R&T( M4U^\;*<8<0IA\OC(&B -M/4?ZC\ M6%G&6+ZT.H/M9&9_@Q;R[M$;VO/G-@\C:79YS,7SFP4(RRO.(%1^>"IG+3O' M%/J2@GC860PB3_>*6$LJ M5?)W.MC]V1QI\6Z(SUGNF(G_!@AH"Z?+1N&'30 #>J%Y"K# /2<&40(K)Q!1 MR6P4C> "AC>KNX'2%,8:+.:S24(TD,3K+C;QM"GQ<1(_2O)OLG/ZY-CDRH9.K0H;L/!M6#C)V1_EK/(\.]&R/OW"BAVBV5Q: M'V#>.N;QE"LZC^$Z6:'+(XEOEZS2#("DE5K(5KQ:4[^R*ZAAS[!47CU4\96K MJ$E!E51C5^R5#\Q)?R?K&9U 3?:SY2ARSGT-G/.M_8K97EE;DC5J(6]E?7%= ML^RJJ!:F/%>^AB!)!15 8XD2DP'LZU"QJS;#N? 5)0!6%HA(D#\3(E)NHL); M+UI2-8R81WQXR%P$BT?7=H([![.)^!M.$RJ2=J7F L9;5WT2+&P]ZT]G*HO^ MM\(\YYJ492-%%$&")( !@(!2)359"-U.;]<2GU[AK:-<4060)-_!5;*?NY;C M8K SQV W,)5[535YY5W>I?3*Q00JU.G/ZX%-^W-K*FM: ^1UXW_%4DCUOT0# M8AL#.="SW:I@6!I.SL5H/5HLPQ@JI1J:M2:<(-^U1* MJ,F0%!#11!&YX@EK9HX""P7V#'E>5V-5K> ]]Y:$P44]L S]5#D6Z!7:#GLO M$[W@6NWV-NO?5>Z:5N%*3Z@0$Z;@J%".R [K/02A#FK:@.6\=H:XJ7=[;HS] M*703_Z-!RH$^HW,&*DE%,WW-"UA;MZ3AC6).&/.5N)%Q2M6L18 EA MO>EDI$.MNS-8SW721([[:CM$^VC]NAU!H66T;5K/^]1S\&?P+?PL@.R[T?&3>.52D!Q2P:N-1<\5KN#=(;?"\,]&$@*RX<1.Q3C'D.M@LD6T, M!SOE>35G\)V+$S#U.Y(RI[93HKK .)'4T2:'/4%SZW=A_N>1]2^L8PA$J"FV MT^("5UKL:E*LY/O,&L]UJ.G6BA"Y?!;+0@;M?& 22J0?0MCLLO0(*'][Y@E: M8X/FD6!'93B?2GO=5GFYR+3$H*&(:CYSI15"J/!Q!3RFN\:WV3%2'$+:/VQ M+?Y 25Y8!D;>%E[(7%)S4@!L>4SZ(,MVD'F%'/R'@+S?N_H@_Z6%BJYA@)YI?^B2/;@6!7FK MI8%@R351 YVE0(^&L*_#8;HQX_G#%24$0DJ $+F@_P6LBM4%",E]@-\)N3-3 M4;C5A#CI2+E?I540*DH\ROS$$@+GD^E@KGK[YS&5S_IH+:N(,Y5?/-?WGQP/ MP3VYR"=],?DS6P(L::(KV8WGG0O).C_W\8 K5P-!'K-:0=' "0\0Q&X>_OF! M_4J:=Y&&)*2I24FF.Q]6UG/ "F9/+P,Y@"P#"QD:='T68S$77XVP &T@0_%T M24K\ZCKHXROT_D#![=$QBZU,%; \5Z6Q^D84:I.90CR5*J:[:1:\:%95=O1?82_>\#WP7J\)KSJ$FW;'1"_EF#$M-;Y+W>T:KJY J5=Z8OA)1;+)K# M:+8B= :,O:+H#\<]'0HG53*8U1B"*N*:JUDE1[>/.UV3:1Z8.5P75'.;32S$&*N^!TT%Z\07M/.ISOTE]R2BR++4]QZXB1550R3A>3&/7.NPWFL"<]9=4Q<=%Q])*\]8D* 4NJL MBDNC3L)X^#9-!@^DC$EI:NX@JAA/](WB@[,[:&DP'*LN4U6(R%Q?XV M;^Q=K$F\K*@J)'D;N1C[24TKQV W?6-CN--A.Z_#:U;E3KA"!1G.V-]CUMAA MAYV0MRYS9J/BVSY[Z]4OVI]J$I#D!302*W8,:F&SAZ+(LOK*WR^$G#!JVZ=WXN$!!E@DO/M&P[NO=/=".MR3K_'2\6PC0#27Y0%KRM'S M^,5P^. R2^Z5LYRNK5<,R^+RT\%@HD-:GQB7^6IY$19-QE!]0K8=Z!@VW-^? M"J.*[[/"V!)/SO4$2IVBQ5#97>5N8ADZ) DU8CIWHQ412=;')3U.3M9/ S?0 MP60_'E"PV/FTF&^)4Y('E>OR\5C-.GI9..8RH=Y\HD.EVVH.=@+K1*_!%&!6E6*4:AD M7"QV,!P:0VG%P8143I#?W.X*OX'7"(\Z/:#!>X=A0//!-$)5'6I!M1 MY0BQLU-_9^H4].8S6!34(I#J=YJO[AN-5-PY&U)#$WIFV-3P-^AYT D^%H;A M'>%^[>[WMZY'"KQQX\D-*,E\-=]8T'2 OS89MO!Z:(QTR.(_6X!<$\SUZN;I M>@M^6ZS7BX>MH$O?X4P7RU,TF<605-R= 4UI;40.V ]U33P?7E!F7T38S1=3 MW=,V"_B03BJ-[="S[= >#*Y%_^$#04^Q"2J?+Z$QD&E(6E$O'3("*]C+:M+O MD;V@QZ7E>X <4L(NI (B,B"DH_I"L%BZ\*]XW[WS_2.W]98 MU3O'('D1Z :Q_ZTU=*5T5&NQ@)#5"EU"A!6RVPWUB,2?R7Y.S>,&!SX(7'#P MT)OM'OW]!XCH161/4>8K#G,VJ@YY)!;/Z M+EHQRP5]-/WCZR&J NN%YW8][5)FVFH-@P86YSRMTR&G1I#-,[VX"Q!9(;J- M1N35I.&UXGGWS?YX+"L]A7D62Z>!S4@S6W&LPU]H[T#'JZP;MEJ]00?R&I?4 MF+A!%O(\9(9M NES?_+:/SS^:>54X=PIZTUHA5M27J\EQ82D:1%6HFCT96I:D&J8PIU>4SYY90 MC5$=,\H*<%V:+&$;NL',G&J@2TJM$7R ]2I!X0(\H P.DHBA0O#8,J/3+[M#O,SM_"]:)>J28)E M80QF2-H=DV#2R%ER?,)LDC(AKY#E>FB-#%(GR[9LMO'Z"0T0WOC+B>G@A(F( M*^:6E5%BEY,(]GNR$C&;.6KB,A2[;D;*=2/E);'V$X+X7)&AV,EFREZJ^B?V M\7(^XB6[< V[R+Z7PTO:0D68CG?/,F"V&2%D*2T.69/-W$T]PTPH#-X]W6- MC"<\66G@4JKHG/DJ+"D4..V:H7Q]G$'CWWS?;Q'GGK>HSCO.$H Y2T;96R M&>]7A5#,?9ZB\4A6I1_N1B7 7RZ5/T(!&">*3VW+%KZ<1E3(]Q%:X54"23[; M/4N.\PW/ILE2%>^\A;$E-JRJ)U"JB948*HN)P\%@JL/KM$9,%[9'.T#;I)E( M,'2FDJW4$X57B"ESH^^!/4U@2M0L4-TC*ST4%Z(CSFW*-8EVAG'&OO?F.)Y1DE4^ZDIV1+U/J(Q+PYH@I[68^$*B44 M$XVOFN7X3!F,W6ZD0Z>,YISGRJ,N%YO$^SS05UUTHVAGB 3\2(A78V,I1E>[ MN9>)5+6[%^&&1321J46!JV9<%[ YWM5-74MS%FVE@P27JNNUFKY#Z7X-J2([L> ML-8-P??HG<2,HM??ENWY) KN(>QVND[PXI.%0B _R^&(R+W]YI[IG<=4-%/^ MO(!-3DPA"78$,49HH$,MGK.8+]#MT6=26++@VA@71D=3I4T*V5AM"1%FUXS1 M>*Q##8,SV2]0W?$G4MU;/)8M# PCHZ?B)D5LJK>$!JMX,![U+%WOH<2Y+]#: M21=:ZWM!0F/QWT[:BO_RCS7F 14\$\G\UKU>%3)#E"7U WOR9UBFTO:J)2SE M2P-CL Z;J%9,[U<6^2S,D"_X7_FTIW^7-.U%3,73GOR17=WOK-U 96V4"K9RT\Y =6EAE=Z7?D/V M\TN S,4;_M=GVJ*!Q '7,$"/"(\5-[Q#I[S M>=SSTQ+V+);\+21X"1E%$,63 893_O:U3'86S8E^W"+O-=MCJSD9312\1$1A M!2^@$>YMQA"I[-#9#O?U%=R+2(81;5)^1BL]OW9],5/- %7I:I)-OC82*+:I M#OKF7(?6TU7\56J4X6IYNTP6Q\JZ=IVZN:U91+4!AF(QJD(*:2PVH9.=.=$U M:%O&;X4"ZF"P:-VN+:W;M0NV^$,E52@XL/*TK)39I&(5 H8-SJQ^7P==$F Q MJSX4Y9+@ ()T 0A:E[4C5I[];#MP?^]"9^&883_GC\6SAVBJ-?\MORBFI&<= M]02)WWF(H;&\C]%HHKY.7Q.&S^<\9P I,1!3 UN7:>E"GI9&)<<> M\1"]X$U\Y9G(*RNB4P(NN>Y@"81D34[E6"7/)+1@780**VDU3 M<9)="8D'UP:BI8ZP-?#9 M"US3&@]T"$):BA"4+1_.1#K5[:C&;U;Y?H6?#W1[%[T5TN.^@ M76"1Z=_B>23+PX]6&F<$2N"E-LPH9SK39Z$8F*58F*-97P?5$F0S5R0C,EW@ M2-*,P3XT<0;%U7 [CJ]7SMF0RXBHW9*KQ:O:E/D4F*,VFIE]'2[1SN&=6^KE M#=I[:B.QF\EVY5"O21:\]KJ]?#_8'BVP=H,M.^]N6 A3K19S!*E2W0P::_ S M-X<]'9H1U68XEW2'WMS]&[T4(8KX"@-V^#'5[^)%LI78@IQ67@F645G$A A H+93?0:T\?S\RO<[]''%73^*(E2\T!E1:/+ M63U%G8OAPDNJWF2@O)2Q$(>Y*#)# @P+$#35=L:%#JGH0;9HWBI(@4BT)P6L MI6Q(XO?0I>Z-#)45T*HYRSV5?7P$>PRM;9AB$Y!B#&%:('SF]Q41)Z!#\((G MEE@<(XO-7FQ,![N!#NULFO*=UTB$LI3TJ"'KK!4)JES MBQR?=4 A+5*?Z6W8U<<))'RZM_@&/7-A8E@.O5U\?EPV:Q MO5L]B/1#E;)F6<%@ZMH0J05:FI5BR%LO HPGM;T$G$W@<#;6HF:0,*-YAY.6 M?HXQ3TW*S@^=G-^ET_6#E;6!>U3<1ZH$3F)G3AZ3J9Z<62 Z*R,$)W,=JO!4 ML)=+J\+@Y J!(BC6D=#$+AQL=DDM26)>22>TY3LQV:A4;P1QY>E2+6&2^B6$ MR"[6QT9OKD,3BP8LYQ-$]YCR\P4(:=%TJC0UQ=JY1C["H_M"&R2_H;U[($96 M1#>%,.5I9@U!DGHI@,9.,*AG0AT2"&HSG#]R,0)4%Q,D%"OB8D_I(K/8JPT% MY R**+(\=:PG3JI%C! FFV-K,NOIT :Y"<_%\2<_<(T_+G>$ FT!%)'0(0:P MJSYJ[;)'K5MH>[^2DI<+WS^^TAX3/AD. P]6VW0]DS*S_J-PR!EP_&K2WH4TV0G;-?:#L#4 M^?(GB-75'\A6(G;BGV65'7:#B18]B*0+G$M1CF'_3$MW;?M_W'H()2\W9C9-?U;MGS4,R% TXR!A4FP3@F*-^CEZV'O?B"T(?Z+?7C$ M@BPWJ\?$M>'5!_G'DONU1I3D;:)G")K<%AN086\9^Y-Y3X-11"*C(._+N$ K P% ]GI@ZWJ)4,5BS>N$@%69_REV:]RL]] M:SJQ9*7>5BU-/G>< M!*N@HV/N6<[YLJ8H'.!9S->T-9=WLEFJ+%&'Q*-U61 MXJJ=MT\18_K5E.YF]S ?19UT^O*:$:?U?Y)5:U::K4W1S1H M2%E=..9Z\[3%4OK0H+R7U!\009-U/R,NPNE*I1J'A5E,.)ZI#/(VXS:7U,P" MN90"32+%-$"2B$ 7(QUMV\.1,+VRZ*_^(JI1=.MZU!5MU:15?"NLU3E!/5F7 MWP?JAF\"Z 6=6+-: F._A_LKVC,-;RQ7.+W_AW\!GVB'*.C.[3I>9, M+1WT3#+^Y06R"^3,-[1A#@B-42/SLVX.U=K4_4!_BBU!CV7WJ6L!",@F.1), M/R[7_C=.#Z/2X/-/E0IV\@%V\N_U1SK8? D2YF(;&*D=4]]B)JR(1G0Y9%IG MLJI?+BI;K74K5'ZH;2YVY/^%QB(3L@^8&1]!UMA(5?^CRN4,E M>D* M%7R&'1G[L]E4AS+0G0O(.WH8I,+Y?D\*FCGX_YO_>?1+MR<==4FW2$M_:,R@ MK#L=%@E=.MV<;&N)6QT'18YY=A"4UVSS&/@!I/1#W4[<'(A=[-0F(:O]9C/1 M3GTXZ^&SNIM]0VTEKO,YSYF\$['H/ =2ET-)@I_+ H;B)"1D"[>+O33W$59) M?CHS)I,_R>V/F*2\+=4]H25N?FC*3O#B'GW\T^*3S5GOU%F+/I>X MD?V&+*X_+RB!B J:A"=!L"! M(',BSI]\LZJIM&KF[3-M59_$"JBLNZ=*7GD![5S=@H@A0#G2/O'*/Z=\1"N& MHTT.-#(>[0]L+0/2WN?#,I8&FJKLKZU<\+H^Q)_C#4HBHLY."+9'*71J$;KE M22,;(6/P.[I'JL\0B\M/9N.>%@%8?8:BKF6)+ZMTMRU5IC@.-JMT+VHRH9'U MZ&1X6W4R:G' ZA":0SC2H;&U2MGK&H3X+O-_@FG='2NA-4#2:MC+OM41E_ZL M4%H;Z>K*7>+J>+D"G_A-SHKDD3C,L/HFH\$(_1EN#5H:!F'[00LJNJ*I M>5I:&982OS@&+ZYG_Q8D,>=*+RK_Z2)TCUV0Z2IH1=O(EU9:AE8&J M7O-G?88]^![,1AH'.UH4,% MT2[QC$(@E'R?7^4C_;ND$AY%3,7U.9(_T@GI#7;X_RK4N JVLGKR+_T?AZ/N M)G-0,9D#%9,Y*)O,06+4X&P^G\IZ7E,^F85L%4SF9'2)_SN;=#>EPXHI':J8 MTF'9E X38S>?]V8CE=EE%6SEIG3P8V]XB?\[ZG4WI:.**1VIF-)1V92.DE6# MIA/#4E[OB,]6P91.)V1*Y\/NIG1<,:5C%5,Z+IO2<;*=L#$?6\J[N//9RDWI M\,<1GM)AIU,ZJ9C2B8HIG91-Z20Q=K/>P#)5IMM4L)6;TMF/O1Y>I:,?9QW. MZ18Y%;.:@) YKSG&TC,;_\R\2\L<]G9:S"V'L4*WMW)V-0ZY*7QTWNN-+%/6 M6S\)U8$JI&S^Y!S\?V'U3!VB7;OJ =K5SMY:HU=HDPOH:]<)/&@$1[@G#3$' M95,EFQ/)T3(U ]U*6]?F;+ .#GUK8FC3HD+E %3F$WD1'6"<"(&];2'P_=]I M<]@XEIZP,Y]]I](YZ78$9[O^GZ%Q[#FRMY!RBS>]?P$_:;3QG3&&X4B1.MB= M5E@$2>?Q^\\8Z#;]#L;L,&J@PVGYNC/X'>>/0!M^IT)ZZ*#'6G'NBIX M+R/\]4^YY9/@-^0^ M^"G= \ZP=>0%9+[&;LIGT_%4F_<&$N1LEH&96L&=W%\M7P][]P.ADJY,.1!) M-U@HK'5C>\C ."6SS8.4 M-.GEC,9S7PS&SMN#^6"F/.M A,&L)E 2XEEI\S19*3%TX469,CM>HY#3JKM-6)6=RI=_O-H M!Q]W#AZ'(RWOL@I>D+=]@8Y(W3CZXPW>_F^A[77RT4"T1%B2,K8Z#+'2MD*5E7 < MC><[Y]<_1HOZSKFWT7%E74/_)=R>;EUO _?0^U@C\\BZ M$A=FK-8G(BL'N*EXIS3ANA3"]GGFI&>I5O,S><^J=/+00II=[3%%HK &I@D. M83D0$KSS*5FLP1'=3E2WB;_ERSBY:,>=I,6FD\B95:P/:^$2&_=&LLJX<,V# MKH/2WE:*+1;/4'5BDAZ]D\6EH[9RUN@-.4>TA=XS"K88VW]Q]Z;_%;[;K\?7 MHFEI0$32 F\L7KP.:U-@>2'8R^HI?^QZ)N]9K7Y,;:?T=HWHLL=(@H#2Q.H< M$<5:3ZEVH[C(PQOW*RF3SCGR-5?GMDC+4O)VA^*D^NW094=ONMX7OO]G!"SFOVLXSN9\I'+NR@:Y-2O+2:RAJ;AG5I,.*B8\F M%E2YR;4G06&95!]\(X30GI8G]E$0[!$)=V-^]B" [QU=(3=>X'[E"G]P';9* M"Y^M2_^ZQO=HYPWH6?=DS3[-HG[C@:ETDU(J=.']^FE_.CIM[%!EB[;FJQ_! MNS]./?9X*+A3H(H=FMJ,0M82W&5>Q.'S:&0- MLEYLFY4R>+;B%"=:.";^*O_M%!=4UAHK9_6D_\5P[,9VU#-F*M^?B'-8&.F- M G-$1S!>-X\F0_TWL.[;;XC$ >]?DEEUPH$60\J1=@^/:\L@V8%I^8[8Z<\ MS:\&GUF%(7" X8.8 WI*KFRB5Z"4CW.STH)&#O]]^906M,;@LK#OL M9#J8] ?7(VE"2J;OUUS4M&]8GP[+KYA!6$TX9.G])^;3+X>4KZM#\M;98 :H\[%OV'X[G2;B*Z MC\LY90/#^_^BND/9QH\[U%Y1P=;?-A4^P&CW]0?G$QK?C@@,30M/A0KILX!- M?S)'G_*>0UBRW%%V\_@(#M$!UB,+49>")V5E75)']NC\3=M(EB71-:&F256? M:H&%R_KP2;%[K^&\;VI?UT=4B$)]I]G.P*:D%6MY+ ?RWFP#%:_]^#J"76?2 MPVKVR/#@!G]'P1H9[K-#O/NJ6%?[WY.W4CH?M,(H9ML?8X9YAH9#E:%IR6)F MU^.3X\60P.=DP/]9UR@S:+>N%_X3@>,=/&4S\2=8S:7#*V6)%W+ FNJ.1KN9 M#L6B5>1 \4!JT6(5WHD+?B)-HEF9GNK1/DG1*6%H1\UP6;]#>DQ,I'AKJ MJ;=[!FC,A/;GPC.'MXTB$\TX8)>)@\$,Z9%*HTYVOC?NXS4?HM+E3IQS\DA1 MXFW+&NTA#7)QSQ;B07P16DKO6\2%K;APJ2;$#F2S^6QB*E?_5D00?KCI,<(D M&$F"ED3;N]/G7* W?.P72Y=(5?))KI+ :_:6",O4]+:&(:WVYU)E=W:CZ7BF MOIQ0^_+4?ZP:QO/#9+AN/+NE']BOY+MX<[*0'1RQ("OK*71M3[:! M.;F%*5PU*"K>^RH2-4&/=,+.0>O4YKRY]$U=.?0^@WDCS;.]6 M#^#NX7:U_LK^_'U(LR3]O*O9)I4(R(K$"XR3Q9N#8''#L=4?3M6GBHJPF ]M M$G! X;O9T+BC6LJUM"7>=-+[*ILK5O&5J[:1FN:2RAH=C++O!?]8'CWW4#"^ MV=^H! B:LXFLVX:2Y53.7&YKII!=7 )@/A(7 /AOI^ _;VPY$LA85+6GNZ^R M<1F?H^+Y!;\S.+E+* J#/Q(6O."#G/;)MDP>6QS(%OV 4IZ'"#P['.UF<*)1 M@W=QAG.E_4),EF 5H5T !REV?!^@1WYZ0ZUXP 74='.%N0+7]XESI%@7P(DU M'*N\E6I5B/.\9!!3[Z2Q><76\Q7^I^M='_&9\Q5Y_N+=SL8C>$!RMB$^>]%F ME(=@DS. /5-EOH,(;UG%H? @1@ $0W%.0FIEK&W_CZN/+?Y<@:((84^* M._M!;#?Y,8HR:$E.6#7#L9/%!V4KW8+CH7(G2I3)K'(0/! B)K:\ZL/9&A-I]_8?8VY&TD+S'&GE0PL M^0'T>_\7J1[_ZGKLO2VMC1%V;%'3(V)U0$0^Y_D>01^M29;XRGKRT<+WB\/S MI0CL+AWUQ]*JS K$YVMPG)W'&!7L4?R*\]*U+H_X+Y#@*X\B''<^^N<1:^62 MU)FHB%1QH25&#LH93L4,BD%9KX_)#"KM4%.+R5R<($8"%(L%I:J"!O)FA5]Y MK!"0.5"S'C1EY6"*-(JIYC0W+4]7F^7?GLA-QO)7_-^-7HN[T#.L@%6VL)NH MT$"+DEGE[%4NY4Y/"#?(-SR;IO2NK.L7\K;$OW.^ND[PLO\@&9EK5/SL21!1 MTJFBEACQ>4,(B\7@$)H.E*P@J#SB)L9@KFWS" M #!"4>)0W-L.PDKO(=,.;J%A[^W@8_E^L-EABC0R*CP<"J"QD]>X/YC+RL$2 M<#9J\YTK?8_>W/T;/6E@4N 5!K0D+>G,I-@)H:PB].JC*&^%BR7=%*@0H\D,X*'2JAJAO[G1R0H28+?- ("&04+'@Q?9, "-" MDC::Q$AR[YANT,'U[8 \L+M!%O*P80Y[,&]>7"\@I?.XUT\"N/\H+LIS]BR: MKD&[*42MGS*347(Q)<;TOVWA[KB''C!MW]B[_M&+Z_X1ILF?X>G%.GLT2'XT M7$S0/[@.Z= 4/LWR\2\PH*\0/1M;&@IW]#SJ>V \!\]=^-<=W-.VN)B\&3(7 M]ZF&?L1!!.6_(!10B_7CY]*HFWA0M^@]N,)F](]SE*R W*?4NV(Y/KTJ)O\! MNW]_X'^,_@G_AQS+_NW_!U!+ P04 " #=@"U6)[0GUQ%- #+000 %0 M &%E:'(M,C R,C$Q,S!?<')E+GAM;.U]6W/C.);F^T;L?]#6/FQ/Q&05[Q0[ MIF=#MN4LQS@MMR173>\+ B1!FU,RZ28E9WI^_0*4*%$B 8(7"6!F34QG9=H M>+YS<#DX-_S;__WVNAJ]HR0-X^AO/ZD_*S^-4.3%?A@]_^VG3?H)IEX8_C1* MUS#RX2J.T-]^^D#I3__WW__G__BW__7ITW]>S>]'-[&W>471>G2=(+A&_NAK MN'X9D5]]@>D:)9\^[5K_MOW.7T?:S_K/RGC_\RN8XEYQE/7!OU3WO[G!XXWB M8.21D;.NBOJ+:ORB*9J^;[2(@_57F* 13+R7<(V\]2:!JY&/TO Y&F'"1UM M?QU-_H\WNGF!R2M\2] KC BHT>1]_?-^K.OX[2,)GU_6H[]X_S(BGQG=?7J8 M+D=7FS2,4)J.%O%J0TA)_W5T%WD_CR:KU6A.>J2C.4I1\H[\W7"K,/KCK^0/ M%^,;849'Z5^_I>'??GI9K]_^^LLO7[]^_?FK_G."^8KD]A M1!CNH9_R7F24JGZJXSB_9+_-FY9:?G.35?X-_9><'-P\#?^:9I^[C[V,N1S= M1M06Y%^?\F:?R(\^J=HG7?WY6^K_A+DQ&FWYD<0K-$?!B/SW:7ZW_R9$+\G/ M7OSZ"_G%+]\'*+U"UJ''EQU M)[QRN+.@6*SQGV0S26?![ TEV<1,GR*X\?'*]EM!X1SS['BNXU>\[;S@-N$[ MPGM'_(KNX[1'<+P?.#O2!=YCT4N\\O&&/_WG)EQ_] >28^SS2Q*F+[>K^&N? MLJ,.V14-/EU#_(''!)].T3J;_)/(7VQ>7V'R@?F)#\DPP L[6D\\SXLWT1J? ME8^81B]$M9M>+X-W13A''LH^D(^?Q!'^J[?E;1T$OMZ=:9S^-GUXFM82<]RL MZU>G,(DPI/01)=FZJ?L\K7WG%85G-_D?6;#O<$48BZ?)7?2.TC67D+@'Z$KI M+0R3W^!J@V;!;8@51"^$JSNLCB4;+CHYNW>E\!3>CF;WTT7=415-.WZ=;R:_8VW_ATF"=Z$.'8T:H?. M:V"3KO&)G-R@MS@-L_E[@P*4),B?HW<4;;"R%2=K?&%ZK5T-S8?J2CV>(IO7 MS8H<6]F4.=(UB)911S/W )WG6Z;X+.&W>EE7-.WZ]?OI9%$_T8];=3[AXR2) MO^)]&\^#W:Z#_T[F[S/?$<@]0&?NQ-'S$L_*&^36[E!5;;M^?[&.O3\RJT%]%M+ZOC\D)J-DIWFK.S:$D4"@[2*AKWK?_RD<+N=79=F(_( MAL.<62_FH[G1(-WU ++EQ F>T'S443OTKH/RT5/3[8+Z*.>,;#O@V753/OH; M#M-9%T)8H^ DK:KM>70A/GIX^O:D%Q6T&$[::OKU=*K=H#4,5[S'VDGK?FE0 MFQ&AGH<*K1D5VGFH>""[Y1HOV&;4E+KUK7EP3I>:;F>BBIMIO/W/KB-QLK/I M.)>BFYOAK0<\L[['R?]FHUR&9F[>MQRN1[V5D\OT'KUKKIP4U?6[H.[*NU.T M'O'LVBLG@J;C]&AG;;JR.+KVHUUSLJZR<:\4U*IHU:U[I8%;/.Q>9[=6-R6W M]8!]6+/7.PMU8QYS].WEAN>>WM(XUP17Y[-26+MF^'J?YY[,>^GAZWU6/NJ= M^*A?A(]&)SX:%^&CV8F/YD7X:'7BHW41&NU.--H7D37W/MYLE//["GEW]Z8# M78QR?LZW'K%G+VACPOFZTZE\*W@D[_$/CCJ@;VL4^8?P04(Q3Y3U.ER3ALKV M_]31IT-<_Z=1UG+T")_1J.A5SFC*J5K%WA$A*Q)6'I]$<1,Z4DQ(%CR>(N_G MY_C]%Q^%)*)?(W_)6)6Q"?\#9-^=N/C.#;U]$, *NFB5C0]PFY,FOYR=IBF^ MT*X_YN@Y)-^,U@_P%5635MWRF,*B+">)-XH3'R58#/F(,/&.)%B.O-^U^.4M M"]+^Y+V$J[WP@R1^I7%JQY>XAMPB^_"G+L?AZVQ)K^[P9/[V'^B#Q>)24RX> MJ\)X3(%V42;GJWN)1ZSF[7$++I9J EA:!>2BG)S@K_N$@ML5?*YFY4D3+E[J M GA9">6BS+S>) 3#;9AZO<+7* M$]Q8^^Q)0RX>F\)VV4I8(MC[@E8K9,$7H9MM-;([>XH3$$9),I@USZZ#UX&+\6)RF MQ@0J1&%[1$D8^\QCD=*4B]>.0!6N$IJ Z7T;KE!RC6EXCA/F;G+2D._:(>YN M5XE+R"3>JC];>=_BGU'V#D9S/EZ+N./58A3(<:)PX_]V&$5!;G*YOS<5W$Q;,6 MHSB.7^._SI)E_#7BX'>Q,9^C1MPEE(I/'*^SW6Z6/";Q>[@MNU;'\%(//JZ+ M^U9VNU>WYV"[B7EJ/\K)^-4),@B"=S<2BK"3U$E>/+W'$U+[+K?A8*N(J24-T4;8ND+=)L&Q5S5V26*1JMI9;\;%5 MQ)V1ANBB;"6%GHCCXN/5C5?5/#UIPL=0$;?$2BQ")NGTF_="\@OHP5_5+?EX M*^(2R$(FY!:^1H32\!W=P#7<^>'8U^_J'GPL%W?G8R,ML?[??BGAP#>6/\X2 M'LI=T+80.ZJ-/HWVA2U)Z.CLX6;ZL)C>D+\M9O=W-Y,E_L?5Y'[R<#T=+7Z= M3I>+KI&D 4S=3$";]-,SA&_;J856ZS3_R6&.[7X ]D06TCL?XZUMCQ%RNNO. MTQOH2',,J_NB:0-ODJ980O5 CML!5W,A,NM636EN]KMVVO#X>'6QP1T"0,5) M9K?.>05TTASHJ@''M0?*9>1$X3)#(C0TAS!2$8(AB?8DG> DWWY]#9/D ^L= M63(X75!61ITEK9-Z@A6%(LMRY#:!=B& M$^C&8.56#^P0$RMD4]R5H,U+TAY*T:8/:$U7_W*.\'0'OJ;K6JU!6EH9-@-Y MB+\5(<^\)L5'H9)P66S%5@"YNNZ4MO[!2*<2RR%.5X00'A/T!D-_^HTD)AZJ M/1>QT67#T1GXEF.H<+ B:P+Q$ ,L7&?DU!5!8)G(D427;[/=58(YA 1C(-L" M+?=;/E )S:A38P]TP MN; =HI*%:)#;YV*BYZPD2O;,TRQXPEL%0,/=-/G %8*=A:G^ M6W /<>35[9N5S0'R5&CZPQ44$U0A0EK<@59WD@'7\<>65&:.%D?8'D4A3GI8 MA]=]"-UP%9)*;J0$.@GR/7J"J=Z*Q3L"L&U-@^/!2KPQSD+DMF#)++<%#J8S+204:(4 MO"C(B0S08 ?@(:F;I>!Z(M-J"+<3" MRZ&6-%%'@*5X1GWDN:0BJX=5")D?UCV"LFEP7='KN@+-=<>*)':5GG?5"I2% M0'X1DCS90'@D2.T"?,_S%$E\JVTE5X^ND 0@S"160%=C#2NT!&/=,G1)[N2M M5Q8-5"%)0/!)QW7$ >@Y2)/OBMWV;-OC*>04#.M0:V,.8U@C#,]2G8$O-@YX MA7P'(;%>AW(%=6%=)RV!:9L:E,3MQL'H2@%1017R)8282'P_"^^$JT<8^G?1 M-7P+\>HND,NPE=3V!;JBJ.6 W&&)K@',0JZ&('L7_462[1L@Y%V2![2>!4OX MC6D%:S(0\!3-1,' Q=P2R#@4Z_L"+1@; M8TFLGFTEVP!F(3M%#LVFB48#=%-79+'"M!46 U8NG,%98>H<8^V]N,"P7.@- M7#?B!IE'MRO=)X!,65V/&7-?T#KTX"'+LI#BI;=)\1K]Y6C;U+,D(]C/]/G^PD^N:0^N,=0S/,B5Q$3>21MT=J!:QV(RQ4FV]R6;] M$B?A?Q]6/%.@IYV J7BF*8D-J5=!4I$*SBP[I? N33>-A+?M )GK-FE-.SO M1G G*,6FCS6LXTG#5.@%QH:EFM)<3'L77Q74T[0RP9K.'G4Z"W;.-OS;IPAN M_'!]&+:H[AA\ZLYBB?_S9?J 59W9[6CV.)U/EG>XP>@OFWQT(4K/UE:P!U"O MYU Z $6S=5&FI)U7C>$BR5L ",>:*DEP31TK*?:!$R2BE8\4;Q$[HEC[7J$9 M<.T ZJ6DC0$)H1J.6"WB20A68@U(P+*O+ M/K1CEV[(49N#V@4@W[9]29R$K21;#TUL/OH"K5;DP14483I7D\B?^*]AE+V, M1RKU[*AF& NX^@/#0[HL0=?U(JFVD#9#*C8M?8X9BYGRDH5 OJ-5G"4#/Y)#I MH3% @6WXDH1\=I5J!:RAYKIG)>U0NMY"VO&CIA!(=0]@FU"7Q:'44L*UV#KE MN%-2)#[#,+K% &XQ5'P*DR<09\'CV]M]#*L*BI,^K"Y L0U8SA4>AARXP(6".-E% M[RSA-Y1.OV'TF.PP@LG'';Y 9:GZN"=FZ2K#N=T[ZJQU9_DHL*#KC(=].[D$ M>P:;UK\'O>/I%=X7F<8E2@=@P$"Q)3%'=)HH=&B%/'U.(3M;(4?HF3@>!(H9 MZQH\"O91,V"KCB^+!;>E2*L!%;+U+[I:*8K:GL@\YH!A%B0=J.V!BR ,),FB M:J.BU2,3G+^?!VSF]%W!-/3HZZFR.? 5J!FB#1%\[*Y<5&Q4@O/U3XF["5>; M-2O.@M(!N ZT3=$'6H]2.L75+2V_LYQ^1Z1L&/(G[WB;>-Z].C(+2E$$]2Z2 MIB,!QQ^K4'0V?P?)M@8L.*.?2?ZS2*( ,$I.%3,: MS&P3#78]^_(XG_Z*V]W]-AW=/>!_3T=_N9\M%O\B.CRL$ :XY0"I[E_F2Z/P M>)Z!@(,D)[:Z$0?0]Q71FGM'9G/3Q$K7=5+0/3_GY)P$3]14P+N-$ZRK1=NB&][' M,H%12MZ(P_*,_.Q?JTRZ.>I>9V6/'PEN^0^)[E+MBD)Q= =C ]F.(+OMGL(E*:_,@21K!Q1=0[+4CVO&Y,IE34&W MCQX2%#ZT)PLO;93%+7 (:-\6^'Z 5-FNM\<<9DNC#&5OMQ(NDNWT(N=!')$M MMG#/]A57. 5,>U)4D(X.-Z MM1.1"4ZPH K)QU\0L6,S==#CI@!!1Y$E[8;-99I>20$DN,8LI39=G8"8W8!J M&([PB(GVPN(#)[@*+++6HBM!I7@>K1\96&.JJ1HGAE8DOBI&4IXM2Y8!:2MQ^DMLY9A$I*U5&6@ M60I^15$YSY/%4-I8FG0X!T_/8&6ZG:5%P^QV]N;ACRCSH^'M/Y-2C=";#0:0 M[TI4[[3%K&B)5ZQ7AD)Y5AJN)ZDSQ@(!\@U-MNMC-Z'SP.WDW:!$U\]1NDY" M+S-/GU09RRSQVQ_1GF7R/&W<5>K, MJQ3DNQDMA"Q2QI;4;MH>,%7B)$.U& E8FNJ/I7D[H,$B[@+V4%E"D!@GK^1! MSS[$N!T)F$B!BB39T.<3XPG80R$),5;!_]JDZ\PUO(PIYK!LWKFGNL$VRL0<>?%SE(U2\W;+N;\,\,2&SM!FTZ69TZF^A:#L5T-7O=*N M-PRY5B,IU+9H&&B"+_4BHWE9X3B\05:'J=X^*J[;]\#8,2 :Z(PZ,TL$E^TX MA)(>8DCOHG>TVQOI,Z6F(PC&GBI+^8RF(N?%5JA],1"SN:H$KCE4DUH5D.:5 M*8YLK--(9&V*CE9S-;!5=Z!+C &G=8V*:I%*%!EZ#=.7VU7\E9UD9[=*LILL M?AW=WL]^%UYRO1!CN,?;*/RSU M W;5=0:$V^, F!.$+Z'N(I\'5QQ,6\%VT MK_$QP%XIPPJ8;?V;$F1)'J[_I+X9YE-V9BUC#<7P:. MICJV) 4@^IZ#%V.>8!=L4S=KM6_1-VQ'ET39OYCDZ%<'.H/$II9E*%-,SVV< MW,0;=QUL5A//(S9L]JE#[05\TW1]2>)IQ$J>BTUB/;4W" O&"^'.;#1YC9-U M^-\U2Y[1"5C>V);EDB]6^CQ<$EO7'\_%!&7D%6@C56G2[1S%5#\FZ#7PST$4!4+&I(\ZREV[VG.LW.\GE"F8IE GY3, MR5QAN?:$.8+"=THJ-!FH\3A@;#N.*TG)H.:R*.\2[3D@^#&&,N'DK(OPAT+6 MRT/,;D =^UXY87*8TFT$N.#BE4,I*).-59HW&/J[@M7["9JQ@GMYLP8!IJ): MJB2FT?.L;2[XS9]+D%@IR#>P1_C!+HE1VQ5H8PO?Q;^/Z=$8=&LGMGA#>B7( M9(/I#Z$;KC+EI^&\..D-3-_Q74E<8.><&C39B\I;BFEOYU8Z2!DP0_"P$=287WA1J=SQ4#P(T M&SK>=R+\#O %OS7![]CK(QH"Z';@*))4_>E)Z"W0%]ZM&-936Q2L6_MI/S$T MC+& K_N:^9U_*$+:2Z5)7R85S!:8[V'!(=F[W$WF!S4,8"O($V6[/*S3Y5Z M-C1_VT*:B^*T8$.AU-IWH8K)A^-"TXB''8(+P,W1VV[OG 7W881(J#Z>T*S'8*E=@*K[OB6W-L(CDDH1 MUZ,N5'L;VHE2S#'/\\FS9Y+R1Q,G=]ZS@1R^XSERN(N3,FG"?^[ %)O(G>D+@!<'=>M M:+:95 X!;,O7-4FJLEQB4V%S(9\UO9;=V<':@CF JX!%\7#P#P 4 W]:DB#, MWL39D@>Y, =GZYSB:>FM9\'TF_<"HVY)L4I1EY"\VKZ\P^9@% MB_ Y"H/0(RX?;QMO2 H1Q_C&5+BD%.N-C$>?1B2]:16GFP3A?UQ-%G=949'' M^70Q?5A.EG>SA]'DX6:T>/KR93+_1_8"W=WGA[O;N^O)PW(TN;Z^GCT]+.\> M/H\>9_=WUW?3A8C2(Y,27J[GC2E]@.=;GBHH!9PBY2/AGM"]Q)/H:L6T4W89 M%4#/1+XDO@L.J57N';TPH,_'P2^W;Y LDR-\21SAOWKH*/2BN#$XIQO#?'H] MW2[W_6J?SQ[PWZ^WA8A$K/D'])6&B3SRG2FYZ3[T.FL3XF/G;<7GX>L\.#!- M1[$$.;8ZT,^QF_0Q.D"&Z8RE,83W)VZ*B[1'C@UT&YK^-GUXFE;L-ZI2WF^V M;86XA+,P:V)]OHZC3+3$A9$'9M=O'9P# -7T8%"*2)("),<6P#L",$S+E>45 MW*:BH;C"&R(?YG+-'PQ[1%NG7=6Z54_7[70R?\#:P6+T.)UOGZH6L81/2:]? ML[0>P'<-TQ!TAI\2Q;$JJ5T ;V&89"]!S(*=I1.N[B+, MH0UU->NGJ_EV MP-0\5RO= L7!X5BZS&Y U0T[*&D,8I8K%^YJHF6^["< MS8D'JF+YFJ?+M]A>2/K\MES0QX$HGM)JU$[ @J95?DE9&!B.ASFZ?KY>CWR7P^>5@* M6GLEVANILSR] ?2@:@NR&QT3V&Q-UO<%MN] 79*5V4@6E4NT >!A+M3ZBC*+ MESA9KU'R6K6$[9*AZ6FQG'W!^N[-]'&VN-O9F&ZFM]/Y?'J3>VY&BU]G\^5R M.O_28H%3(O(YD2PQ$L8J)D.U& DXI@_57E^$;4 %WQIN"*UJKEL.U +19N*N M(CI>Z#URY?1)FLNM8GQ-W;QNLJRJ\K.$Q5=JBFNW%-^%KZA/7Y[NLU>DMI?6 MZ]F7Q_GTU^G#XNZWZ>A^MFAS(%/F=RW--:N4NS\P3-4T!>F^%0]$DIL7CPFX MIB=P/<-R1,==M9-$M068%_ P3]I"T:ZJU5@*JKI[P*MO.EI._E/4%71';[,K M*+43<,:^9@FJ2U9!%]<5E-X+.)9AEN$(JQY5RW;*%90#X3#7V_UTLJ@T]FBE M>*)=4Q'&3))\PW&K/&X'K,#Q=4%/A]^C-$5H7YUL2QF/H979#_BF9I1KCXE9 M3A1N5QM3^6 -)8A90.P-=,QY>DCE4-GRN7 M81TN<7>S^SAZSFZ.F,*JY5**U;F?/7S^1&PCHYOIE1#_8)%DCK.IHC7P-!18 M@AYG+1+$Y0&L: X\#]_I)5'OF!RFN/A8F(9Y&&4E@Z@U>(I+JA0PLUC.KO_C MT]5D^UCVE\?IPR)+7A-RZNP)RVHA[8'LJN)X M@>[H@A8L-^E71=)Y3KMN P,'^?98DN"ZGN1;?7KVQ*>!;BSHF> AT8=Q1)+A MDFS(NRB(DU?J)E.*^%E,/W_)TN >R";S0%+BYML4V;N'V]G\2]L=AV(_K:>Z MQH#*/P! FF%Z@EX2V)$Y1V_DW<7HN9&ZR]$9J)YF"D]!:2F0RM7)JL0USG76J*<&H+:&50G]ZJ2TQ^DO^S7_Y#LI, MF)H2B'J-82?X$^H^MG_R%Y2HZ0^@:B%#M N37Q*5:[\AU#XW@DN[LJ,4@_(S MN7#/!%8O8&LNTB5Y=J&M_+D YK73Q$CN*<7WNFFZ#K$6R7KWX+@=OM49^EB2 M7)6VTJ% RJL\"=*>.I;KX:Q+H^FN,Q[X[MH0ZDZNQN55)789'98N5(JAK"NG M(UC-D;ZRCJ5#[=B3B[&RGVA-7>&>1';A:$N ML^RLJDVD%,R91UK_9=M'R$YQL6(YFHYL79!RA;D.GY\3\L( %O(L*(J*ST51 MWQVHOJ/[DE2+;2H4FL>A 6QQWOM261'J"BP%<):KW0A=C#V6O5%LQX2":E,M MO!?D;U9$JS\ACUS$/1*Z'ZXVY'D1S@78J9;E/N#D5:J,5W79L,(8!]"0Y M;SFE6+/$.[-"W&JO*9E#7^NE2%2.PCE"%_H9*NCH8\;\J,ZLW7>P^? 8X3:+)8S;@D6[/P^^2)N#T@ MKY5 K'[4]5X*I2U4\1"ZKOLOYZ':CBO*>KV?6GL*K_'4P7]KOF#9(P"DZ6JY M:HF$93YVXJA9BIQHQ:VR4L$$^EHKQ=B6BW<(77(7J.+ACP,/";\&GY2HR#?W MC^:+D6\DH"HHT"4)BFTDIYK5V1"^P-LO?\T.^OHMA:\VK=S1975W+WFQK*M> MU["NP_%X0%,]UR^%I%T26X^5/$XF,+20HHE>O_V(YWA%]\,6B:MXT%=S*=B5 MIY;'&5;PY8IZ>&,?6NU6:(^'+Y/>;7+]7G"-SN)6 P-/AZ[PF@3MY%AS.'?C MA\#LSVT^.'7AE@)AM[4(A*K.+8L20--5R_5H+D@R25/B76F4#L"TQP:4Q*M# MX6_E2JG#<[H"Q->,V.O77^!ZDS2XL+08#"B!9?BB=9Y68FV/]33F5'2F+GT3 M+$7 T?)UA6Z+DB;N^H'OEEU5%W?&O[ZMX@^$%BAY#SUT2!8M(IJL,C)V 1]> M_!R%_XT190^G9C";N>O[_21Y(%*39>OO:4[4N?W/Q$&QA\T!7REE>?(5)GZV M.\W>"**4.$:V*--T\[K]67-EO8_O@, V$9(D"^XRTZ]7MHG-L*@#M5]I!-SC M)O%><(O'%8S..0$[?!0XKE%1K._'FXU]\%!PLDD%PJ/]??O,>@M_09/Q@.%: M)I+$K7[I"=6 /:<)+'+-E>+>W/>\J1\;^+KM2U.D3. <:L"JW7P25;NC>@D< M"@A>?51ON_GYCU+,RTGD3[^](8]$HL;D1[/-.EW#R-\6)IQ^0XD7IAE^WKDH ME"Z@>[:")(DN/.L\EH/-NS70KO0PQ=$Q3S?I8X+_F&."DI 0ET$A#B=\-\HJ MMD0>.OWM9^):1OZ:$+K&A+H,#U^?GP!00Y;Z/>MS9^/8;O;T^K8#(9301&C= M3_*G+ 07^3<;$H:WO6!SN8);C@9TTS74[UDEZX,Y._&/!5A1MV6<"N6?Z!;4 M4OI?7HRL4'I,J/'TM"851]TC2@_@>RHL)]Y1%DP[=7'9Q0_ M)_#M)?0F"8+<5_=FXX"Q!15;$H6A5B[5CHQV@,4Y;G?1(C=H#<-5Y9HK)?SM M4VYWG;[OG%M740Q%5&(!EF^F0&;3AK&''+4# 41F(,F!UY3-U0IV-;Y\U0@7 M#UZ Z [_E5%SIMP6F)KMF;+L=M4<9DNC#"6W3BN]BB1-U@5QX'\=1('_D8= MSY*=?V?R+:P2!&Y:U1(XJJ5JDKQQRR6&.B![(5Q;C*AQ=KB#17OG7&2?D&O+DHJF)W%BIXT ^.Q:I=? M\LE@Q#M@. M9@RC5!#EU(PQ4K]O0X;N0D41%:O6SI!A(0\%H@^?EFSF,63D^ 9NR!@KEE=^ M%%R*&W3.85Y#1@[E/(:,)GG=*Q@]P%>:,2//"RZT JYON(KHBT<+,52".(<1 MHP7[J5:,$]IWFI)OJ[XKVGS!8BM3 "<@!-B1]M/FX#:!*[H]C]H<*+JG^9($ MN7.M!2XT>=3<)26R=8,526)9]JC-@3L>CP/12X.+RV7!U(+J)AC*5?)IP;Y& M[G\/_$!U;-%72/9F4KX[ELG/N=BGDEHSO2=I"*E,Q@T.OP=(TSQ#M#+*-1M+ M$[@"1<[K7DUZTTT2O]582X_: -?U?5TT4YO.W&H(.4<%Q;\+MWJHGJ%:IE,U<%I,=OH%;3%3D..6Z2W)<3W8H6?!,H%1BO?A M6? YCOVZJ)!=;X[.P+,U?8A":X)-L-FEAM0Z:PQ7=^!8KF])DE[51#9MA'L" M^2QA*!6.PYP:K M-UI/'."3QW9A4Q+P:-!\(6 @Z*AR$+$]$4;Y6=(!_UN"7 M A$SK+36BK&V'T &U!W1MJ">I,:/MEL4S? OB(J%;%V2M$TL52,O71/WW;_OZZ*+7%@.E9+ZNFA;EC669"-N MRF:>ZV*.;^#71;PQJ5"V@*)C#O->%W,H0C(%]O0L/!3!)(PY7(O%IN2M1D.1 M[0AC":(6B0@G[XZ.IRA]0UX8A,AGNA1IS4& ;$43G>Q=R^&R0&H!"13*;9P@ M#Z9KEE.LNBUPH*J5218@CEK^4D5"0=3M>M7]7;2*XW!?'9-^D#"[ =09["E%$OC ,=3QY9L06!]B)4.56Q)O#U=9(?9 M5EG("W#,W%6X??BU]G+![@Y<_-5RS>EA2+490K%%Y+AHQ3_T"-N?&?>LA@,! MUT%0NMC-/@5<@?6T!IRXUX[IU0^,TOM/5<\=BRR$T.-[QYJFVHZ@;?0!K0_/ M&]!I/VH&3,\/A&N/JS&%Y6B+^C\/F%E!YZ1PE>Z0\;HD7OJONE MA7)FV;O+="$W&@8HR-,L24)]VTV"=G@[J3TTET_VR:<4^7=1]K7]_,P17<.5 M1]XGJ59J,H=(DS'P8: $AB118PVEUQZL6"6G8$KVP.D.-HFB0FIW9B9^,Z%&#M'@DL5KR[>JD#BG.ZC9L R#=^0TVW/%$0U"L$Q MVK75[E-:N?L#G,CG3; _Q]> $G@&E&1A5LNX>EV>DQ=G"0TOON#!CADN-030 M\9 K22K363E?856BWS7KW MD%Y)&WB--RQ+4B_#8UYIJB7;=E\^2ZNW_%XY(*XBUS5,7\C_IO_[WR;WTX?E8C1YN!G=/?PV72R_ M9/\6ZH?KL?*_BC07E6SB4E]!;,LU#4E,N;5\Y;F"Y( &?@4)?'=L2^(?9 _LT=/KO'T>HX3K+6P%TB#08#JC1U3MO@WCO73!F/N M'!:XO$[(XUEIE5T \@S+EL0=T$86U#7)AMM-A-1J_XRH_&UI_'W@NJY8JO!G M%-A;6/G66T%_SLA>\YH_)W&:/D4)@BL21TPBKYA\I;8'T#*0)DGP"C>;Z^'D M7.^W-EBZ#E_)&W>W,$S(J]+L)'):BR5DN*"3H2QRACR\P M^0.M;S>13U\/NP[5[8&FJ%"12,=B[]*5FWL-LEQ.@B)VGA9+\HK<)ODXV(;J M9$7O P+=L12)UE(+>7&@RV4FZ#F"4RL8!I@D'V'TG.T#=+FQ^P'3<'0D.OFQ M_K9>*31.:&(3N,A3CDN4O!9LEG1A530&2%4MZ=YWXY00"X_8?"LR=]B+!KB: M9>B2J&5MEL8>@-@X84+*)/*[[%^UW8'O.*YT&?4-9,6/\!#K.[3HP&I?SN(E M3M;<&R3_&, *$$(#W3=;P#R$!(N)YF@BQ4H@ 7(-68P\3>7%!'2(YY75>\J, MW[0ZNE$%QW3VZ%"U5-<057:MI4-5LP)+EZ2D?RU?>1RJ.:"!.U0-A"Q9L@TI M'.9UJ.90ANA0-0W?EM0AQ!1#)8AA.E0#-S!-259")5MY'*HYB&XB.+NCP4>N M$DCRPAJ%@TT<#3FXNSY8'"?O6&$BJ_\V3A987SM&_1BG(;L* M3)O1@(KW;VD"9.G'2^4R[ 187%3CWGTS"V[#"$9>"%=W$=:&-G4QC?:I,GX[ MN9N/L K^-!W-;D>W=P^3A^N[R3W6Q!?+^9,$ 8U[K >RTWH=G-4+>*9CHV'E M5B%S[#N2V!*Y>,NCB^>@!JZ+*Y;E6Y*D<5 XS*N+YU"$Z^+[.7;UL?_KKR%* M,#->/K*7Z]E:.E]_X*JJ@R11:)J(KB$\P:E:A6@#XB+=9JJ4Z:Y3_!L- QP( M=5,2RT5#<;%%W@B]+)*_^M@ZU5JS!C?A$=]U+N^8M MP3+:U,;-!Q50ED6J3E5\)(G>T#2$/0SB_(4Q-N& M)"&R+>5<@RR7<2]U42\KXT)8;86'E2YK=C]@>;H-)5G;#(]CI; YHB,$, MCQYWB<@0'!M]AM@,RW4,V"XV@Z+.G%RBMM?49;Q5C?/GLM-MQ3*5HN$T&H.$ M'"%97H/G8G99!6H'6&RFY!SO%4GHK5&6"O6 ;\#XCHQ8=?YH/< X@(HL8>\M M),@+3VP*Y7['S!_7PRI HY./T+K^.*MJ#0P?:HJ@$,,]07/X]0M6N!(\ M9U),W"S &P)*L$K% 8;:%QB!8NN2A+LQ>4]5*3D!BCW-]H3^'B=_W$6/2>RA MM+$8Z9V!96M^.;QO<'+D0"CVF-M3BC?P,'U!_N6J;#Q8 2(WA)!;A0@$4E=8SHBLKVP$8((DDVS2XBJ%RX-9C;ONOZAK6E MV,5?9>F&]:;87S]@8F<0);7C"XT0:@\$*M 51/[F"#T+4Q) M(8"[R".^'W2#MO]M*GO&4&!L(E.1)$[@0M. AQUB-3$*W=OW3EA!Q2]2GVQNJ=LST;(O1,"HM*=RXT5@P"4T?E0K_?]2388V[[+.Q6,9A& MOB#M_GJ3KN-7E-R@-Y*D38H4W>SHGR-\A]F@K,#2&B6O#+U?+14J>EHL9U^F M\]'-]'&VN-O5*+J9WD[G\^G-:#[];?KP-!TM?IW-E\OI_$NG6P&MW'9C: R+ M95;>NO6 P LL?=QKJ%$],:U1 ,=5#"2Z+D%/'"\[Z!HPH*VZ+SXDXA3D=9U# MC](!Z(9NJ:+M,&>9"YS Q6KP]6MZU_)T"KLFGL*B'Q XI]QH@,4Y[[!.L'G= MK(@R-UN_H(2\\Y:@%Q2EX3LB=5 8)ZAV>H).KJ^?OCS=3Y;XN)PM?\5'Z?7L MR^-\^NOT87'WVW1T/UMTLZ51SI5:$#6')'=_8$.(8&F&7F99M:PEXH]M!XD. M3VG'Y5:0\R^XBO/'AN>9M.1Y5F*1N)I)> 3T&=YA_EZN]WC M;V5YURVN$N=NKS+1TH*,J>+.H M$)3-S@JJZP<,1W.A)%&6G47%#S>7DJ#+&%/KRD'O0FF6\!M]&VTX$%#]0%VGA^_B.;W!\W82>R'M/LSH DP(H2I)>#6W>+A1B?5TLJ9/ MZZ5&)A@<0UN6F/@^UU01V\&7^4.=LQZT74.2D(5SG[,YUJ%Z+K>0,!+$DRQH MZN6O9E^EH.?G/J319@7M,!TIYLBBHG8"I6K[9+MR0<@0^)O%[F&+9W<;) M_LN4LZ^R+7 4&P62A(?Q\*Y\^K%QB!1BPO@W&Z".ZGDX7HF-PMU?7S M_+@=>7W+U4J.R4N1G*8(S? 6"$FLU_TVT"OUDO MF[\<6+@& )JKC)$D%S\* M_RL/HZ;XQ"8,'=-9'PQ7W1X8MF8%DBB&3050K2VR<9[>L 1M=&K53F?6['0C M5=\S10CIJSMR;#<>)WV04H"#7,$LZK;A],B?WHT!LLXVR:@2 --^2I1!/ M*_EP[Z-,^()?7&:1^Q3Y>$$2NP'RI]](SN'6BM!2^+3A@.ZIQE@6V_AE9D(M M+PY;]=!BDRF(FVZ.'\"$GJE)M&5.-O]J S[H<"NN+8_H\]$8[X=#TK"B,!RT&*)TD, MFIB)<,2&W3RP!=_PF8;]TB/IIS=]L2;]EM9-37=,4<\)MPR.5C7?'TM2(I7" MS2?TYXI-Y.$R-A\RIW$4"0BLP5-%I396G=HGG;L1E^JV5SL0GP ]?1!\/F2M(% MA^,>*[2_H_#Y98W\R3O^Z7-6UI.80.=X)WQ$B<=,?FTZ$E!=PPYD.UW+)R:' MR; !6)FJF>0]HLL&+SGH_)OHY3 M[M5+V@(3FF--$A]0-XD=P9'/FD_FS"RXCJ,6 2_'?0$R_+$GFP+-*;,&\$YM M[9>SJ5S%21)_Q>1-(G]7$AO_G=2S>4:\CRZ8]JFYY6HVG\]^OWOXG)5XV3VZ M0/Y%*CY^GDKUZL(-B2F,PH'.8UTN10A&>JMW@D6QO[@Q1#)8C]DA#+_H:/9-L.A+XDAW\E M6YD". $A6 19/9UE5D_'72_QA]A+H;(Y>;W4]@:X)MAH<@5:%LG4K1)*!^ A M)? ER:%@PNHF)DKDR2\)GK/6N[F,880UX]]CAQ^0Y0=GD8J;D\W4& MIJ]#60I?4#:G8X&TP)8+I]=2"0OR[K(_P9_SLX4>MY)2PU% $!AC69X7YQ97 M6Y"YW'K-B,ZKNSUN$N\%7WIGY",UQ4BH/8#OJI8J28QFW1Y5%@P/LEP([4PX MM'?ZPB1==UT[S08!7F#ZJF0*6^W2:8DQ%YJH^$A\R9H%UPGRP_4M]+*HG9U# M9F_2N89O^#>LN.@FHP#;,%13$NDR+IO5MK@V0,7Z-L@6R\JMH6]_ZOC/DH?!T 3G_RRJ#0][*0<4 5G$U00/?WV%B;;8F28 PS7 M,$=GX"JZX\M;4ZFQ1&GX3O,!+AC\&T?/ZYWFS>.3*CT$?C][^)P]*W SO5K* MXGPBJ/+[!$<\<$5K8'J^XXIV=31S/"FN;]F26$28/.5Q.^5@!NYV&NM(-63; MP8XYS.MVRJ$(=SM5[:QLNSNM!T"J:JFBJXRW$$\M(,'%CZOHNR=G4E)GAJ_K M"50[T"U)2N?6BH%;>)40SU+>>(&_Y\71;W"U0A]7,/J#;>:M;@T,PQK+\IPO M-S\K#+PU\,X1W=Q(CX$1R4%CJP'%5D!#AJ=)H@0P#I'JA5$%1%9S40;.WP7N MPF?F>S&\8Y $84T:9V-#Z;6 >8["L+R?)) M25,4I5M;!;W*H7-J#E@L9]?_<3593&^R1Y2F#XO)\F[V(+;LX>(%"_3J%%8A M'/?JX]!DEZ0](>]43GRL4N"FV8 ML.R.%>5SOH1P>"P=.5<&;NG0D&7+$N!!X3"OI2.'(MS2L:UX>Z"0ZP4H1B=@ M:P$:R^;UXA 2#R;!)@\*B77V#F8W8"N64DY_$%G F2V#)L([@2A8?"3Y:Q8L MX K1'PS:M2TU!8$WAJ8D>BD?MRL%10?JSM !APK]HIDN5KS\8FTCW9=-DRBIDI30;0A3W MR@'3'E!5#-Q2FAH$!%4'_RY- IJF^8Z@9=_6)*"IAO#2+!<5#I=)8,>5@9L$ M=&BYABSVGFH.\YH$/J=7E.7G2;5;1@"Z) S;)W8-CO$)<; D=U M];$LB_:=DB-O:DM3[* OA;3-YGS](+,+O/<%/A M_SC0\)*6KG!ND]EW(?Z(3;OJ%>D\3/^X31 JA@==:!)6?1J8ANII\@9<76X* M,KG3*:2(IAJUH#[-R-\I!I]QRW5Z%SUFK^.>E%O,?DF2;/98:8K7A62X/97$*]D^UTO[YB64 U<34Y]L320HG'L#-4?:N-7$% MIB7UBFTEYZJ9>T*V8!/O]/5M%7\@ MM+5#?8U0DKZ$6>V;Z6+V6/#N7'V0'[)-\2T& XH+322;789C5^J"57#!0#;I MY+]UIGK>$8CA4_$EL7MTD5B+*5#!A7/(O>\71.P *;HLV^G)7EG:4*M)+]02 MY'R86-]>@O#]S(U3)/!AXJ,I51<55M$80.CY4!)'=./U4;_*3E!VJSYXF9>/ M#-5TA-=%X%Y0E:07Z@L.;4&UMASV9GKK:L)L:5+RQZ:J2E*;GW&#Z]??L^.7L/6344V(]NYM]T6_#GX MV7[H*2R;DSCP$;)%W_YDF+Y,[AS<=-TGKR0I#@<_:,'%IS5.<=#_3''H*XI> M5^T F8/R#WIC9)FR''X7$0Z/^S#GRL#=A[ZM&=)5J#WF,*_[,(%IB6E-\'#3) M>:#UQ#ASRN9X-C1ECPQ9$6W4BH<-@3$+LM^FDW>L+I,M\S9.,H/D M&;3,FB\"UQT'2%XC6WY(]WO7XV5*6U/P6V9RQG"2]1!M%)4&],])S"IF>(:/ M@3'R7$TV9?/<)&HC:8WC7R1YGQ:QLXA:K5@SM>;9^P8?]KS M^S(9^SXRU)+93FI[OCNV@J!TT9;4)-&+<'CL^3E7!F[/'YN:;> MGT,9ICW?,0,H::5BIB"J4?QIS^]J)\5[D04E\>]4R_AR]OR<%V>QY\\VZW0- M(S^,GG>WD8(AFMNVWW 4$!BF7W[T6])#M8O,RL:+MJP:JLU_![( >WLI.9]Y MH?0I8+A64'X\0YJ[7WYTG\6X0.?&G^9]H>9]6]&A7HIM^C$F)8L?/V!@MRQ& M6-O5+5>23-5+3TD6/P;L%R"ZQ5V:;I!_LTGP&;!%MK4'%NLN3K^AQ M3Q)IQ MC<<"OH,L5Q(UOO&$:@^W<6RT//-ER&J>@^RQ_:>:=\*-?FW[PYJ.OZ&4)#U& M_CZ'+"8_NN LY:4 Z)KI!9(DK5]Z\C9FTFY.ERRWPYB5!5PG>;GY4?*8A-X9 M\Z@Y"0"J:03V#ZH/-N71;DK:W^EMFFH$XTDW[VM:]T<$,!17'TVH@,$2(?2/'1QZ9VW':MD]R=_+_JNH3FJ+V^]("GTW9Q'!7_DGW:%\H55 MS$3O1A?0H&4&/^C\[XEU^;(8VNL=Y5W@+EHG892&WIF+NE$_"71/]M@'_0C2=VK0PV?0J*,T;CNE?EGGDQ?J1C66!\K MHFRM[?)DS+%KF;+X+R\B'$K42"57!IXG8SMC*RB1+D5Z1LYAMC3*4(3GR51/ MTEVFYF;]$B?A?R/_"6_PQ=HP),X\O?HXNGRR'N-AKHA.'P.V8;B!;(9)KLF0',5'PY_Q;65R2D;Q?7B:G;,AETNN#Q-F7C'J9[)H BSP#(TO T.5EJGL&P%D0&C\N'(I,R*7C*CGIX><:8,"SU=DR=^G MVWC.[>\ZX<8/^'16;?#0')'5B7]^'4>9^70#5^0A)ZUFNEZ6&!# L2YQ]DW] MA!;$KT.R]L#W4+D#$Z%F!(:\3Q)=:K_EXM$/^*K6<7 QL8"?6R4H?0KXF@7+ M;]#^&%.4S@T)RK=V.!D*N#A/AG,\E=F>&"R&P#7A@">E('X=>+'=R<7LF%X\D2/GN9S$>!X==9L,\^288>\Y8&J>/N'V1QI9#+K=4 M!:T/?N-"G)[9O*"U)210[T#D+"B"FZ,5*7IS':?KM"0XCDB\;N,""ZDP*%VM MI ZU4[7 0)*4LN^)^^SHK6/8 X^EI.3U]?5O%'PBQ:TJ?M *F M;^N!+#KK.7E>]F#26-&M)C1%.E@6N;\L [. MT?Z$<#(%OL#D#[3.9#^+EB^(S(99@/^2T3(+J@FE"*N7L8%K8KX-;2'W#[^3 M,Y(6BIAN\DEV%]V':#,+KF'ZLMM1;N-D 5*&4Z6*O: \5VC+$D'H%69BHZ MI()A_\)ALCVN^QX7-S#]L0F'>/'OA+;D09 DU,6N"G6QFH>ZV'_6I.JK[)&I M.I;RW9FMMU7=SOC<7D,*P-AS/4,6Y?(B$^K"]FL*OR7PRZ2/,/1OXV0)O_T> MKE^(RAU&S\0@5,F,FLG:<#1@CRVHR&+<$#SQVO+N'#Z.UKQ(:Y?"0QR]9ZN! MFB[4UGC4C@!@VHXM39Z;@#DHB-WG\ JU"=/F-#E2ZJSNT;'FL1B*@!N,?5WJ MBCX7FMB"^7_J I.D N\#3,C[1>^HZMIC-Z[$NQ_NS]M/;]/:U0)K6&D"/M04 MY\=0Z';"H1C"*KDR\"P"W? -Z5R1QQQF2Z,,9:!9!)KMV[*%,G((HAK%GUD$ M72.#+>0KBB17F&H9M[.W=.&%X%F5A\]O72)?\3&2OH1OF5=D,7LL'"A7'^2' M[-7?8C!@6- /9/,M<.P17; *KH3-)IW\MVYWX!T!0,\$SOG?EMQ]ZYAR5E*4>?7=@^3CB^CA%A- M4=FU1)E]@#%V%&TH9I1^)O$ M+P'(RDE)(]13H [ $ M=3T[E/BA/-4G53F[_F@$GJ)!4Y:0D38;E5QL/)LWM%4"1F6:1>^I,I5? 4&@ M69Z\9;X9V]^9&"&XG"VX^(+!==5Q^^4/R>=$3 M9K&E,?<$HN0]]%#U/-^[O;=A(9GJ=JH&/,3K?Z#U''GQ'DV?-OE=ALGNQ^1=@PUZ[)T ,7R%"A+X1I9IB2;5>?( M ^R0KWJT@Q>W\&W,VW:?G[S#<$640PPJ.^I[5ZA:TH&5T+'NRV*COHS*U955 MY\A"K+X_[XI:+F.JGM#(_E _'$"&9T))O,D]&" :(.Z40,B2:NFRN4N-V]-6 M\)6DQ%G"EU':R]C "#3?'MI5OG_XYRD[F*[#5T('WD$"%*Z)&W06/.W.P\.$ MW9Z,-/]4HT& KM@P*-T5!B#/ECA%YA.BY\PX%.$9F'G)DFS(NRC+52X$VU;% MV(Y+,;;3SU^F#\O1Y($$V3YD/CXG)9,+6@! AFDH:0&H>"&QQ^#P+? MUE71-V\N/I987X'B+*6AGZ(P4_[PW& &<97: =LR[+$,\[HA<]EH"L6P2)9,$ [X1ICP@ M1D8P=!^ILIW]906K4B'C M;G:\P2WF*9*:-.M^MLMP32KA?;_+KN2Y(YVDHY8*+* ]A$26Q+4VT1@&(S8)B>.Y9-(DPN5PNH$E0W@5"N=;=8 MP;\G=<+3]?Y 91H'Z1V #O%Y*OJ.PW7DEZV$'+!R_O=JDSUH,4RNGS8#BF^, M74E2:7GV_S+'J9!R/O=:AG'_M2L^/N^:@;&C.XXDL?(=^7P**>=SKYDR3POV M1-[_'B!7<:0Y/2LWW I?0HGZG(F]OLI$'$+L7;C0 IBNB:#H6UE#1E;1G[-2 M4&Y&:74]HH3\ #XC1H [JQ?P77,T.$O.CY'L$4 MS4F>X"QX2M$D35E^%68W,%9\WY"M,ANGS/B0'9*#!^59V;@I^N<&#S4EV(W*D_E5;^BE= N>5!%SF!, MMG!J\ @VQE>05VN!HG4!GF;#0!95HH;OO,(Z@2:7N.I*5E4V!XZN>M)<1&LY MSB.H$V"%ZG!R/!9V@U(O";,\HEEP_4)2#-.[Z$LED-Z=T!!8^I*5Y,ZGE256'[;3H#MUJM/L-^8-D(__[_P=02P,$ M% @ W8 M5FSPMIJ1_P X1D2 P !A96AR7S$P<2YH=&WLO?MWXCCR M!_JOZ&9V=[K/@6[,*X_NSCUT0GJXWR1D SV[L[_,$;8(GC$VXTJ2J7/_^_;5$.OQ+140_]R)GVHG2&BRX:BZB]? MSAQ[7+TX^W^O/T]L> J>U*TK]>W+V<2V9U/#V\C4/ACFR\=Z36I\ M5'5-UM\.?7S[ZT3:Q;HT-BVI#\]\B.:<+LYHL7L='X;_(_A2_6Z]Y75DC^:+"12Y>7EQ_? MZ)+X[WVSU+ 'Z[6:]/&_#_<#>4*FN*KJEHUUF2R^!0/_,YH _=1_=./)P++7 M&A_IQR-L+=\,GZI;GM\8"7RJV*NKXCW<^NA^N/*H&OIHVWU4]1]5B!J^T/!! M<(VO=&<:/EC%-C_:\QGY"$\04Y477S#T&-\Q].K:]TPRCER5]D?X= $XRVC6 MI?-M2^@^X7_!L:JFH9$E7L;8&K&G_4]69BP;CFZ;43AT/USY@F.;D8.Y_ B? M^@]:IEVETP\9R>*CE3?#>JU](7PYX3NU:DVJUJ4 J5 BJP.WJB\8ST+7A7ZP M\C FD^4TZ2\?9&/*GI"D1NT,]!#!RO5G6[4UW+F4W>[(^NG'^\_OS1)3XRE#FR[+E&W >J6%-?]*L_',M6Q_-/ M8_CRE52;V13DM=\^AFIRI>? MZ81N>[_^?/U9?;NB R.F^Z.J*$1G/\*K'UWX(QU/8;0@=E=='19J?@/3,['6 MTQ7R]G]D[DWYS7ZF\G$'=.B25VMMX+=ML)\EJ4H94 .-5FO6FN>USQ]72$13 M[ O%,J/.PV_Q*:$7#7^Y0Q4_]7( '"^AAKH.*NV3^QR=\PI6[?J9:,M=\( M-KNZ<@NPB#_G:E6J@PV)3=''GTOR"3XUE#OXFQ6?Y+_K>U*C$TQ("WYN1%"[ M,[%,+:E'SI/8JQMC.C7T@6W(?SYALV\.;"IFOV+-(3#;P02;:ZO;L?ICEWR+ M&6-'5]T/O@]NG]CS,%Z%R.H46/OEK/=X!TC[4%LLN3^.^.-R7]IQ[(EAJG\3 M)>9X-L<""W3>JK'_'3J:GF4YAXVD?B[5TQA)W[&I_:<^7L1P/"'<-9SS1CWY M<#J@@A15QJ<- +1]:G2DU MCU'XOES#]^_,2K"Y]V?TA=8#F8Z(N6MN4I.GB4D!P94.FUAK#_Q@:[(-)^Y0 MOIF&97W7P>9J5.+NX;>-$8&\KPUGG[%TJ='&&B@]JV/?8-.32'V4'5W)QV#O#?UE2,QI M3W\EEDTMN\4Y&.@(KNZP:K)U[%@6L:U[\DHT:6BP?^M#MB\GIN6J."F^=W#J M(:W;PPY0>W M""82OC59]7#@9ZGN>3@ !W@>D*"1^5>L_QECR%+[\F*+4(0SG7E+-(BF4"^- MZ!9STSHF*(H7ME9?Y\M'GO"<_JGS YM*4,\X4]<7Z[[-")5QBAHI-LL8<%1] M"9R%^NY.9YHQ)X3Y>PM0M1]B;1-/-,,PI[58,PS;;VP(_XX9UJ,4 Q880"8>/_NGN*7Y-,\5=#@]> 99D_)PC^),3K4B<],6NU$=*X3!K2.-5: M'"Z[.]9"2A[>.2$N#I3R'6M1_U!KY&0M#M<'.W'1/.E:/*O6GW?@'/5@ZB:X MZJ?4%K7&Y7DNUB)S;0%K4:NU3$2_.^@T> MM*V>[F9V_D/4EPDHS\XK[!9?"/N0YI<6"Q<7)?'2(I+T0Q-5(\F0M-(#0;',XQ3-,<,$>IEF"2"S&C[W>3?+>.J>HO[GA= M BN# %TF3V"V3QK6(S.U:?),JEV>=CYA'L(!\SG?)XMEZ#(K>Z"?41,&TZ%_ M !T6?W?/0E)WZBNYQ^8+F+X;Q[(-V-1NQM.C=H 7F\/^N%JW89(QH75HQ+K^ M3 N[KBQ6/@9O1:PF[(J6XWSYV5)AW+_IBKT][%*3,3(DM"ZO9O> M_ZW6DZQ_^=K_T^K;9PR%_F^6#7J:'JU/U5 6)O,TV5 M56\,2%'A4[?R;6D]HA@N5_D@X7 MO@\Z^>?!8A*\\!^&N>37DH?1TRB5B13<+)*E%-PLDL$4W,R3W5PM MH6:Y^:YC&C/"+\L6$;9OQ'@Q\6RBREAS.4<_#@X_L_@:6ZW4(YQB]4\37UYB MGT;'<[OVR\'G$/=BY4^!>3>GHJLV4=@4<\D!-Z>R/HF?D M1?$F/1DD6)U;5RE,.0M6%U*!)ST?)UB=6YWJDEDV^"US&"; MQQ4^@[)88<'$_-G7\#VL8&)^U&GD#E8P,3_N3Z0Z]7V"'')O;>A%5*"1KHQ@ M&\_.2W2B6;"-8R49Z:X(MN7207FF_8*&1.>;:^'=CM;O(_FN*\0,!-Q9YYRO M\^X;,675(D^F*A,VWP#O5^=?4(G=PGK.ZP@R9GP1JWYBL;U5:K:WRLKV9JG9 MWBPKVQNE9GNCK&ROEYKM];*R72HUVZ4"LCVL+%ALW++:N!VKL%OLO[+8?QV5 M>V(;E6?NB=U0GKDG-C5YYI[8F^29>V*+D5/N!2XI]^Z!""P N[[5[9^?PRQ> MPJGQSKU=^5;!R2PXR6>^MG:Q:"PBV'X,ML>/\##6I!CA"?20$:S.7%>GW7=& M".I1N7>16=>@C6.;^>98C.GDQQ\*-XR"8[DV@(E/] OVYLFM#?-O!$OSX,<( M+O'FK^RZ'SKV/<"=( (>26:,:/3Z[[1&BY.K^_PN=?396-*%A=Y MW!LR*SI;97&,^171[]G6&5:PO*C&([*7I&!Y(=W0;9UB!:8=GLN6![*6VZ8'LI[;I@>REM^XUAV?WQ &N\M_N+ MQ>*-V93-9@MVYM$61RIEP<[<*=MMKI5@9^Y!B*F70 M:XPYN%B]5JTUJ_6&8,RAC/$6\G#&[&I2=Z>:EMV!(2ITF$/CWL"T%G] 9,>D M"_!B$F8_^.8=S=\^XFGP;$&RB174C8FXR9/ TTH1F9YP9J7B>M]47U0=:X5A M=KP)%8K'H:>CDV'>_=*-8]FP/3"?'%.>8(OT3868N4- 6N(>>PR#B6':0V). M;\G(7CO,MF5),W(2,FU.)(Q$!@KD:)VEA*[/ :LVZC=Y8\C>-9H MUCO6>2/>UCO06."[;A*LT19_]X9E]?6>_DHLFPZ3\P!JWYX0D[8L-,F$?O9* MW)#J:B25::>=<\R,<6GW&@C8$,&X/$E<@'$WSM316%JSY++0KPSH6!;AG5=W6#5_Q9I# MOL[9<&\T;%FK)0'!:>2&$ZLU&H(3I][Y^9Q8S+*GSQS;NJ>G,;S+$O+*K<6/ MO\ ;Z2F3.9O5*NNVS/OP(#0OT,E6G88M8;VDT-EU0X6 SD[H2"6%SJ[K,01T M$ANL!T,G\P=L_DGL.T=72@"BU$S7+1FK.E&^$AU^L&F>Q^N]P! %.ZH7PU3) M&JS"U[M %LW:^4#6&H&3@ LCO$K'\!2,X,"8/D"3QGYM1H-$7OP N_!LTDC MBCUX"?;@QX?.NM;Y/AB:!%N..??JN53>#]5QI8/V,FW1:UX@H*WKJ'("[;2; MJE( ;7UC54Z@G79S51B@N=4^ ]N;C943!(54:T=/(F\O*+;5"ZEJU.89;*0BCX M9E?(]B1J"GED!^W@E3L&+ >=LR7?'>?)"U>.%6H1,-D"D[SITCR IDC*_9MI M6-;JV;A<^]TA[(J3Q=O268EU#RCGX;A.AE:[ .Z981!\RV@T1 M#"^9ZR(87BQW9_9UC\N=Y+,9<%A,F.)47RR4XE1>#)3C%J9T* MY]206/:M8ZKZRU?'U'LZGVRCCH07! Z+#X=/HE1\_ \>$Y.U0LDE!]>'7RK> M^3F-7')N=?"EXML-/(MEVS#SR;GUX9>*=X.Y!;O6?#)N9>P%Y5KXKEIX*[G: M6=\%;RR3?AK>27=\);X9AKD?%*X:WD*IH9R4?AK>27=\);R2?? MA+>27]X);X5OKH7GP86WDK3@?A;>27]X);R6??!/>2GYY)[P5CKD6%A'S M6VL^$QO3?I1=;.I@\#GEH%]QM"B3[?[EP+ANC.G,T.'7M7:9X9,J8MAL&VL[ MLNQ,'0W>K_3M"3'I:IED0M?TE?1TV>#];&M,;L>>9^D H"@J;7V'M2>L*CW] M!L]4&W/JT29E^K:YE8W1L$A30V?-#@O!W(WY%(JABR;7M8MJ0\J:53%69*4= M,QO4XD6'=_)F[Q/N1HH-L[/ED/ :,O0:CLE'8?QSQ2]APWGAB]@@K5 M(UDKS-ZQ]I&\ D#8RW(P6AC:/#'4\Y8D'LN$I)23KI(H$TK9.$63Z66*7\*&GY@OT7X6!R;ZY$Y+="4%AZMSPEL+U]O1 M\+8ZI^WMPI_#FWX=+R]LS_;0:YU#3K)![3=)1U?=&7X?W"ZF-278JV),KJ5;[ M)Y"W1X8"$+3AB[;B/_^U_WS;?:Y^[0^'_8_[A5B[T+L#W>=A][];U=H_6WHH?/\ MK?=XA>!]GQ 5G2K6U!?]2@;Q)"8=OF6;AOYR_?VQ-^S>HL&P,^P./G_T_GH< MVH/NS??GWK#7':#.XRWJ_O?FE\[CMRZZZ3\\] :#7O_QR /Z3V?P2^_QV[#_ M6$&W'VX^H'JMU;P\TB".P_49UD/0>3&SEZMPUW]^0)]!^'1#9_I%E9&G@)_) M>-MQSS.D8VI %*)>W1JP8P>ZP_D,-()4J_Z;"?3RG=>!=:7#.M[RKJB1D6&" MAJG""&15?[FJ?0I\62-C5VJ9_&X0#>@<)!--FV'8Z>HO7\YJ01WD$YH0]64" M;VI1$0_H&/B6FK5,A?4"/^%J9!C:"&N: 5-G6NSRO-G^M,GUF:<[Z?\/G=V_OW>>A]WG M^]_0<_>I_SQ$3]^?!]\[CT,T["/0+T-0(DAJH/XSDEKO;M^C_AT:_M)% =6S M4#N=FR']6+IL-)>#W*[@\Z@#[@P3V1."_O+YB5QG"\&6@2C(UP*IX>:)O;WK M[D=64'.ET-@$O'BBX/F<@$^BGUT_&J]N,*-1JR#ZYBUJ(^_JN/\L=![7.F]H M8MUBP!SVFVH362ZCU[ 5'?;4WAE>@W_W_(=M8_O)[_E4, M#>RJ%HT)H[$*&D!WJ'*]2D_-=]E^_P[>_>BX@?!:K5:MUR\N&Z?7W-NUWIKX MK2M!5^2J].3Z33V%U>/M0]3AFN;S)]J[']("FXV,]_Z;-\9I .2 M9_*B6E0 [4?XY.RZT_WE&<&VM329KA@[[IO M6+;9W) Q1LLY(6PA:T9D&@Y3D*HCU;:0/&%.UGL.5.MQ9.&BE:TL>)Y#ZY_' MD8IT@$\3U";X#YC:'9:1NS$>.NB@G);9CC?GRG-)1*QU%,8EE>?_=S51OX,>^.31^@(6[,UD@:'U^EKK MFT]@6T'-@0MZTXEE4?DTGVO!DY%AV\8TAYA_,L#CT?ZGSI@[!':TU;CDVX1Z M Z?F_PVKO\;;[.+Q"S=8:6;9S/KON MZ0KU) D:S9$\(?*?"#;/?Z(?$\+\;QJ5-)=1A'?2>S3!%HO6*0AK&GQ(0\\6 M_/N7HYKP1_ '1L1[ -XY(*[O+C6HMRZUWBGOJ6*B[X6/P+NW59A"]TV>8/V% MH(YLTX]IP!X6/A_] 3.@S[-'X4MT%-Y[:!3> M8H-@@\26C2YK2,%SZT.^H!*J9=(QHS>.:<(KW10%K!WU M4M:=W.9_8:NSR&#D:7$SD$.*3X#F5+5M #/H+IDJ3NIN:7-$P/6:HQZ=#9:9 MR;_%-D8T"KXNILMWS!S3")&>;* B/*@.T3NZ..>?ZHWZ M!^\!>Z*R2.*,1A*SEEEWO M1!"]&"-HRCK=@..6W)W<1@N9*E1"W>.(&",=( MPR88*"S+(&XF/>O#$&A2HQ'Z5P0+7@W]P)J"G (5T]>)P//I#.OS"K61\#HP M+#2 _8)>3..'/?$__@ FD["Q*62LZBQ1R-Q\ZL;4:Y^B1L@^EC[YC^U\('I\ M_H/43GH/1XS5?U+5774BU4?5NF_Y@^;^* *,\I-D<%_26(N+[YF,OP]'1'0\ MOIX.W:#B"*63TOPZIY]9_(W^J>I%EDEP\P96ZL4PYYMI';N",]O,3K*-$PS\DZC65M4W9,I#R#K\/=:20<-<#[KHU 1?,YSMZ!]QD3K-;_;+=)2W" MIA)V?1Z9E$P27)'3'8.55MCM7X$RV#F-&Q96\NNMD[=FYS/-#I'_T_T M"\'?V?+0/\1:+H^%@1<$%K!^V@4T,0M2+E?-/P XGXX,[1U-E.9K/4\+R$>O M]I3AD?A6=6-U0=']F*@L^>)KP^19="Z9<(*E/]3$>\9I#AX1TR=N93X-^=.> M*^@)F^@5:P[CZS]J'VH2=7<1.ZB]+18@V),.>SP5Y2HDMS)=+/O.91^"^Y2: M9/C; W8V8#-X!I_ZY="/G<%M9^,X,?+Z2J$'V+<0^\C[\5!G[PB^[Y*N6_I! M]8?;WL'W;\W-4@S953T653T57]WX&JB"#,=F.V56F<'>MEPRFV2T5\273TDJCM3Q; 5(JM3K)TA[P?KRUGO M\>X,T,R);W>!Z@+H+]%C_U? MNP]?X=?EN?F\3]0]D^AI!FQC, P>)46U9AJ>7R%5UU0=W 7:>PALR=DUU0#_ MS;*A2':&OCQ$$@7!]C8LGT98_O/%-!Q=J-Q6EECC"8F=3U^ MFDEGUT\@C*CW =WU'CN/-[W./0+_!)1.9\CZ&.'44[C9UWRS;<:"N!V( G$:9''6W2RM="[[SIV%-4FRGLA M64*R+Z(%JP+Z6K9F)12U5C4.3J7RF4FA\Q]06X<>WI"J'EX M9ZZ$VIA%"G7 MAICU)\1]_3_\N#-$-Y!F%P/U#?TX!XUZ+(*G7#QI_VZ\VV; MFQQ!)]\"G(G3Q!%W3BW81>\5)F@6YS!*5\"[2PV1G;['%=;#B\Y0H"00QZX<"0Y7$T+U;VT M4/T#>L Z?F&BM2AJNU4MV7$[75/KU]&Q-K=49D.7$DE%UCU-1I]Y)I:CK<>\ MCB&J,=S5#"3-"!%11+^H/F_4XG6#'I1 MF(4Z(\.QO=)>]*Q:?Q993H6]+<$[^9?3IB>GS0_4;MJFH5E,1I],0R:*PZX0 M%#(H9#"_[^1=!F=UO["P]P'UA[]TGT]850GP#8=1;,L8LD_%] M1EN*$%TUS(#8"A$5(BI$] 0B&HB@/J@Z 9L]27L^M![]MC9_C]N3LHL+@=H\W"2=H,YK5EVUJ#NI$&\A#H=HDV M6KJ%-8FJQR*YY$0J7=X^DVE A%CCJ2%C CMD"2-;E'S3!V/ XW ,IHVT?;MP MQ>B%5)CF7 F7QFUL8Y,IDOP>S1\VNC8O^S@O5V\P[(!7!&(P6&U]D_.%/%6_ MP81L8\U0^E0-#;JW"'X:].][M\"16_2U& M8V%=L2JT_35V^WE^L426=G/+#VK'Q/@ M#IL3N4*Z\81M M8L6C%NB^7$S].+')Y0YX,& ;R)C*)MO@L'>O/0)($-NZXA.B0B,5F_(.C52H MZ?*8(UJT0'&5#FM#1*M_9?H#^J\GO]+.*2I."E6(Y5?<%X=D67O*,K])_N,6'W-S$-!11\7,15N0-;#EQA>E>LVZS( M8(7#6)9A4#:]=5XF8%='&JG >VQ.<%Q<"6HG4=P=CTO@ C%A>EXPRWHDMA?R M2$.)URI2J\V=7)64TS9@Z"DHZG?7E>YTY"2DHY:Z1=)E'2:2.M5:FU).Z0E@,W^\DD,ZPJ MB+S-:)-M*^!QRRL)*DY0'*_6@@/!2J$:9)?$2;4DRMWC=-=EM.\==1AST_.* M+NJ-G6(86EY2)E4L0!P L93$;AP'Q&TI'R#FZ>SAZ<6)&ZDI9OJ\I)3+Q&*N M_=4&&_+0L+'&M6O*'T8/M]&)*BI2M\:M2JO1XFYS5U+*F6,M4;E%ZEBK56JU M<^ZP)AP]OE%?M.F6D7*96,RCHT=CD<8,7CQG,4A:_#JCQ1Q,S^.\"2JSEIP[)XR[)F^NS_^;A&VBTI!>EIM_G*P):6< M.? 2U61E#;Q+*>=[]J/YV&X77J&=CR,DB:JO JG,1T.7TRM4Y/"<4$DI9PZX M1$5860&N7N//#1 1U*)5GF2Z0#Q4=PB@"*#DUM,,3=OSZ':NX:#5*XWZ12Z M)]Q0OG=@19MN&2F7B<5[9X9.WXSOOM?YVKOO#7O= >H\WJ+!+YWG[B_]>[!2 M@W_]=%&7SC^A[K^_]X:_\9X(\SOY:2H>J1J["Y27=GY""@N_T(+%W"G:TQSE M]!L?H!F>TW8'/"Q;;IJ\U1/5/_E+_>2N='KUQXW*99._GA)<4>84/XFJF#+# M3[,B7?)W5()'MVU3>9H.69Z#YQ3\W!CWPP4F:5\IRI[[I8>=GLS4*ZVV:"7% M">7,89>TEU1FL&M4VARVH=QK8=E>0M>CNR@F@"RQ*R:J;5DH ?8F: MIR=/+0X; )64*A_(=@65>L!RK?.$$6*Y7FM+NJ X/6-YW^U!,J>)&>(J9DRDIY3*QF&LW M-JPC52 8P0=K@)AL30*WD6.7X!W M7_ F[Y:5,GAW!W)Y "^/WGQH$BXO=H-_H!6I5;;3$@@BSWYR9U7S[)HHQEZUM5P;,N&'U3])7J.[41ALXTYNN32 MF5_]O'+>V*PV\>9'I^2)4=14H@KV0R,J&U/I+YH(;E_K2!X?D;@ZZ]$F_.@OW@V%(='YJ+J\'>)!--C:=20 MG/-WWU1)*6>.M:ABTUTZ*SVL\=?7A,?BD?6&;HJBTK7"&G@6JE)5=23CF6IC MC1/@%EADHFIDPUN[+1CU!'SJZ3)>W MXR#PO-*^X.^H: XVNAU9=J:.1C>BR& %@K(QG9ED0G0+'&ZD&19G]1XY%JEW MD3(554T;U;#3YQDKG+H)"?I M)OR> S87&6!1P9RHUIPG U@M6X#EP;L.J&2%C%59M3F!:1DKF*)%*JK"-51G M/Q,;JSI1NMC45?W%"C#YUN5QFE+4KE=:,7K=;RUQRJGV%N!DP?NHP':HOC\R M.-N5BW;RNPP/!:=HH\&WDU.TZ9:1!862NJ MS#W41V3A,(]17<:@-%JWMROMMLBH<4(Y<\ EJ@+(!G"URN5%SL]DI^C^K6WN MN4)C@;9,F2X0#T>!!% $4(KEEP9.%+.*O;SXJ6L8:\"T%,,9:62_\,2N>Q1W MD4O%;4A4]!4XCMG1E4R09";@ MHSTRE#G]EUZ#&B"2TF7S?SB6K8[GGU;(,UH^H9%A @?8=&D5=BW(?HV,W?FQ MF6Y0]5:L5OLGH "@-\,*+4W^A\4QL-? M.)P0BGF%WI*JT)^8[\(2@2.L85V&I9T08M/JZ6")-)I@"XT(T0'*IOH*CX_A MYWUEXU5'5ZFTM@0/8(P)?1F:WBG/8'_T$<^\("EM(G(,$UB?G*7 M&N!7;>A<('ND5 OD<#2(N0]P$CVR66\(%"X78\X29>I:8 MH3&&V.D.H0)RP$Y)L+-([!3262AV\B:=IS36)Z\L"'!]8R]7T'2B6'2QZ&+1 MQ:*?KB[I:+UG'XF-+*SQ=JE!)F4;Z15GM-?JA>Y@;FYQQF6U)MG&MG.0[ :H M5/JX-RL7DKAP+(_P:8;"1PK 1\H5ML1?]R>N*'.*GE:4\FD?3_G46Y4F MAQUGN*+,*7S:4 M(.5L?^S)51HUNI7+6C[N?1/@Y06\%_OZHFF#MU6I7>Z^;ER 5X!W"=[+?5WA MM,$K-6+U !7H%>A=H/>\MJ\GGC9Z+RK-&-XX#^#E,XKZS30L"\U,8RQZU?$H M:-*^#CIC[!/C:PIB=EZYC!%RXT',!'1Y@6Y]7_<\7>@V*RTI'W?&"NCR MW( M)-DNYSQ=Z$KU2D-L+ 5V$V$W,D.WRS5/%[OMRD7(I5\\0E=?$1/;M/,)>9O1IB;6%0^+)5!9AH46+"[\0@L6 M%WZA!8NY"0\KR3-D#X_6 MA9>TQLCO>=S[YO*NHRN=%7,\1A>$!HC:7=$/#8Y MO*2@I)0SQV-XC6>,3-S1\-BJ-&,D.DJ%B@+C,;QL,T9V[6AX;%::S=TY8Z[] MX=-<+\8(6\$LV8T:[ G$!;)+F78G@17G\:ZQ2SRV00P-LEB].3 M/JG2:HE".0'F)& .K_&,=:8Z:S WI .O>Q5@+AF8PZL^8QWQSA;,C4KMT(NU M!9A+!N;P.M!8!\ZS!7.]TF[DX\P6UX'PX*5FQD9J74@D?Q(97MT:P_%?5$YX M0IA&+PC8:M=W=Q+A00H%@'D!<'@+G!C.?A8 ;E0N:N)\@0!P$@!'9BQW.?A9 M /BBTA1.O0!P(@!'ICAW.?59 /B\4CO/APMQJFO8^10E;B2FF.53):4L6%QX MRH+%A:=<)A;S&-X[N^[ILC$EZ)UF6-9[]TIE+[QGZ)R%]?C#Y^$>=F315NP@ MGV!?*E&.YH6H8.6$7"@7YQU^T3HLL:=T5>#J*3DMP-O^(P:=L MWG)Z096.<$F_F7BDBA2-S8!Y.)>4491Q^] M6[*M/WZ:S>Z!9ZM2\3XA8^ GGEH)PY\A(WZQ'( M*P?ES)&7N"U/0N3MV3ZA?7G!'03Y#(SV[0DQE^%0+S[*852T5&=H(O=\4FWO M#CR,TX^&;JQ6'1Q\-GYSZ[>[YF_KN9J1B(?N<& MWJ'J#KC=_<5!ZJ^,K>YS0_Q&K.Z;;6+#5%0=F_.>3:86^.N4NFFPYO=^O4+S&+WB2X6D(F-X[\9Y?&.X66DT$QSP+ .6BHSB MO;OG\8UBJ=(\Y^\6)Q'KXUN>BC;=,E(6+"X\9<'BPE,N$XNYCO5Q&]TK5?Y] M2^'>WLWY%HZYEW+_2G0R5E-QO@_,O(M*O5PC]& M?ADB\L![6@0B7NJN?UY)7\#5']7!PL[MW,)VTLQFDR+9!88"3N MW0,H;20V*PTI^=Y)8+% 6-R['5#:6)0JS3VNKS\%%O>-Z!93*KC9VA4S?5!2 MRH+%A:_1+C0C,+@)-CF+>PE8%G>A!8L+O]""Q85?:,%B[OR' M(]6)(?__#3;DK]A291[6*H1RFI&W-.-KX2B+F@'IM;/%C MQMEZCW>K@;8G]@KK[+KV(4; EP-V"B"M RF\$C!&^BHK(-7$B=Y< BF\@"]& M]BDSC20.).812/7PNKL8J:/,-!)_0.(Q*K3FU=VJFF,318 _$?C#2_SV\.N\ MY4]#CPJ#G$LHA1?)[>'9I0WAW*6HE_J D:H%$B+@<"RU87/B%%BPN_$(+%G/G%1RM%LAUI)!C$06I^K(> M" $EV='4&ZP'F^^GFE=;[[PK%2 M@:/(L$Q\D?F)8-FNU#F,(Y>4]]M'B%*'N=<8>@[MF5C75'UEY0DZK)2NQ"*GA/* MV:-S[YO-3X/.BTJCR9^^+RGE[-&Y]UWEIT+G98Q>OZ7"2)'1N??MXZ=!9[MR MT>0OX,5\Y8_VR%#F]%\\TDB R%W_<5@=]/[7O4*,"F)_N.L\].Y_NT+K=-!# MY_E;[_&*^KF?4("7?SB6K8[GGU;(ITU$)O0&*: QG!"$9=F8SK ^!_[!ZMGP M"IK*QH ?>.K%Q!J:8=-&QAC9$V(1=UP )X7VU54HL%CC7PR 0&-5Q[JLPG< M$C:9 B'K0R9S"%THQA2?T,@P%6(R7,#4KFJ,\0P"&U0\*-5J_P1! 2&<887" M^YV7(Z'[I+.@@(\F8TFYG(\V_=7*]NHM0YU(PWV7H&6RFC8_>^PVGN\ M[3X.W94(8V8S%LDE)WZ>@4171R;!?U;Q&-YQA;#V \^MGZ_C;!"]MY'I]6>, M)B85Y9]L0P90,28 7.AE9Q0 GS]B>!%],(8<'2ZLF4E+I_O+,[!B,$2#WP;# M[L,@6W*? ;FZCRULXY>%:5!4:Z;A^15(J*;JY(QI>GEV=GW3IQ@9=&\1_#3H MW_=N.T/X93"$?QX / /4OX./'IZ>N[_ <[U?NZCW"+]W/W^DQ*ZSG= [50<5 M8C@6& NK A8 .PIH;N4]+PHB\&V-C.W,%$:F_LNQW9:)XKHMLJ%1#'TY:^_A MPBQ!GZ&M,PE!#S#?B86Z8+W"0TI']S<%O\+Y-5#?>.%6;)-:('B$>R;[7//@ M,@AP?6,O5[1LB5ATL>ABT<6BEZ4"DP- ZAB*O]>+QLD,.^"@0M(Z@R&-F?%Y2R $G!8;6,11Y)HS/ MRP6Y]MM$\[#,-PR%WB24E+)@<>$I"Q87GG*96,QG-*=O3XB):,VU229$M]17 M@MYIX)V]]X(\%?BB6VZ-WT03L3(!MJ24!8L+3UFPN/"4R\1BKIN(N34/-&DD M3[#^0FB+4D SNF7E&?LQ@[@O8N.X$5>%K8K M%\7\Q9N@N^@&]+XO6/J+H='#)]^PJM,H7U\?$-DQ55LE5L=4+?CH%G[57YZ( MJ1H* *,_'N*W_8.!,&/X>S JF."ZJ"01UO<<0"/_H(S$9#/RWK%=N:WC8/)O M8AH*MB9Q8]-5[N+2):6%%7I"F4/_>T/A"GHFQ62;R=TIW:#%_F2Q&&>5AB\L5>8_= MOKL%+@1BT_MJ[JZ1VBH:.77)!,Q=F(<7?!ZPLQ P%S#G#^;A5:D';%8XA7F, M%K%IPUQ4(_*]U2_:=,M(6;"X\)0%BPM/N4PLYC%X>7:]XLAQ>PBETYP,?P\3XS@8HCCG6)0D)Y33>XO-T1@L#C(#+_F*4:4 M+UMDML]WGSH3N"PP+B/KIW:%Y;+%9;-2;R9K<@JJEV1M&R1*54: MC7SH3'&Q@KA887U/=!84ZQ-?K-"*17+)"7&Q0D)IX?MB!?)7S(L5!K]TGKN_ M].\!<8-__711E\X_H>Z_O_>&OQW_>H5L[E18TCKRY0THAA;*\^T-Q^@V&MZ[ MF^LI''59ELWMPIW"LRPU( "0^F=8BYA^V@2WKG7VQ+8P(& MC@:PY_F3TZ7F9R2[=4-R/FL*E55YW0Q^1E)SMBZ$LGD=$GY&4G.F+ON M-?.WH/R,)&>L97<$LO!1VHR0*WER&HBZ].?5R M'M=7S'0?Z%X>'K;(^UQ%4V95E5L(=*:&H]L" B6&P V>J6OA"(&!DF' K9] M[^C1HO<""25&PBT9J[(J+$*9,=#]RU'M>5H0*/0)@*]8P[I,K KJ."^.9:.& MM&7K4J:BQ6VG4^)@?F?IX.7:6?..U1^[1:T7U8;TNUVNUPO M)'1W03W+G>QNR( ).D\TJ[?2% QB_(HIM2M)KQ4+9, M2$0UH\@><9N=)J36[J-S>>^>PC^$XKE4S\3&JDZ4+C9U57^Q3H&7=KN2R!P* MR&1CVMK;$',4H]62*BV)/YLE^MCPO0$MVG3+2%FPN/"4!8L+3UFPN/"4!8L+ M3[E,+.8S%T53Ύ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